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Abstract 
The proteolytic degradation of articular cartilage in load-bearing joints is a key pathological 
step in the progression of arthritis, a process mediated by enzymes called collagenases 
(specifically MMP-1 and MMP-13). My research has focused on the transcriptional regulation 
of these enzymes in cartilage cells (chondrocytes) in response to a pro-catabolic stimulus 
which mimics the complex milieu of elevated cytokines found within the arthritic joint.  
Activating Protein (AP)-1 transcription factors, specifically the c-Fos/c-Jun heterodimer, have 
previously been shown to be crucial in collagenase gene regulation. c-Fos/c-Jun gene 
expression, protein production and collagenase promoter enrichment studies identified a 
temporal deficit between transient c-Fos/c-Jun peak following 1 hour stimulation and the 
initiation of collagenase gene transcription following 6 hours stimulation. Protein synthesis 
inhibitor studies indicated that although c-Fos/c-Jun are indeed important, they are not the 
sole regulators of collagenase gene expression. 
DNA microarray studies highlighted a number of genes that contributed to transcriptional 
regulation early within this temporal deficit. Collagenase gene expression was assessed 
following the siRNA-mediated silencing of these factors. This confirmed that new factors, not 
previously associated with collagenase gene regulation, were demonstrated to have a 
significant role in initiating their transcription. This included factors such as activating 
transcription factor (ATF)3 and early growth response (EGR)2 which demonstrated differential 
regulation of the collagenase genes, with their silencing affecting MMP13 expression alone. 
Having identified a number of contributing factors, I then assessed their temporal gene 
expression and protein production. Comparisons to c-Fos/c-Jun induction confirmed that a 
number of these factors were transient, similar to AP-1, yet they peaked following longer 
durations of stimulation. Subsequent siRNA gene silencing of c-Fos and c-Jun led to decreased 
expression of some of these factors. This demonstrated that these factors may be regulating 
collagenase expression indirectly by controlling the expression of other transcription factors 
that, themselves contribute to the regulation of collagenase gene.  
The present study improves our understanding of how collagenases are regulated in 
chondrocytes in response to pro-catabolic stimuli. With an improved knowledge of regulation 
it may be possible to specifically abrogate aberrant collagenases expression in disease. 
Moreover, by exploiting the differential regulation of collagenases exhibited by some of these 
factors, there is the potential to mitigate the side effects associated with broad-spectrum 
collagenase inhibition, thereby removing the barrier to successful treatment. 
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1 Chapter 1: Introduction 
 
The cleavage of type II collagen in articular cartilage represents a key pathological 
process that, once initiated, leads to a cascade of catabolic events culminating in the 
degradation of a tissue which is crucial for normal load bearing and articulation of the 
synovial joints within the body. This loss of function increases disability and is the root 
cause of pain experienced in patients suffering from arthritis. This process is mediated 
by the aberrant expression of matrix metalloproteinase (MMP) enzymes called 
collagenases by the sole cartilage cell type, the chondrocyte. Previous broad-spectrum 
metalloproteinase inhibition demonstrated no benefit to arthritis patients due to a 
lack of specificity [1] and so targeting of this pathological process remains ineffective. 
By studying collagenase gene regulation I aim to elucidate specific transcriptional 
events that could be targeted in order to reduce the MMP-dependent cartilage 
destruction. 
1.1 Articular Cartilage 
1.1.1 Structure and Function 
The synovial joint is a highly articular joint in mammalian bodies. This articulation is, in-
part provided by the presence of a lubricant called synovial fluid which is 
compartmentalised between the two ends of the bones within the joint. Articular 
cartilage also plays a key role in the functionality of the synovial joint. This tissue 
surrounds the epiphysis of the bones in the joint allowing load-bearing through a range 
of functional motions minimizing the stress on subchondral bone. This is achieved by 
creating a compressive, friction-less surface upon which the bones can articulate [2].  
Unlike the majority of other tissues, articular cartilage is aneuronal, alymphatic and 
avascular. It is made up of 4 zones that layer upon the subchondral bone. The 
superficial zone is the articular surface exposed to shear stress generated by 
movement and makes up 10-20% of cartilage thickness. Collagen fibres are aligned 
parallel to the joint surface providing protection to deeper zones which are crucial for 
resisting the forces applied to the joint. The next layer and largest zone of articular 
cartilage is the middle zone which makes up 40-60% of the volume. Collagen fibres are 
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thicker than in the superficial zone and so provide greater resistance to compressive 
force. The deep zone which sits between the middle zone and calcified cartilage 
anchors cartilage to bone and provides the most resistance to compressive force. 
Fibres are thickest within this region as they are bolstered by high proteoglycan 
content. They are also aligned perpendicularly to the joint surface and hence to the 
direction of force. These properties make the deep zone the most important for 
physiological cartilage function [3].      
1.1.2 Chondrocytes 
Despite the resulting low oxygen environment, the tissue is populated (be it only 
sparsely) by a sole cell type, the chondrocyte. As a consequence of the cartilage 
environment the majority of chondrocytic energy production is achieved through 
anaerobic glycolysis [4]. Chondrocytes have different morphology depending on the 
zone of cartilage in which they reside: Chondrocytes within the superficial zone are 
small, flattened and relatively densely populated, whilst in the middle zone they are 
more disperse. In the deep zone they align into columns parallel to the collagen fibres 
surrounding them. Chondrocytes are crucial in the development and maintenance of 
cartilage and bone. In the context of bone, cells differentiate from chondroprogenitor 
cells into hypertrophic, then mature chondrocytes capable of mineralizing the 
cartilaginous growth plate into bone bringing about endochondral ossification. Once 
bone has been laid down these chondrocytes are then capable of undergoing 
apoptosis. Conversely, articular chondrocytes (those cells that exist within articular 
cartilage) do not fully mature and remain arrested before terminal hypertrophic 
differentiation. These cells retain the ability produce all the components of the 
extracellular matrix (ECM) that surrounds the chondrocyte and constitutes the 
articular cartilage. They are also capable of remodelling cartilage through the 
production of enzymes that can degrade the components of the ECM. What was once 
regarded as inert tissue is actually constantly remodelling in response to external 
stimuli (e.g. compression and cytokines) to improve tissue functionality in a 
chondrocyte-dependent manner [5].   
1.1.3 Extracellular Matrix 
Cartilage is a complex structure that is made up of ECM generated by the chondrocytes 
which populate the cartilage. The functional aim of this meshwork of proteins 
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produced by chondrocytes is to trap water in the tissue thereby creating compressive 
resistance to force. This is achieved through the production of only two main protein 
types: collagen and aggrecan. These proteins make up the vast majority of the tissue 
with only 0.4-2% of the mass of cartilage accounted for by chondrocytes [6].  
1.1.3.1 Collagen 
The main structural component of articular cartilage is type II collagen making up 90-
98% of total collagens within the tissue. It is composed of 3 identical polypeptide 
chains (α1) which intertwine forming a triple helical structure, a property imparted by 
the presence of a glycine at every third amino acid in the protein sequence. These 
trimers then congregate into collagen fibrils formed through bonding of the 
telopeptide regions of one collagen molecule to the trimeric region of another. This 
imparts a great deal of tensile strength to the fibrils and with time, as molecular cross-
linkage continues, type II collagen becomes very resistant to proteolytic degradation. 
Type II collagen is not the sole collagen type within articular cartilage. Type XI and IX 
cartilage specific collagens, as well as type X and IV, are also present however, they 
comprise a negligible proportion of the cartilage at less than 5% of the total volume of 
collagen [6]. 
The collagen within cartilage forms a complex structure which is essential to function 
as it provides a framework of proteins that enmesh other crucial cartilage components 
within.  The turnover of collagen is therefore very slow indeed with collagen laid down 
during development will endure for an entire lifetime [7, 8]. As a result of this the loss 
of type II collagen has been suggested to be a rate-limiting step in cartilage breakdown 
in diseases such as osteoarthritis (OA) and rheumatoid arthritis (RA) [9-12]. 
1.1.3.2 Aggrecan 
The other major structural component of cartilage produced by the chondrocyte is the 
proteoglycan, aggrecan. These molecules form proteoglycan aggregates consisting of 
up to 100 aggrecan molecules attached through link proteins to a single hyaluronan 
filament. These in turn are encased within a type II collagen framework. Aggrecan itself 
is made up of 3 core globular domains (G1-3) which are intersected by a 
glycosaminoglycan (GAG)-rich region comprised of a keratan sulphate region directly 
adjacent the G2 domain followed by 2 chondroitin sulphate regions (Figure 1). These 
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regions impart the functional qualities of aggrecan. These sulphated side chains are 
highly negatively charged which creates a hydrophilic environment resulting in 
hydration of aggrecan. This allows it to resist compression from loading and prevents 
chondrocytic stress that can lead to aberrant protease production and cartilage 
destruction [6, 13, 14].  
These aggregates exhibit a relatively high amount of plasticity in comparison to 
collagen. As the cartilage ages cleavage events re-model the aggrecan molecules 
bound to the hyaluronan leading to altered proteoglycan composition. However, with 
time sulphated regions are lost and the tissue is less able to resist compression, a 
suggested pathological process occurring in OA and RA.   
 
Figure 1: Protein structure of aggrecan showing three globular domains encompassing glycosaminoglycan region, 
attached to hyaluronan via link protein.  Taken from Porter et al [15] 
1.2 Arthritis 
As previously mentioned, the destruction of key components of cartilage, namely 
aggrecan and type II collagen lead to the progression of cartilage destruction that 
characterise the disease endpoints of both RA and OA. This loss of cartilage leads to 
pain and narrowing in the range of movement, increasing disability and decreasing the 
patients’ quality of life. The process of articular cartilage degradation is due to an 
altered balance of anabolic and catabolic factors produced and orchestrated by a 
number of cells within the joint including the chondrocyte. Under normal physiological 
conditions chondrocytes subtly re-model their ECM in response to pressure exerted on 
the cartilage due to loading of the joint. Cartilage degradation occurs when this 
balance is disturbed and the catabolic factors produced by the chondrocyte surpass 
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anabolic factor production. The reasons behind this imbalance are dependent on 
specific arthritic disease and its pathogenesis.     
1.2.1 Rheumatoid arthritis 
RA is a chronic autoimmune inflammatory disorder which affects the synovial joints 
(including hip and knee joints) of the body. It affects between 0.5-1% of population in 
developed countries, with incidence increasing with age and is three times more 
frequent in women than men [16].  In an ever aging population RA is a significant 
economic burden with the total average medical cost amounting to approximately 
£3600 per person and the loss of 27 to 30 working days/year/patient [17].  
 
Figure 2: Pathological changes in a knee joint due to rheumatoid arthritis and osteoarthritis.  Taken from Buckley 
[18] and Hunter et al. [19] 
In the initial stages of pathology, CD4+ T helper cells orchestrate an adaptive immune 
response upon recognition of auto-antigens presented by B cells. In the context of RA, 
this consists of activation and subsequent infiltration of T and B cells, macrophages, 
dendritic cells and other inflammatory infiltrates (Figure 2) into the synovial lining of 
the joint cavity. Here, they exert their pathological effects by releasing pro-
inflammatory cytokines into joint tissues [20]. Tumour necrosis factor (TNF)-α has been 
demonstrated to be one of the key cytokines that drive the disease. This is 
demonstrated by the striking efficacy of anti-TNF treatment in some RA patients. 
However, there are still sub-populations of disease-sufferers that do not respond to 
anti-TNF highlighting the important role of other pro-inflammatory cytokines 
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(reviewed in Feldmann, 2002 [21]). Interleukin (IL)-1, -6 and -17 have also been shown 
to have important roles in the pathogenesis of RA [20].  
In response to this complex cytokine milieu within the joint, many cell types are 
phenotypically altered. Synoviocytes (macrophage-like and fibroblast-like), under the 
influence of these pro-inflammatory cytokines, perpetuate inflammation and bring 
about synovial vascularisation and angiogenesis within the synovial lining. This forms 
pannus, a synovial infiltrate that begins to cover the surface of the articular cartilage 
[16]. Chondrocytes within the cartilage shift the balance between anabolic and 
catabolic factor production, as mentioned previously in response to pro-inflammatory 
cytokines. This leads to degradation of cartilage and the subchondral bone. 
 
1.2.2 Osteoarthritis 
Osteoarthritis (OA) is the most prevalent arthritic disease, affecting the majority of 
over 65 year olds. The symptoms include joint pain, stiffness, swelling and loss of 
mobility. Hence, OA is the leading cause of mobility disability in this age group [19]. 
Although associated with age, OA can lead to about 6% of 30 year olds exhibiting 
disease symptoms [22]. The process by which synovial joint function fails is due to 
mechanical factors although other factors such as increasing age and weight, an 
individuals’ genetic profile and gender can affect susceptibility to OA. Local mechanical 
disturbances like abnormal joint loading, joint misalignment and muscle weakness lead 
to loss of control of homeostasis within cartilage [7, 19, 23]. Though it has been 
demonstrated that OA has an inflammatory component [24], it is not the driving 
mechanism behind cartilage degradation as it is in RA. Rather it is secondary to it, with 
abnormal mechanical force causing chondrocytes (as well as synoviocytes) to not only 
release catabolic factors but cease producing anti-anabolic factors. Pro-inflammatory 
cytokines are also released which perpetuate cartilage degradation and exacerbate the 
aforementioned inflammation [7, 9, 23]. This eventually leads to advanced cartilage 
loss and damage to the tissues within the joint (Figure 2) leading to attenuated 
mobility.     
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1.3 Enzymes and cartilage degradation  
With cartilage loss a common feature in the pathologies of both RA and OA, the 
process by which this occurs is crucial to our understanding of these diseases. As 
mentioned previously, the imbalance in favour of increased production of catabolic 
factors leads to increased cartilage degradation. These catabolic factors include various 
enzymes within the proteinase family that degrade articular collagen. Their actions 
lead to irreversible cartilage damage with chondrocytes unable to lay down enough 
type II collagen to recapitulate the normal cartilage architecture laid down during 
development. This is due to a very low collagen turnover rate that has an estimated 
half-life over 100 years [8]. In contrast, aggrecan can be replenished by chondrocytes 
following proteinase-mediated cartilage resorption with a more modest half-life of 3-
24 years [25, 26]. 
 
Figure 3: Schematic of the sub-divisions of protease family.  Taken from Rengel et al. [27] 
The physiological role of proteinases is to cleave peptide bonds that hold amino acids 
together in the polypeptide chains that make up proteins. This can then allow for the 
catabolism of proteins for degradation or formation of new, active proteins. There are 
Proteasome Elastase
Gelatinase
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5 subclasses of proteinase based on their catalytic activity. These are: aspartate, 
cysteine, threonine, serine and metallo catalytic types. In the context of collagen 
degradation serine and metalloproteinases are the only extracellular members and so 
are able to directly affect collagen breakdown. For a detailed overview of proteinases 
and its sub-classifications see Figure 3.   
Serine proteinases have indirect effects on collagen breakdown. For example Milner et 
al. [28] demonstrated that inhibition of various serine proteinases led to significant 
reduction of collagen release from human articular cartilage explants following pro-
catabolic stimulus. However, rather than actively cleaving collagen fragments in the 
cartilage, serine proteinases were shown to cleave pro-forms of members of the MMP 
(a sub-division of metalloproteinases) into active enzymes capable of a direct 
proteolytic effect on collagen within the cartilage [29, 30].   
 
1.4 Matrix Metalloproteinases 
 
 
Figure 4: Schematic of the domains that make up various MMPs.  Adapted from Murphy et al [31] 
The human MMP family of endopeptidases consists of 24 zinc-dependent enzymes. 
These are categorised into groups by their structure (Figure 4). All contain a pro-
peptide domain which retains the enzyme in a latent form. This pro-peptide is 
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positioned close to the active site and prevents water binding in the cleft (thus 
preventing peptide hydrolysis)  through interaction of a conserved cysteine residue 
with the zinc ion in the catalytic domain [32]. This domain is also common to all MMPs. 
As well as the catalytic zinc ion which is necessary for substrate hydrolysis, a secondary 
‘structural zinc’ and additional calcium ions confer function to the domain [31]. The C-
terminal hemopoxin domain is another domain shared by the vast majority of MMPs 
(excluding matrilysins). Small structural variations within this domain have been 
suggested to give MMPs their respective specificity to certain substrates and 
proteolytic function [33]. Other more specific structural features of MMPs include a 
furin recognition motif (MMP-11, -14 to -17, -21 to -25 and -28) allowing activation by 
furin-like proteinases; fibronectin-like (gelatinases) and vibronectin-like (MMP-21) 
domains that provide greater substrate specificity as well as transmembrane domains 
that anchor membrane-type (MT)- MMPs at the cell surface [34].   
 
1.5 Collagenases 
Collagenase Alternate names Substrate 
Specificity 
(collagen type) 
Expressed by 
MMP-1 Interstitial 
collagenase; 
Fibroblast 
collagenase; 
Collagenase-1 
III > I > II [35] Macrophages, fibroblasts, 
chondrocytes, epithial 
cells, endothelial cells [36, 
37] 
MMP-8 Neutophil 
collagenase; 
Collagenase II 
I > II > III [35] Chondrocytes, 
neutrophils, fibroblasts, 
endothelial cells [38] 
MMP-13 Collagenase III II > I and III [39] Chondrocytes, 
macrophages, fibroblasts 
[36, 37] 
 
Table 1: Collagenase activities and expression 
10 
 
In the context of pathological cartilage degradation the most pertinent of the sub-
classes of MMP are the collagenases (MMP-1, -8 and -13). As the name suggests, this is 
because they are the most crucial MMPs in the cleavage of fibrillar collagen within 
articular cartilage. They are the only proteolytic enzymes that are capable of cleaving 
the three α1 chains of type I, II, and III collagen. Other MMPs can target and cleave 
collagen (MMP-2 and -14) but at an incomparable efficiency to the collagenases [40]. 
For more detailed information on collagenases see Table 1. Cleavage of collagen fibrils 
occurs at a glycine-isoleucine bond resulting in ¾ and ¼ fragments which in turn 
unwind at physiological temperatures, making them susceptible to further degradation 
by other less specific proteinases [9, 31]. Collagens provide high tensile stiffness and 
strength to the cartilage as well as heavily cross-linking with, and sequestering 
hydrated proteoglycans which allows cartilage to resist compression. As such, this is 
seen as the rate-limiting step in cartilage degradation as this cleavage leads to a 
cascade of proteolytic events which ends with the structural and functional loss of 
cartilage.   
1.5.1 Collagenases in arthritis 
All the collagenases have been demonstrated to be present in cartilage and are 
significantly elevated in both OA and RA articular cartilage [37, 41]. This is also true of 
the synovial fluid however levels are considerably higher in RA samples compared to 
OA [42]. This is in line with the differential pathologies, with RA cartilage degradation 
driven by MMP expression and secretion by the inflammatory infiltrate within the 
synovial lining.  The difference between these two arthritic diseases is not only evident 
in their respective pathologies but also by the differences in their MMP profile. This is 
because MMP13 is preferentially expressed by chondrocytes and MMP1 by synovial 
cells [9]. As such, current dogma implies that RA is mainly associated with MMP-1-
driven cartilage degradation whereas MMP-13 has a more important role in OA. 
Corroborating cartilage localisation studies demonstrate that MMP-13 is found in 
areas of cartilage degradation occurring at deep layers within the articular cartilage 
suggesting that proteolysis is chondrocyte-driven. Conversely, MMP-1 has been 
localised to cartilage degradation in the superficial layer adjacent to the invading 
pannus leading to cartilage degradation driven by synovial cells or chondrocytes in 
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response to pro-inflammatory cytokines released from the synovium, at the site of 
contact between synovial pannus and/or fluid and articular cartilage [37, 43-46].  
Although this paradigm is widely accepted, there is evidence to suggest a less specific 
association. Studies have shown that both MMP-1 and MMP-13 are co-localised in 
areas of type II collagen cleavage in samples of OA cartilage. The localisation of these 
collagenases was peri-cellular to chondrocytes demonstrating that it is indeed the 
chondrocyte that mediates collagen proteolysis but that this process is driven by not 
only MMP-13 but equally MMP-1 [47]. Expression studies also highlight that the 
deficiency between MMP-1 and MMP-13 ability to cleave type II collagen is negated by 
the fact that chondrocytes express around 10 times more MMP1 than MMP13 [45]. 
The assumption that cartilage degradation in RA is dependent on MMP1 expressed by 
synovial cells has also been called into question. Studies have shown that both 
collagen and proteoglycan loss is present throughout the cartilage of RA patient 
samples irrespective of age [48]. It has also been shown that destruction of cartilage at 
the pannus boundary is orchestrated by chondrocytes in response to pro-inflammatory 
cytokines released by the synovial cells [49] and even that MMP-1 is derived from the 
chondrocyte and not the pannus [50].  
These conflicting studies only serve to highlight that no definite rule can be applied to 
the orchestration of cartilage breakdown in either OA or RA and, whilst key to cartilage 
destruction, the disease-specific collagenase profile is not certain. 
The fact that MMP-1 and MMP-13 are not solely responsible for the proteolytic 
cleavage of collagen in either OA or RA is somewhat overlooked. A third collagenase, 
MMP-8 has been demonstrated to be up-regulated in cartilage samples taken from OA 
knees indicating that MMP-8 may well be important in the pathogenesis of OA [51, 
52]. However, previous study has shown that MMP8 is not expressed in HAC [53]. As 
such, it may well be other cell types, such as fibroblasts or infiltrating neutrophils [38], 
within the synovial joint that are implicated in the increased production of MMP-8 in 
disease.  
1.5.1.1 Other MMPs in Arthritis 
Though not seen to be as pivotal in cartilage breakdown, the other members of the 
MMP family have an association with arthritis. The gelatinases (MMP-2 and MMP-9) 
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are produced by the chondrocyte and are increased in OA articular cartilage [54]. Their 
substrate specificities differ from collagenases as they cleave different forms of 
collagen as well as denatured collagens generated through the actions of collagenases. 
It is suggested that gelatinases have a more crucial role in activation of pro-MMPs, like 
pro-MMP-13, rather than in collagenolysis which is modest [55].  
The matrilysins (MMP-7 and MMP-26) have also been shown to be elevated in OA 
cartilage, however their substrate specificity favours cleavage of proteoglycan rather 
than the structurally integral collagens within articular cartilage [54].  
The stromelysins (MMP-3 and MMP-10) have been demonstrated to be crucial in 
collaganolysis whilst only demonstrating substrate specificity to proteoglycans within 
ECM [56]. Found in arthritic joints, they are essential in activating latent pro-MMPs 
(including MMP-1, -7, -8 and -13) and are therefore key regulators of cartilage 
breakdown [28, 57]. Specifically, MMP-3 is a marker of disease activity in RA [58] and 
OA [59].    
Membrane-type (MT) MMP (specifically MMP-14 and -16) have both been shown to 
play a role in RA and OA pathogenesis. MMP-14 (MT1-MMP) is found in the superficial 
and middle cartilage zones of OA patient samples [60]. Synovial cells from RA patients 
as well as chondrocytes have also been demonstrated to express MT1-MMP [61, 62]. 
MMP-16 (MT3-MMP) shares a similar expression profile in RA tissues [63], however is 
not expressed by chondrocytes leading more to RA pathology than to OA [61]. They 
also have a common ability to cleave latent pro-MMP, for example MMP-13 [55], into 
its active form and whilst they have some collagenolytic capacity [64], MMP activation 
is suggested to be the more crucial function in disease pathology. 
1.6 Pro-Inflammatory Cytokines 
Although RA and OA are different in their pathogenesis the disease outcome is none-
the-less the same; irreversible cartilage degradation leading to pain and loss of joint 
function in the patient. Furthermore, this is driven, in-part, by a common pathway 
whereby chondrocytes produce pro-catabolic factors in response to a complex milieu 
of elevated pro-inflammatory cytokines produced in the joint locality. 
13 
 
As mentioned previously, TNFα was demonstrated to be important in inflammatory 
pathways in RA hence its therapeutic targeting. However, other pro-inflammatory 
cytokines have been shown to not only be elevated in both rheumatoid and 
osteoarthritic joints but also lead to chondrocytes releasing catabolic factors which 
degrade articular cartilage.   
1.6.1 Interleukin-1 
One of the first cytokines to be demonstrated to be within the synovial fluid of a RA 
joint was IL-1β [65]. The IL-1 family is composed of the peptides; IL-1α, IL-1β and IL-1 
receptor antagonist (IL-1ra). IL-1ra has no agonistic effect however it binds to both IL-1 
receptors in a similar configuration to IL-1α/β thus achieving its antagonism. Many cell 
types produce IL-1α/β including monocytes, osteoblasts, synovial cells and 
chondrocytes [37]. All the genes for the IL-1 cytokines and receptors are found on the 
long arm of chromosome 2. IL-1α/β initially exists as atypical 31kD pro-peptides which 
are cleaved to biologically active 17kD, mature forms. However, the pro-peptides have 
some activity, with pro-IL-1α exhibiting DNA binding capabilities and a capacity to act 
as an autocrine factor in some cell types. IL-1β is much less active as cleavage occurs 
extracellularly, unlike IL-1α which is cleaved intracellularly and released in an active 
form [66].  
There are two IL-1 receptors. Type I receptors are synthesised as an 80kD protein and 
type II as a smaller, 67kD protein. Both are monomeric transmembrane receptors, 
however, the shorter type II receptor has a small cytosolic component and as such has 
been termed a ‘decoy’ receptor as it has capacity to bind IL-1α/β yet lacks the 
structure to transduce an intracellular response [66]. When IL-1α/β binds, type I 
receptors recruit proteins called IL-1 receptor accessory proteins (IL-1AcP). These 
proteins facilitate the transduction of IL-1 signalling. Further recruitment of IL-1 
receptor-associated kinases (IRAK) and TNF receptor associated factor (TRAF) 
accessory proteins follows allowing initiation of several signalling pathways [67]. 
Within the context of disease, IL-1 has been demonstrated to be one of the key 
inflammatory mediators in RA and OA. Studies have shown that IL-1 co-localises with 
collagenases and other pro-inflammatory cytokines in areas where ECM depletion has 
been observed [7, 37]. In RA, IL-1 is also found to be significantly increased in the 
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synovial fluid and inflamed synovium compared to healthy joint [7, 68, 69]). 
Chondrocytes have also been shown to produce IL-1, suggesting a pathological 
autocrine function [37, 47, 70, 71]. The importance of IL-1 in the destruction of 
articular cartilage is shown in IL-1 stimulations of primary human articular 
chondrocytes (HAC) isolated from OA cartilage resulting in a significant increase in 
collagenase expression as well as marked cartilage degradation in mouse models and 
both bovine and human nasal cartilage [72-74]. 
1.6.2 Pro-Inflammatory Cytokine Synergy 
IL-17, -32 and -6 are among the other examples of elevated pro-inflammatory cytokine 
associated with arthritic disease. A common characteristic of a great number of these 
key mediators is their ability to synergise with one another to bring about a 
chondrocytic response greater than the sum of their individual effects. Many of these 
cytokines, including IL-1, TNFα and IL-17 have been shown to synergise amongst 
themselves and with Oncostatin M (OSM), a member of the IL-6-type cytokine family 
[75-77].  
 
1.6.2.1 Oncostatin M 
OSM, so named due to its discovery whereby it repressed the growth of cancerous 
cells, is a member of the IL-6-type cytokine family. Other members of this family, 
include leukaemia inhibitory factor (LIF), ciliary neurotrophic factor (CIF), 
cardiotrophin-1 (CT-1) and IL-11 as well as IL-6 itself. They share common structure 
and functional properties as well as an association with the glycoprotein (gp)130 
transmembrane receptor. OSM, like IL-1α/β is secreted as a pro-peptide which is 
cleaved resulting in the active cytokine [78]. This synthesis and secretion is observed in 
many different induced cells but is primarily produced in T cells, monocytes and 
macrophages [79]. Upon release into the extracellular space, IL-6-type cytokines 
generally bind to a α-chain receptor (IL-6, IL-11 and CNTF) which associate with a 
corresponding signal transduction subunit, which then results in heterodimerisation 
with a β-chain receptor (gp130, LIFR and OSMR). gp130 β-chains also have the capacity 
to form homodimers [80].  
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LIF and OSM exhibit a great deal of homology in both structure and biological actions. 
This is demonstrated in their neighbouring gene locations (27% sequence homology) 
and the ability of OSM to signal via binding of both OSM receptor/gp130 and LIF 
receptor/gp130 heterodimer receptors [80]. However, along with IL-6, only OSM has 
the ability to cause proteolytic breakdown of ECM. Furthermore, the distribution of 
these two heterodimers throughout cell types may offer an explanation as to why OSM 
brings about proteolytic ECM degradation and LIF does not. Studies of chondrocyte 
surface receptor profile using flow cytometry have shown the presence of gp130 and 
OSMR and the absence of LIFR [75]. Further study, showing that OSM but not LIF can 
signal through OSMR/gp130 heterodimer [81] highlights the potential biological 
actions of OSM in relation to chondrocytes [82]. 
In relation to disease OSM levels are elevated in both RA and OA synovial fluid [83, 84]. 
However, its pathological role is somewhat unclear. Contradictory evidence suggests 
that OSM has both pro- and anti-catabolic function. Research has shown that 
stimulation of HAC and chondrocytic cell lines with OSM leads to an increase in 
production of anti-catabolic factors called tissue inhibitors of metalloproteinases 
(TIMPs) [85]. These studies suggest that OSM is a “chondroprotective” cytokine. 
Conversely, other studies have shown pro-inflammatory and pro-catabolic function of 
OSM in murine models [84, 86, 87] and others have demonstrated that whilst there is 
an increase in TIMP there is also a corresponding increase in proteolytic enzymes 
maintaining the anabolic-catabolic balance within the cartilage [88]. However, the 
capacity for OSM to induce TIMP production by chondrocytes remains well established 
which only serves to highlight that the context of other cytokines is an important 
determinant as to whether a pro- or anti-inflammatory affect is likely. 
1.6.2.2 Interleukin-1 in combination with Oncostatin M 
Cawston et al [76] demonstrated that stimulation with IL-1α in combination with OSM 
of immortalized chondrocyte cell lines, bovine nasal cartilage and primary HAC led to a 
dose dependent increase in collagenase production and collagen fragment release 
from cartilage explants. A corresponding decrease in TIMP-1 release compared to 
control and IL-I and OSM independently was also shown. Other IL-6-type cytokines, 
other than IL-6+soluble receptor, do not share this synergistic ability [75]. These 
findings show that a combination of arthritis associated cytokines leads to a marked 
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increase in collagenase expression and release, a finding which is supported by many 
other studies [72, 73, 77, 82]. This may represent a significant contributing factor in 
the breakdown of type II collagen associated with cartilage degradation of the arthritic 
joint. 
It must be said that IL-1+OSM is by no means the only synergistic cytokine combination 
that has a marked increase on MMP expression in chondrocytes. Many cytokines other 
than IL-1 have been shown to synergise with OSM and IL-6+soluble receptor [75-77]. 
The reason for its use in the present study is because of the large body of work that 
has been built up around this specific synergy. With this work has come a great deal of 
understanding into the cellular events that occur in a synergistically stimulated 
chondrocyte. Perhaps most importantly, however, is that the pathology of the disease 
strongly suggests that it is a combination of the many significantly elevated cytokines 
rather than a single stimulus that brings about cartilage degradation in arthritis. 
Therefore, the IL-1+OSM cytokine combination offers a well-studied candidate for 
complex, pathological synergy. 
1.7 IL-1- and OSM-mediated cell signalling pathways 
1.7.1 MAPK 
In order for these previously mentioned pro-inflammatory cytokines to illicit a 
pathophysiological response by the chondrocyte (e.g. to produce cartilage degrading 
enzymes) there needs to be an intracellular transduction of this signal in order to 
induce transcription of collagenases. This has been demonstrated to occur through a 
number of cell signalling pathways within chondrocytes. The mitogen-activated protein 
kinase (MAPK) cascade is one such pathway. It consists of serine and threonine protein 
kinases that function to transduce signal (cytokine) from binding to a receptor residing 
on the cell membrane to a series of phosphorylation cascades that culminate in the 
activation of effector molecules such as transcription factors that induce transcription 
of certain genes. Three distinct pathways are encompassed within the MAPK, with 
their differentiation from one-another dependent on the downstream end point 
kinase that they activate; extracellular signal-regulated kinase (ERK), Jun N-terminal 
kinase (JNK) or p38 kinase. These three pathways have been specifically linked to 
transduction of pro-inflammatory cytokine signals which elicit collagenase induction 
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and/or cartilage destruction. JNK and p38 kinase pathways are associated with IL-1 and 
are implicated in MMP1 and MMP13 regulation in HAC [89, 90], observations which 
are supported by studies using p38 kinase inhibitors in which IL-1-mediated cartilage 
degradation was blocked by these compounds [91]. JNK inhibitors are less established 
but do show amelioration of adjuvant-induced arthritis in rats [92]. Mengshol et al [93] 
further demonstrated the importance of these MAPK pathways in IL-1-mediated MMP 
gene regulation in the chondrosarcoma cell line, SW1353 and in HAC. Inhibition of p38 
kinase led to the complete block of MMP13 expression in both cell populations with 
similar effects on MMP1 in SW1353. JNK inhibition led to a 60% decrease in IL-1 
induced MMP13 expression in SW1353 with no effect on MMP1 in chondrocytes. 
Complete suppression of IL-1-induced JNK-dependent collagenase expression was also 
demonstrated in synoviocytes treated with a novel JNK inhibitor. This inhibition 
translated to total abrogation of radiographic evidence of arthritis in treated mice [92]. 
The same study showed only modest effects with ERK inhibition. However, other 
studies implicate the ERK pathway in pro-inflammatory cytokine induced MMP 
expression in chondrocytes [94, 95]. Specifically, ERK inhibition and gene silencing with 
siRNA led to decreases in cartilage explant resorption and MMP13 expression, 
respectively [96, 97].  
1.7.2 Jak/STAT 
As previously discussed OSM exerts its effects on chondrocytes through binding to 
OSMR/gp130 heterodimer. This binding leads to recruitment of a Januse kinase (Jak) to 
the cytoplasmic tail of the receptor complex. Auto-phosphorylation of Jak and gp130 
follows and latent cytoplasmic signal transducer and activator of transcription (STAT) 
proteins are recruited to the receptor/Jak complex. Further tyrosine phosphorylation 
events on STAT lead to dimerisation allowing their translocation into the nucleus 
where they directly regulate transcription of genes [98]. Evidence for the involvement 
of this pathway in collagenase gene transcription is illustrated in studies where STAT 
inhibition led to decreased activation of a MMP1 promoter-luciferase construct [82]. 
Litherland et al [97] also demonstrated that STAT3 silencing with small interfering 
(si)RNA led to a significant decrease in MMP1 and MMP13 mRNA levels in IL-1+OSM 
stimulated HAC. Other studies have also demonstrated reduced STAT-1 
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phosphorylation and collagenase gene expression as a result of Jak inhibition in OSM-
stimulated chondrocytes [94]. 
1.7.3 Phosphatidylinositol 3-kinase (PI3K)/Akt pathway 
As well as Jak/STAT pathway, PI3K/Akt pathway is also involved in chondrocytic OSM-
dependent collagenase production. This pathway consists of lipid kinases that have 
been associated with large number of cellular functions that include the ability to 
activate Akt (Protein Kinase B). This kinase is a hub for a vast array of downstream 
events corresponding to cell function. This activation is brought about through a 
complex cascade of intracellular signalling events. Firstly the binding of a substrate to a 
receptor leads to the localisation of PI3K. The receptor being bound to dictates the 
class of PI3K which localises to the specific receptor: auto phosphorylation of tyrosine-
kinase receptors bring about the binding of class IA (catalytic subunit: p110α, β, and δ 
and regulatory subunit: p85 and p50-55), whilst uncoupling of G-protein receptors 
allows class IB binding (catalytic subunit: p110γ and regulatory subunit p84 or p101) 
[99]. These kinases then phosphorylate membrane-bound phosphatidylinositides. This 
generates phosphatidylinositides-3,4-biphoshate (PIP2) and PI-3,4,5-triphosphate 
(PIP3) allowing the binding and co-localising of Akt and 3-phosphoinositide dependent 
protein kinase-1 (PDK1) which results in the partial activation of Akt. Full activation is 
achieved through the actions of the mTOR (mammalian target of rapamycin) protein 
kinase and TORC2 (transducer of regulated CREB protein 2) [100], a co-activator of 
cyclic adenosine monophosphate (AMP) response element binding (CREB) 
transcription factor, a key MMP13 regulator [101, 102]. An insight into the importance 
PI3K/Akt pathway in the context of disease was demonstrated in mouse models. PI3K 
inhibition resulted in significant reduction in joint damage in RA models [103]. Studies 
into cell signalling events demonstrated that OSM-dependent MMP13 induction was 
down-regulated upon PI3K and Akt inhibition [96]. Further study silencing specific Akt 
and PDK isotypes in HAC highlight the potential for the differential regulation of 
distinct collagenases by these different isotypes following OSM stimulation and the 
complex signalling inter-play with other pro-inflammatory cytokines [104].     
1.7.4 PI3K/Protein Kinase C pathway   
The phosphorylation of PI bound to the membrane can also take a different cell 
signalling route and is not confined to Akt activation. PIP2 can act as a molecular 
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anchor for other signalling molecules. Phospholipase C (PLC) hydrolyses PIP2 into 
diacylglycerol (DAG) and inositol trisphosphate (IP3), which facilitate the opening of 
intracellular calcium channels and release of calcium from intracellular stores increase 
cellular calcium concentrations. The second messenger, calcium, then binds to the 
serine/threonine kinase, protein kinase C (PKC) allowing its activation by DAG. PKC can 
then activate RAF through dis-inhibition. RAF functions as a MAP3K initiating a 
phosphorylation cascade that activates ERK. As mentioned previously, the ERK MAPK 
pathway is important in signal induction culminating in collagenase expression in the 
chondrocyte. Study on isoforms of PKC showed that silencing of this kinase leads to 
diminished IL-1+OSM-dependent ERK phosphorylation and collagenase production in 
HAC [96, 97]. 
1.7.5 NF-κB 
The Nuclear Factor κB (NF-κB) pathway is another intracellular signalling pathway 
suggested to be involved in pro-inflammatory cytokine-dependent MMP regulation in 
chondrocytes. The NF-κB family of proteins share a Rel-homology domain within the N-
terminal region and a transactivation domain within the C-terminal region. The 
canonical pathway is activated by a number of stimuli including IL-1. This pro-
inflammatory stimulus leads to the activation of inhibitor of κB (IκB) kinase (IKK) 
complex leading to the subsequent phosphorylation of IκB which is bound to NF-κB 
dimers in the un-stimulated cell. This targets IκB for poly-ubiquitination and 
proteasomal degradation leaving free NF-κB. Dis-inhibition allows NF-κB dimer to 
translocate to the nucleus where it binds to DNA thereby regulating transcription of 
genes [67]. The blocking of components of this pathway has demonstrated that NF-κB 
does indeed have transcriptional control over collagenase expression post IL-1 
stimulation in synovial fibroblasts and both human and bovine chondrocytes [105-
108]. Furthermore, treatment of chondrocytes with NFκB inhibitors leads to the 
reduced production of MMP-1 and MMP-13 [109]. Conversely, other studies have 
demonstrated an increase in MMP1 gene expression with NFκB silencing in 
chondrocytes [110]. Contradicting studies of the NF-κB pathway and its regulation of 
collagenase genes suggest a regulatory role for NF-κB but as to whether or not this is 
positive or negative is yet to be determined.    
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1.8 Cis-regulatory elements and trans-activators 
The aforementioned cellular signalling pathways culminate in the activation of 
transcription factors (trans-activators) that work in concert, in order to regulate gene 
transcription. This is achieved through the binding to specific regions of DNA called cis-
binding elements which are conventionally just upstream of the gene being regulated. 
However the sites can also be found several kb upstream, within the 3’UTR or within 
an intron of the gene. The process of binding to these elements then allows the 
recruitment of transcriptional machinery containing numerous factors that initiate and 
perpetuate the transcription of a gene. 
The characterisation of collagenase cis-binding elements has given insight into 
transcription factors that potentially regulate their transcription. MMP1 and MMP13 
along with many other MMPs contain a TATA box approximately 30 base pairs (bp) 
upstream of the transcription start site (TSS) and a binding element for the family of 
transcription factors called Activating Protein (AP)-1 at approximately 70bp upstream 
of the TSS [111]. Other cis-element have been identified within the promoter regions 
of various MMP, for example Ets [111], NFκB [112], STAT [95], RUNX-2 [113] and Sp-1 
[114] DNA binding sites (Figure 5).  
  
Figure 5: Schematic of MMP-1 and -13 promoter regions.  Consensus transcription factor binding sites and the 
positions relative to transcription start site; SBE, STAT binding element; TIE, TGF-β inhibitory factor; S, Smad binding 
site; SAF-1, serum amyloid A-activating factor; OSE2, osteoblast-specific element-2; TBP, TATA binding protein; 
RNAP, RNA polymerase II complex. Taken from Rowan and Young [2] 
The profile of cis-binding elements within promoter regions is somewhat subjective to 
the individual MMP, providing an explanation for differential regulation of the 
members of this endopeptidase family. However, the majority of the proteinases 
contain at least one, if not several, AP-1 binding sites within the promoter region of 
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their genes. These AP-1 binding elements can be found within very close proximity to 
the TSS emphasising its potential in orchestrating the recruitment of co-factors 
necessary for transcription. Other AP-1 binding elements can also be found anywhere 
from within close proximity to the TTS to approximately 20kb upstream of the TSS 
[115]. Complemented by the fact that many of the aforementioned cell signalling 
pathways culminate in the activation/expression of many AP-1 members, these 
factors, therefore, play a crucial role in the regulation of collagenase expression 
following IL-1+OSM stimulation in chondrocytes.   
1.8.1 Immediate early genes 
Immediate early genes (IEG) encode numerous proteins involved in various cellular 
functions such as cell proliferation and differentiation. One of the most well 
characterised IEG is FOS (FBJ murine osteosarcoma viral oncogene homolog), which 
encodes c-Fos, a key binding partner in many AP-1 heterodimers. FOS, as well as many 
other IEG encode transcription factors and play a key role in controlling gene 
expression and the regulation of cellular function. All IEG are rapidly expressed in 
response to stimulation, a characteristic which is imparted by a number of regulatory 
controls; IEG are very short primary transcipts with very few, if any, exons and their 
promoter regions contain a great number of transcription factor binding sites and high 
affinity TATA boxes [116]; The structure of the chromatin associated with these genes 
is also open and therefore highly permissive to gene activation by transcription factors 
[117]; Moreover, transcriptionally active RNA polymerase II (pol II) is found in a 
‘paused’ state at the promoters of IEG ready to initiate transcription [118]; Finally, IEG 
require no de novo synthesis of proteins in order to bring about their expression [119] 
as such transcription factors that regulate their expression are constitutively present 
and therefore IEG can be expressed very rapidly following stimulation.  
However, because of the prominent role that these IEG have in regulating other genes 
that control cell cycle progression and apoptosis, strict cellular controls exist to make 
their rapid induction countered by a similarly rapid reduction. This serves to mitigate 
the response to the robust induction of IEG thereby preventing unregulated 
functioning synonymous with cancer development in which high, sustained levels of 
IEG correlate with cancer progression, angiogenesis and metastasis [117, 120]. The 
attenuation of IEG is controlled at a number of levels including mRNA and protein.  The 
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mRNA of IEG is very unstable which is conferred by active targeted degradation by 
RNA-binding proteins [121] but also by microRNA and RNA interference [122]. Protein 
products are also rapidly targeted for protesomal degradation [123]. Moreover, the 
transcription factors encoded by IEG also control their own expression via auto-
repression [124-126]. 
There are other groups of genes that do not require the de novo synthesis of proteins 
in order to allow their expression to take place. Delayed primary response genes [116] 
or ‘slow’ IEG [127] differ from IEG as they do not have many of the gene characteristics 
associated with IEG that confer rapid induction and therefore take longer to be 
expressed. As such it is proposed that IEG function as mediators of signalling in which 
their expression leads to the control of secondary response genes, which require de 
novo synthesis resulting from transcription factors encoded by IEG. Delayed primary 
response/’slow’ IEG may contribute to controlling the expression of secondary 
response genes or are themselves the effectors at the end of signalling. 
1.8.2 Activator Protein-1 
AP-1 transcription factor is an umbrella term used for a dimer that is predominantly 
made up from the Jun (proto-oncogene) (c-Jun, Jun B and Jun D) and Fos (c-Fos, Fos B, 
Fos-related antigen (Fra)-1 and Fra-2) protein families. Activating Transcription Factor 
(ATF) and Musculoaponeurotic Fibrosarcoma (MAF) members are also capable of 
heterodimerising with Jun and Fos members [128, 129]. These proteins display similar 
structural and functional properties which are conferred by the presence of an 
evolutionarily conserved basic leucine zipper (bZIP) domain [130]. This allows these 
proteins to dimerise with one another through the leucine zipper motif thereby 
forming a bipartite DNA-binding domain [131, 132]. AP-1 dimers control the 
transcription of many genes that contain an AP-1 consensus binding site, also known 
as TPA responsive element (TRE) (5′-TGAG/CTCA-3′) within their promoter and/or 
enhancer elements [133]. Other consensus sequences also exist that also provide a 
target for DNA binding by AP-1 dimers; the cAMP (cyclic adenosine monophosphate) 
responsive element (CRE) and the MAF-recognition elements (MAREs) [134]. These 
sequences are preferentially bound by different AP-1 heterodimers. For instance, Jun-
Fos heterodimers and Jun-Jun homodimers bind with greater affinity to TRE than CRE 
whereas ATF-Jun or ATF-ATF bind more readily to CRE [135]. The individual 
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components of these dimers also have varying trans-activating capacity with members 
such as Jun, Fos and Fos B considered strong activators whilst other members such as 
Jun B, Jun D, Fra-1 and Fra-2 displaying modest transactivation [136]. Moreover, the 
constituents of these dimers also govern their capacity to trans-activate gene 
promoters. Fos members are incapable of forming homodimers capable of binding to 
DNA [137] and therefore require heterodimerisation with Jun members to bind to DNA 
[137, 138]. However, Jun homodimers can bind to DNA yet lack the affinity with which 
Fos/Jun heterodimers bind [138]. As such the ability of these transcription factors to 
form any number of possible homo- or hetero-dimers, the preferential binding of 
those dimers and their ability to actually activate gene expression confers varying 
regulatory function in relation to different genes and therefore different cellular 
processes (Figure 6). 
 
Figure 6: Functions of AP-1 subunits in various cellular processes.  Adapted from Hess et al [136].  
Their main functional role within the body is that of control over genes involved in cell 
proliferation and differentiation. These genes include many of the key regulators of the 
cell cycle progression which include cyclins and cyclin-dependent kinases (CDK) [139]. 
The capacity for varying AP-1 dimer combinations and the level of regulation that this 
lends is characterised by the variety of cell types and the dimer-specific functions. For 
example, Jun family members are crucial for regulating the proliferation of 
keratinocytes and hepatocytes [136]. Likewise, Fos members have been demonstrated 
to play a key role in osteoblast/osteoclastogenesis [140, 141] and chondrogenesis 
[142] over that of Jun members. Contrasting roles within the protein families are also 
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evident. JunB inhibits proliferation in the context of lymphoid cells [143] but, in 
contrast, positively regulates growth in mouse fibroblasts [144] and the production of 
cytokines which drive differentiation in T Helper cells [145]. AP-1 also regulates 
apoptosis with Jun and Fos members often having contrasting apoptotic regulation 
within a number of different cell types.   
1.8.3 AP-1 and collagenase gene regulation  
AP-1 members have been demonstrated to be involved in normal cellular function 
such as chondrogenesis and act to balance catabolic and anabolic factors that remodel 
cartilage throughout the body. In the context of pathological cartilage degradation, a 
great deal of study has implicated AP-1 in the aberrant regulation and increased 
expression of collagenases in disease. This is demonstrated in immunohistochemical 
studies of patient synovium samples, that show correlation between c-Fos and active 
RA [146].  
General consensus strongly suggests that IL-1 stimulation of cells leads to the AP-1-
dependent trans-activation of many MMPs including collagenases through the MAPK 
pathways, JNK, p38 and ERK. Study has shown that increased MMP1/13 expression is 
due to ERK activation following IL-1 stimulation [93, 147, 148]. Cell lines that exhibit 
constitutively elevated MMP1 levels have been shown to do so via ERK1/2-dependent 
phosphorylation, activation and subsequent promoter binding of AP-1 [149]. Inhibition 
of PKC isoforms upstream of MEK in the ERK pathway lead to decreased collagenase 
expression and cartilage breakdown. Furthermore, AP-1 monomer, FOS mRNA and 
protein levels were shown to significantly decrease with ERK and PKC silencing. 
Decreased IL-1+OSM-dependent MMP1 and MMP13 mRNA expression was also 
demonstrated with FOS silencing [97]. The JNK pathway also leads to the activation of 
key AP-1 trans-activators such as c-Jun and ATF2 [150] and has also been clearly 
demonstrated to be important in IL-1-dependent MMP13 expression [93]. Cis-element 
mutations via transfected reporter studies have shown that p38, as well as JNK, are 
important in AP-1-dependent collagenase transcription following IL-1 stimulation in 
chondrocytes [113]. p38 has also been shown to increase the levels of c-Fos and c-Jun 
thereby directly contributing to transcriptional regulation of collagenases [151, 152].  
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Many studies have demonstrated how the direct binding of AP-1 elements to MMP 
genes is crucial for transactivation and expression [153-158]. Han et al  [92] showed 
that inhibition of IL-1-dependent JNK signalling pathways in synoviocytes resulted in 
decreased JUN expression, phosphorylation, accumulation and collagenase promoter 
binding. Martens et al [158] demonstrated that both c-Fos and c-Jun are transiently 
and rapidly enriched on MMP1 proximal promoter in chondrocytes and are vital 
components in the assembly of the pre-initiation complex that transcribes the gene.  A 
study by Aikawa et al [159] provides probably the most robust demonstration of the 
importance of AP-1 in the trans-activation of MMP within the context of arthritic 
cartilage degradation. In this study the authors synthesised an inhibitor of c-Fos/AP-1 
binding by 3D pharmacophore modelling through previous study which elucidated the 
X-ray crystal structure of AP-1-DNA complex [130]. Use of this inhibitor in both 
synoviocytes and chondrocytes stimulated with IL-1 led to significant reduction in 
MMP13. Administration of this inhibitor to mice with collagen-induced arthritis (CIA) 
resulted in >91% reduction in arthritis (blinded scoring of paws) with significant 
reduction in MMP13 expression in hind paws.   
Recent study has also highlighted an important role for enhancer regions in the 
regulation of collagenase. Enhancer elements are regions of DNA distinct from the 
proximal promoter regions that have binding sites for transcription factors that 
contribute to regulation. These elements are usually many kb away from the proximal 
promoter/TSS but dynamic structural changes in the chromatin allow folding, bringing 
a distal enhancer into close proximity to other transcription factors bound to the 
proximal promoter to effect full activation. Schmucker et al [115] demonstrated that a 
-20kb distal enhancer region is crucial for IL-1-dependent MMP13 induction in 
chondrocytes. ChIP revealed binding of not only c-Fos and c-Jun to this site but also 
markers of active transcription, H3K4me2 and AcH4 modifications and pol II. 
Chromatin conformation capture (3C) highlighted an association between this 
enhancer element and the proximal promoter. Reporter studies then showed a 
recapitulation of endogenous IL-1-dependent MMP13 expression when the enhancer 
region was combined with the proximal promoter region of MMP13.       
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1.8.4 Other tran-activators and collagenase gene regulation 
In the case of Jak/STAT and NFκB pathways the transduction of signal through 
cascading phosphorylation events culminates with direct activation of pathway-specific 
transcription factors. A STAT binding element is found near the proximal AP-1 binding 
element in the MMP1 promoter [160]. STAT-1 has been demonstrated to be involved 
in collagenase regulation as Jak inhibition in chondrocytes leads to decreased STAT-1 
phosphorylation and binding to MMP1 and MMP13 [94]. Inhibition of STAT-3 as well as 
direct STAT3 gene silencing leads to significant reduction in collagenase expression in 
HAC [82, 97]. However, direct binding to the MMP1 STAT element in chondrocytes was 
unable to be shown. Interestingly though, STAT-3 activation was still required for 
transcriptional activation despite lacking the capacity to bind to the promoter of 
MMP1 [82]. It is suggested that it is the indirect effect of STAT-3 on FOS expression 
that plays a role in collagenase transcription.  
NF-κB has also been shown to have a role in IL-1-dependent collagenase transcription, 
as discussed above. As with STATs, NFκB has a cis-element in the MMP1 promoter but 
at nearly 3kb upstream of the TSS this is most likely in an enhancer region which is 
looped into proximity with trans-activation. Although studies have demonstrated NFκB 
binding to this site following IL-1 stimulation [112], binding in chondrocytes has yet to 
be demonstrated. 
The tissue-specific transcription factor, Runx-2 (runt-related transcription factor-2) is 
crucial in osteoblast and chondrocyte differentiation and skeletal morphogenesis 
[161], co-ordinating the resorption of cartilage into bone during development. Study 
has also demonstrated the pathological role of Runx-2 in MMP13 transcription 
following IL-1 stimulation of the chondrocyte. It demonstrates that MMP13 induction 
by IL-1 required Runx-2 and that binding of Runx-2 to a conserved binding site -138bp 
from the TSS in combination with JNK-dependent AP-1 binding acted synergistically to 
induce MMP13 expression [113].   
1.9 Epigenetic regulation  
The culmination of cell signalling events to the binding of the trans-activators to cis-
elements is an important process yet sits amongst many other regulatory steps: 
Chromatin remodelling, assembly of the machinery necessary for transcription, mRNA 
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splicing and post-transcriptional modifications all exist to exercise control over the 
production of proteins that ultimately control cellular function.  
1.9.1 Chromatin remodelling  
The transcription of genes is regulated at a number of different levels. Regulation at 
points post transcription factor activation is limited by the accessibility of the gene. 
Chromatin is the structure formed by association of DNA with histone octamers (H2A, 
H2B, H3 and H4 in duplicate) at regular intervals of approximately 150bp wound 
around the histone core to form what is known as a nucleosome. Packaging of the DNA 
into nucleosomes increases the stability and prevents damage of the DNA at the same 
time compressing the entire genome within the confines of the cell nucleus. What 
regulates the access of transcriptional machinery to genes within the DNA is governed 
by the state of the chromatin, a role which represents an important regulatory step in 
transcription. Modifications of these histones around which DNA is wound allows this 
otherwise very stable complex to dynamically remodel in order to allow access to 
genes within the DNA. Euchromatin, the open-unwound form of chromatin is brought 
about through histone modifications of specific amino acid residues on histone tails 
(e.g. lysine, serine, and threonine) that include methylation, acetylation, ubiquitination 
and phosphorylation. An ATP-dependent chromatin remodelling complex, SWI/SNF 
can also facilitate transcription factor access [162]. These modifications act to alter the 
charge of the histones thus repelling the negatively charged DNA and opening the 
chromatin. Conversely, other modifications such as methylation events on histone (H) 
3 lead to the re-coiling of chromatin into heterochromatin which masks genes. These 
modifications are targeted events thus allowing distinct regions of chromatin i.e. 
around specific genes to open, allowing access to the gene. These modifications have 
also been proposed to act as targets for proteins that play a role in transcriptional 
regulation [163]. 
Once this euchromatin state is achieved, transcription factors can bind to specific 
sequences within the promoter regions of these revealed genes.  These binding sites 
are often in a region slightly upstream of the transcription start site of the gene where 
there is a low level of nucleosome occupancy [164]. This binding brings about the 
recruitment of co-activator complexes that both further remodel the chromatin to 
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allow the access of factors necessary for transcription to the proximal promoter and 
allow greater binding of other co-activators to initiate transcription [165].  
1.9.2 The Transcriptional Cycle 
 
Figure 7: Recruitment of transcriptional machinery to gene promoter.  Adapted from [166] 
1.9.2.1 Initiation 
Transcription initiation is a complex process of factor recruitment in a carefully 
orchestrated manner in order to bring together all the transcriptional machinery 
necessary for transcription (Figure 7). Firstly, a pre-initiation complex (PIC) is formed. 
This consists of the enzyme pol II along with various general transcription factors (GTF) 
and the Mediator complex. Core promoter binding is governed by TFIID and TATA 
binding protein (TBP). Whilst the PIC remains promoter bound it is prone to abortive 
initiation in which only small nascent RNA transcripts (2-3 nucleotides) are produced. 
In order to allow promoter escape the C-terminal domain (CTD) of pol II must undergo 
ser 5 phosphorylation which in turn recruits RNA capping machinery to modify the 5’ 
end of the nascent RNA transcript [167]. This stabilises the short transcript allowing 
rearrangements of the GTFs within the PIC. Increasing transcript length and the 
association of RNA to DNA infers greater complex stability [168, 169]. This stabilised 
complex can now facilitate the transition into the next phase of transcription. 
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1.9.2.2 Elongation 
Elongation is initiated by the ser 2 phosphorylation on the CTD of pol II by Positive 
Transcription Elongation Factor b (P-TEFb) [170]. This leads to an alteration in the 
profile of GTF that constitute the PIC and removes the inhibition of negatively 
regulating factors that normally keep the pol II in a paused state. Highly stable 
productive elongation then ensues, concerting RNA production with transcript 
processing events that splice intron-containing pre-mRNA to mature mRNA which is 
then translated to protein. Once the elongating pol II complex reaches the end of the 
gene transcription is terminated through nascent transcript cleavage and 3’ 
polyadenylation and enzyme release from template DNA [171].  
1.9.3 Epigenetic regulation of collagenase genes 
Transcriptional regulation of collagenases is by no means solely governed by the 
binding of transcription factors to DNA. Study has demonstrated that acetylation of 
histones is an important step in allowing collagenase gene induction to occur. IL-1 
stimulated HAC were treated with the Histone de-acetylase (HDAC) inhibitor, 
Trichostatin A (TSA) resulting in genome-wide increase in histone acetylation. This 
allows for more permissive DNA which was reflected in an increase in MMP1 and 
MMP13 gene expression, collagenolysis and subsequent explant degradation [172, 
173]. With regards to disease, the expression of HDACs in normal and OA cartilage is 
somewhat unclear with studies showing opposing expression [174-176]. 
DNA methylation is another epigenetic modification that acts to regulate gene 
transcription. The addition of a methyl group by DNA methyl transferases (DNMT) to 
the cytosine within cytosine phosphodiester guanine (CpG) dinucleotides leads to 
repression of gene expression. DNA methylation is associated with distinct regions 
within the promoters of genes, called CpG islands. These islands, that vary in size from 
as little as 200 bp to several 1000 bp in length, have a GC percentage of >50% and are 
present in approximately 40% of all mammalian gene promoters [177, 178]. The exact 
mechanism by which methylation represses transcription is not fully understood: 
Methyl groups may act to prevent the binding of transcription factors to the DNA. 
Alternatively, these modifications may provide new binding sites for proteins that 
orchestrate co-repressors and HDACs in bringing about chromatin condensation [179]. 
In disease, DNA methylation has been suggested to play a role in the pathologies of 
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both RA [180] and OA [181, 182]. With regards to collagenase expression, Roach et al 
[183] showed that the MMP13 promoter in OA chondrocytes had a significant 
decrease in methylation. Further study demonstrated that CpG islands in the MMP13 
proximal promoter of HAC have decreased methylation which affects its transcriptional 
activity leading to an increase in MMP13 gene expression [102, 184].  
 
1.10 Summary and aims of the study 
The cleavage of type II collagen and subsequent cartilage degradation represents a 
threshold in the pathological progression of arthritic disease. Type II collagen is the 
main structural component of articular cartilage which imparts tensile strength to the 
tissue. It also acts as a scaffold in which proteins called aggrecan are held, providing 
resistance against compression following joint loading. These two molecules are 
therefore crucial to the healthy functioning of cartilage in the articulating joint. Pain 
and disability in patients which follow irreparable damage to cartilage architecture 
comprise a series of events that stem from aggrecan loss and type II collagen 
destruction.  
The collagenases, MMP-1 and MMP-13 are responsible for this process. In cartilage 
degradation associated with arthritic disease, the physiological role of MMP-1 and 
MMP-13 in subtly remodelling cartilage in response to joint loading is replaced by 
aberrant proteolytic events. Taken together with the lack of opposing anabolism and 
the slow recapitulation of cartilage architecture, the cleavage of type II collagen by 
MMP-1 and MMP-13 is a threshold event leading to irreversible disease progression.  
The chondrocyte, which resides within the articular cartilage, orchestrates not only 
normal remodelling but also pathological cartilage destruction. The latter, is a direct 
result of collagenase production by the chondrocyte in response to elevated levels of 
pro-inflammatory cytokines such as IL-1 and OSM in arthritic patients.  
The transduction of pro-inflammatory cytokine signals into excessive collagenase 
production by the chondrocyte is achieved by many cell signalling pathways, which is, 
in-part, due to the cytokine milieu found in disease. Therefore, when trying to 
attenuate collagenase expression by the chondrocyte the targeting of any one 
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pathway can be ineffective. Moreover, broad spectrum inhibition of MMP is equally 
ineffective due to the lack of specificity. 
The inflammatory response mediated by cytokines and tissue remodelling by MMP are 
homeostatic processes that serve to maintain normal physiological function in the 
body. As such, interventions that are intended to reduce cartilage degradation by the 
reduction of MMP expression need to be as specific as possible. I postulate that 
specificity may be gained at the level of gene regulation. All genes contain a specific 
binding element profile in their promoter region and so only certain transcription 
factors can bring about the transcription of certain genes. A greater understanding of 
these factors, crucial to gene regulation of the MMPs that degrade cartilage, could 
therefore help to develop more targeted intervention. 
AP-1 transcription factor family members are ubiquitous proteins that regulate many 
genes throughout the body. Previous study has demonstrated the necessity of AP-1 
heterodimer c-Fos/c-Jun for efficient collagenase transcription. However, targeting this 
ubiquitous regulating factor would lack specificity, as with direct MMP inhibition.  
In the following study I intend to better understand how c-Fos and c-Jun are 
contributing to the regulation of the collagenase genes, MMP1 and MMP13 following 
pro-inflammatory cytokine stimulus. With an improved knowledge I hope to be able to 
elucidate the mechanisms by which different MMP are regulated and therefore how 
the expression of specific MMP can be reduced in arthritic disease.  
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2 Chapter 2: Materials and Methods 
 
2.1 Materials 
2.1.1 Antibodies 
Antibody (Dilution for WB) Source Product code 
Acetyl-Histone H3 Millipore 06-599 
ATF3 (1/500) Santa Cruz Tech (SC) sc-188 
AXUD1 (1/500) SC sc-81191 
Caveolin (1/2000) Cell signalling (CS) 3238 
c-Fos (1/500) SC sc-7202 
c-Jun (1/500) SC sc-1694 
c-Jun-phospho ser63 (1/500) SC sc-7908-R 
EGR2 (1/1000) Epitomics 3172-1 
GAPDH (1/40000) CS 2118 
Histone H3 (1/2000) CS 9715 
Lamin A/C (1/10000) CS 4777 
NFATc1 (1/500) SC Sc-7294 
RNApolII-phospho CTD ser5 Abcam ab5131 
β-tubulin (1/2000) CS 4967 
 
Table 2: Detailed list of antibodies used in study 
Antibody isotype controls, rabbit and mouse IgG from sera were purchased from 
Sigma-Aldrich (Poole, UK) and mouse monoclonal IgG was a kind gift from Dr Jelena 
Mann.  
2.1.2 Cytokines 
IL-1α was a gift from Dr Keith Ray (GlaxoSmithKline, Stevenage, UK) and was stored at -
20 °C until use. Recombinant OSM was made in-house (method described in Staunton 
et al [185]) at a concentration of 60 µg/ml in Dulbecco’s phosphate buffered saline 
(DPBS) (with 0.1% bovine serum albumin (BSA)) and stored at -80 °C. Phorbol 12-
myristate 13-acetate (PMA) was obtained from Sigma-Aldrich. Immediately prior to 
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use IL-1α, OSM and PMA were diluted to appropriate working concentrations in 
culture medium. 
2.1.3 Cell and Tissue Culture Reagents 
Dulbecco’s modified Eagle’s medium (DMEM), DMEM-F12, foetal bovine serum (FBS) 
and nystatin were obtained from Gibco BRL (Paisley, UK). L-Glutamine, penicillin-
streptomycin and trypsin (type III, from bovine pancreas) were obtained from Sigma-
Aldrich. Plates (96-well and 6-well) and vented cell culture flasks (75 cm2 and 162 cm2) 
were obtained from Corning/Costar UK Ltd. (High Wycombe, UK). Sterile, vented 100 
mm cell culture dishes and universals (20 ml and 5 ml) were obtained from Greiner Bio-
One (Gloucestershire, UK). Centrifuge tubes, 50 ml and 15 ml were obtained from 
Corning/Costar UK Ltd. 50 ml syringes were obtained from Scientific Laboratory 
Supplies Ltd. (Nottingham, UK) and syringe driven 0.22 µm filters were obtained from 
Millipore. DPBS was obtained from Lonza (Wokingham, UK). Hyaluronidase (from 
bovine testes; 439 U/mg), trypsin (from porcine pancreas; 1020 U/mg) and collagenase 
(from Clostridium histolyticum type I; 125 U/mg) were obtained from Sigma-Aldrich. 
Cell Strainers (100 µm) were obtained from Scientific Laboratory Supplies (Nottingham, 
UK).  
2.1.4 Commercially available kits 
RNeasy Mini Kit, QIAShredder and QIAQuick PCR Purification Kit were purchased from 
Qiagen (Crawley, UK).  EZ-ChIP Kit: Chromatin Immunoprecipitation Kit was purchased 
from Millipore. Subcellular Protein Fractionation Kit and NE-PER Nuclear and 
Cytoplasmic Extraction Reagents were obtained from ThermoScientific (Loughborough, 
UK). ToxiLight BioAssay Kit: Non-Destructive Cytotoxicity Assay was purchased from 
Lonza. Taqman gene expression assays were purchased from Applied Biosystems (CA, 
USA). Universal ProbeLibrary System was obtained from Roche Diagnostics (Burgess 
Hill, UK). 
2.1.5 Immunoblotting Reagents 
BSA, ammonium peroxodisulphate (APS), -mercaptoethanol (β-ME), N,N,N’N’-
tetramethylenediamine (TEMED), 1,10-phenanthroline and polyoxyethylenesorbitan 
monolaurate (Tween 20) were obtained from Sigma-Aldrich. 40% (w/v) acrylamide/bis-
acrylamide (37.5:1) solution was obtained from Amresco (OH, USA). PageRuler 
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prestained protein ladder was purchased from ThermoScientific. Enhanced 
chemiluminescence (ECL) western blot detection reagents were obtained from 
Amersham Biosciences (Little Chalfont, UK). Immobilon Western Chemiluminescent 
horseradish peroxidase (HRP) substrate was purchased from Millipore. Reagents for 
the iBlot gel Transfer System were purchased from Invitrogen (Paisley, UK). Bradford 
ULTRA was purchased from Novexin (Invitrogen). 
2.1.6 Cell Lines 
SW1353 chondrosarcoma cell lines were purchased from the American type culture 
collection (ATCC). They are derived from a primary grade II chondrosarcoma of the 
right humerus obtained from a 72 year old female Caucasian. SW1353 cells were 
cultured in DMEM-F12 containing 10 % (w/v) FBS, 2 mM L-glutamine, 200 IU/ml 
penicillin, 200 µg/ml streptomycin and 40 IU/ml Nystatin.  
2.1.7 Biochemical Reagents 
Glycine, sodium chloride, sodium dodecyl sulfate (SDS) and tris-hydrochloric acid were 
purchased from Sigma-Aldrich. Phenol:chloroform:isoamyl alcohol 25:24:1 saturated 
with 10 mM Tris, pH 8.0, 1 mM ethylenediaminetetraacetic acid (EDTA) was purchased 
from BDH. 
2.1.8 Molecular Biology Reagents 
SideStep Lysis and Stabilisation Buffer was purchased from Agilent Technologies (CA, 
USA). Cells-to-cDNA II was purchased from Ambion (Invitrogen). Real-time polymerase 
chain reaction (PCR) primers and probes were purchased from Sigma-Aldrich. 
SuperScript III Reverse Transcriptase, Moloney Murine Leukemia Virus (MMLV) reverse 
transcriptase and RNase OUT were purchased from Life Tech (Invitrogen). RQ1 RNase-
free DNase was purchased from Promega (Southampton, UK). SYBR green PCR Master 
Mix and Titanium Taq polymerase were purchased from Clontech (Paris, FR). Taqman 
Fast Universal PCR Master Mix (2x) and Taqman Universal Master Mix II were 
purchased from Applied Biosystems. Agarose (electophoretic grade) were purchased 
from Invitrogen. RNase- and DNase-free water was purchased from Sigma-Aldrich. 
Protein synthesis inhibitor, emetine (dihydrochloride) and transcription inhibitor, 
actinomycin D were purchased from CalbioChem (Merck Chemicals Ltd, Nottingham, 
UK). Protein A and Protein G agarose beads were purchased from Santa Cruz 
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Biotechnology Inc. (Heidelberg, Germany). Dharmacon ON-TARGET plus SMARTpools 
siRNAs, Dharmacon ON-TARGETplus Non-targeting Pool control siRNA and 
DharmaFECT 1 Transfection reagent were purchased from ThermoFisher Scientific.  
FlexiTube siRNA GeneSolution and FlexiPlate siRNA were purchased from Qiagen. 
Complete protease inhibitor Mini tablet was purchased from Roche Diagnostics. 
2.2 Methods 
2.2.1 Cartilage Sample Collection 
Human articular cartilage samples were obtained from patients with osteoarthritis 
undergoing total hip and total knee replacement surgery at the Freeman Hospital, 
Newcastle Upon Tyne. Appropriate informed consent and ethical approval was 
obtained prior to surgery. Samples were stored at 4° C in Hank’s Balanced Salt Solution 
(HBSS) (Lonza), supplemented with 200 IU/ml penicillin, 200 µg/ml streptomycin and 
40 IU/ml nystatin and were assessed for tissue viability within 24 hours post-surgery.  
2.2.2 Chondrocyte Extraction and Culture 
Human cartilage samples from patients undergoing knee and hip replacement surgery 
were used as a source of chondrocytes for subsequent in vivo and in vitro experiments. 
Sequential enzymatic digestion of ECM using hyaluronidase (for hyaluronan), trypsin 
(for aggrecan) and collagenase (for collagen) released articular chondrocytes allowing 
them to be cultured in monolayer.  
Reagents: 
 Phosphate buffered saline (PBS) containing 200 IU/ml penicillin, 200 µg/ml 
streptomycin and 40 IU/ml nystatin 
 DMEM culture medium containing 10% (w/v) FBS, 2 mM L-glutamine, 200 IU/ml 
penicillin, 200 µg/ml streptomycin and 40 IU/ml nystatin 
 Hyaluronidase (1 mg/mL in PBS, 5 ml/g cartilage) 
 Trypsin (2.5 mg/mL in PBS, 5 ml/g cartilage) 
 Collagenase (2.5 mg/mL in DMEM containing 10% FBS, 3 ml/g cartilage) 
 
Macroscopically normal cartilage tissue was removed from the sub-chondral bone and 
washed with PBS containing antibiotics. Cartilage was then cut into small pieces with a 
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scalpel thereby allowing a greater surface area for complete enzymatic digestion and 
placed in a 50 ml Falcon. The weighed cartilage was then washed three times with 
excess PBS. Cartilage was then incubated with hyaluronidase at 37 °C for 15 minutes 
with rotation. The hyaluronidase was then removed and cartilage was washed, three 
times with PBS. Cartilage was then incubated with trypsin at 37 °C for 30 minutes with 
rotation. The trypsin was removed and the cartilage was washed three times with 
excess DMEM+FBS. Cartilage was then incubated with collagenase at 35.5 °C 
overnight. The next morning the product of the enzymatic digestion was passed 
through a 100 µm Cell Strainer (BD Falcon) and centrifuged at 400 g for 5 minutes. The 
collagenase-containing DMEM was then aspirated from the chondrocyte pellet which 
was then resuspended in an excess of PBS to remove any residual collagenase and 
centrifuged as before. The PBS was then aspirated and the pelleted chondrocytes 
resuspended in DMEM+FBS.   
2.2.3 Cell Culture  
Following extraction from ECM, chondrocytes were required to be cultured in growth 
medium in order to allow the cells to adhere to the tissue culture surface they were 
placed on. Primary cells where then cultured until in growth phase and approximately 
70-80 % confluent. The chondrocytic cell line, SW1353, was mainly used for ChIP 
optimisation.  
Growth media:  
 HAC: DMEM culture medium containing 10% (w/v) FBS, 2 mM L-glutamine, 200 
IU/ml penicillin, 200 µg/ml streptomycin and 40 IU/ml nystatin 
 SW1353: DMEM-F12 culture medium containing 10% (w/v) FBS, 2 mM L-
glutamine, 200 IU/ml penicillin, 200 µg/ml streptomycin and 40 IU/ml nystatin  
Method: Isolated human articular chondrocytes and SW1353 cell lines were seeded at 
a density of 40,000 cells/cm² in 96-well plates, 6-well plates, 10cm cell culture dishes, 
T75 cm² or T25 cm² culture flasks. Cells were then cultured until 80-90% confluent at 
37°C in 5% (v/v) CO2/humidified air. Prior to cytokine stimulation, culture medium was 
removed and cells washed of any remaining serum with PBS. Cells were then cultured 
overnight in serum-free DMEM. 
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2.2.4 Real-time PCR  
2.2.4.1 Taqman® Probe-Based Real-Time RT-PCR 
This method of measuring mRNA expression of cells in culture relies on a gene specific 
fluorescent probe that lends this technique a greater degree of specificity and 
proportionality. The fluorescent probe binds to the region between the gene specific 
primers. The probe consists of a fluorophore at the 5’ end and a quencher molecule at 
the 3’ end. As the Taq polymerase extends the primer, the 5’ to 3’ exonuclease activity 
of the enzyme cleaves the 5’ fluorophore. This spatially dissociates the fluorophore 
from the quencher allowing fluorescence. Fluorescence is therefore directly 
proportional to the amount of product produced in the PCR reaction, thereby allowing 
quantification without interference from non-specific products or primer-dimer. To 
normalise for different amounts of total RNA present in each sample, 18S ribosomal 
(r)RNA was used as an endogenous control. Oligonucleotide primers and probes were 
designed using Primer Express 1.0 (Applied Biosystems) and probes from the Universal 
Probe Library (UPL) purchased from Roche. See Table 3 and Table 5 for details on 
gene-specific primers and UPL probes. All reactions were performed using the ABI 
7900HT Fast Real-Time PCR system. 
Reagents: 
 TaqMan Fast Universal PCR Master Mix (2x) 
Method: cDNA (4 µl/well) was placed into a Fast Optical 96-well reaction plate. To this, 
5 µl of TaqMan Fast Universal PCR Master Mix (2x) was added along with 0.2 µl of 
forward and reverse primer (at a final concentration of 300 nM each) and 0.1µl of 
probe (at a final concentration of 150 nM) making a 10 µl reaction volume. This was 
then subject to an initial denaturation stage (95 °C for 20 seconds) followed by 40 
cycles of 95 °C for 1 seconds and 60 °C for 20 seconds.  
2.2.4.2 SYBR Green Real-Time PCR 
In this PCR method SYBR green II dye intercalates into all double-stranded DNA. In this 
state dye has increased fluorescence compared to the unbound dye. As the 
amplification reaction occurs the dye is incorporated into all new double-stranded 
DNA. As such the level of fluorescence is directly proportional to amount of double-
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stranded DNA present, which in an efficient and stringent reaction should be almost all 
amplimer, see Table 4 for details on gene-specific primers. All reactions were 
performed using the ABI 7900HT Fast Real-Time PCR system. 
Reagents: 
 SYBR Green PCR Master Mix (2x) 
Method: cDNA or gDNA, (1µl/well), depending on the upstream technique used, was 
placed into a Fast Optical 96-well reaction plate. To this, 5 µl of SYBR Green PCR 
Master Mix (2x) was added along with 0.1 µl of forward and reverse primer (at a final 
concentration of 10 nM) and 3 µl of RNase- and DNase-free water making a 10 µl 
reaction volume. This was then subject to an initial denaturation stage (95 °C for 30 
seconds) followed by 40 cycles of 95 °C for 5 sec and 60 °C for 30 seconds. All SYBR 
Green Real-Time PCR reaction contained an end dissociation stage (95 °C for 15 
seconds, 60 °C for 15 seconds and 95 °C for 15 seconds) to assess amplification product 
for primer-dimer or secondary structures, as shown in Figure 8. 
 
Figure 8: Screen capture image of dissociation stage following SYBR green real-time PCR. Examples of primer-
dimer (left) and secondary structures (right) highlighted in red.  
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Gene Sequence (5’-3’)  Probe 
18s For: 
CGAATGGCTCATTAAATCAGTTATGG 
Rev: 
TATTAGCTCTAGAATTACCACAGTTA
TCC 
FAM-
CAGAGAGTACAACTTACATCGTGTTGC
GGCTC-TAMRA 
MMP-1  For: 
AAGATGAAAGGTGGACCAACAATT 
Rev: CCAAGAGAATGGCCGAGTTC 
FAM-
CAGAGAGTACAACTTACATCGTGTTGC
GGCTC-TAMRA 
MMP-13 For: 
AAATTATGGAGGAGATGCCCATT 
Rev: 
TCCTTGGAGTGGTCAAGACCTAA 
FAM-
CTACAACTTGTTTCTTGTTGCTGCGCAT
GA-TAMRA 
 
Table 3: TaqMan Real-time PCR primer and probe sequences. 
 
Gene Region Sequence (Distance from TSS) 
MMP-1 Proximal 
promoter/transcription start 
site 
For: TCAGTACAGGTGCCGAACAG (-431) 
Rev: CAAGATGTGTGCGAAGGAGA (-207) 
3’ untranslated region (UTR) For: ACTGAATGGGCAAAAACTGG (+8042) 
Rev: TGCAAACAGGGACAATTTGA (+8139) 
MMP-
13 
Proximal 
promoter/transcription start 
site 
For: GAAAAAGTCGCCACGTAAGC (-116) 
Rev: CGACAATGAGTCCAGCTCAA (+62) 
3’ untranslated region (UTR) For: TCGGCACAAAATACAGGTCA (+15750) 
Rev: GCCTCCCCTTTTTAGACCAC (+15932) 
 
Table 4: SYBR Real-time PCR primer sequences. 
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Gene Sequence (5’-3’) Universal Probe Library 
Probe number 
ATF3 For: TTTGCCATCCAGAACAAGC 
Rev: CATCTTCTTCAGGGGCTACCT 
53 
AXUD1 For: CCTGCCTGACCGTGACTT  
Rev: AGCCCGCTTCAGGATAGAC 
57 
BMP2 For: GACTGCGGTCTCCTAAAGGTC 
Rev: GGAAGCAGCAACGCTAGAAG 
49 
BTG2 For: GCGAGCAGAGGCTTAAGGT 
Rev: 
GGGAAACCAAGTGGTGTTTGTA 
1 
EGR1 For: AGCCCTACGAGCACCTGAC  
Rev: GGTTTGGCTGGGGTAACTG 
22 
EGR2 For: TGGTTTCTAGGTGCAGAGACG 
Rev: 
TGGTTTCTAGGTGCAGAGAGACG 
3 
EGR3 For: CAATCTGTCACCCCGAGGAGA 
Rev: CAGACCGATGTCCATTACATTC 
74 
FOSB For: TCTGTCTTCGGTGGACTCCT 
Rev: GTTGCACAAGCCACTGGA 
20 
FOSL1 For: AACCGGAGGAAGGAACTGAC 
Rev: CTGCAGCCCAGATTTCTCAT 
4 
HIF1A For: CAGCTATTTGCGTGTGAGGA 
Rev: TTCATCTGTGCTTTCATGTCATC 
89 
IER2 For: TGTCAGTGGAAAGGCATAAGG 
Rev: AGATTGGCCCAGTTTCACC 
54 
IER3 For: 
GGGTCGTAAGTTTAGGAGGTGA 
Rev: CGCCGAAGTCTCACACAGTA 
88 
IER5 For: GTCGGGGACGTTTTTCAG 
Rev: GCTCAGAAGGCCACGATG 
1 
JUN For: CCAAAGGATAGTGCGATGTTT 
Rev: CTGTCCCTCTCCACTGCAAC 
19 
JUNB For: CACAAGATGAACCACGTGACA 
Rev: GGAGTAGCTGCTGAGGTTGG 
10 
NFATC1 For: CCAAGGTCATTTTCGTGGAG 
Rev: GGTCAGTTTTCGCTTCCATC 
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Table 5: TaqMan Real-time PCR primer sequences and corresponding UPL probe numbers. 
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2.2.5 RNA extraction and reverse transcription 
Prior to PCR, mRNA/RNA was extracted from cultured cells and converted to cDNA. 
This allows Taq Polymerase to synthesize amplicons of a specific region allowing 
quantification. RNA was extracted from HAC using SideStepTM Kit for cells cultured in 
96-well plates and RNeasy® Mini Kit (Qiagen) for cells cultured in 6-well plates and 
using Cells-to-cDNA for SW1353. 
Reagents: 
 SideStep Lysis and Stabilisation buffer  
 RNeasy® Mini Kit  
 RNaseOUT™ Recombinant Ribonuclease Inhibitor  
 SuperScript® III Reverse Transcriptase  
 MMLV Reverse Transcriptase  
2.2.5.1 RNA extracted using SideStep Kit    
Method: Following appropriate culture, serum-starvation and cytokine stimulation, 
HAC cultured in a 96-well plate were placed on ice. Cytokine-containing DMEM was 
aspirated from all the wells. Each well was then washed twice with an excess of ice-
cold PBS aspirating PBS after each wash. SideStep Lysis Buffer (20 µl/well) was added, 
the plate sealed with polyolefin film plate sealers and then agitated on a plate vortex 
(low setting) for 2 minutes to ensure complete cell lysis. At this point the cell lysate can 
be stored at -80 °C until later use. The lysate was then diluted 4-fold with RNase and 
DNase-free water (Sigma) and 4 µl of this dilution transferred to a 96-well PCR plate. 
To each well of the 96-well plate 1 µl of random hexamers (Pd(N)6) (0.2 µg/ml), 3 µl 
deoxyribonucleotide (dNTP)s  (2.5 mM) and 4 µl of DNase- and RNase-free water was 
added and the plate heated to 70°C for 5 minutes in order to denature the DNA and 
allow binding of the hexamers. The plate was immediately placed on ice in order to 
prevent enzyme denaturation, where 4 µl of 5x First Strand Synthesis Buffer, 2 µl 
dithiothreitol (DTT) (0.1M), 0.125 µl RNaseOUT (40 U/µl), 0.5 µl MMLV (200U/µl) and 
1.375 µl of DNase- and RNase-free water was added to each well. The plate was 
incubated at 37 °C for 50 minutes, followed by 70 °C for 15 minutes. Human cDNA was 
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diluted 1:20 for house-keeping gene quantification. All cDNA was stored at -20 °C until 
required. 
2.2.5.2 RNA extracted using Cells-to-cDNA II kit 
Method: As above until addition of RNA extraction buffer. Ice-cold Cells-to-cDNA 
buffer was added (30 µl/well) and cells lysed by tip transferring the full volume to a 
PCR plate. The plate was then sealed with a polyolefin film plate sealer and lysates 
heated to 75°C for 10 minutes. Plates were then placed on ice and add 1 unit of RQ1 
RNase-free DNase added to each well. The PCR plate was then incubated to 37 °C for 
15 minutes and then DNase deactivated the with a 5 minute incubation at 75 °C. At 
this point the cell lysate could be stored at -80 °C until later use. Cell lysate (8 µl) was 
then transferred to new PCR plate and 1 µl of random hexamers (Pd(N)6) (0.2 µg/ml) 
and 3 µl dNTPs (2.5 mM) were added to each well, the plate sealed and the incubated 
at 70 °C for 5 minutes. The plate was then immediately placed on ice and 4 µl of 5x 
First Strand Synthesis Buffer, 2 µl DTT (0.1 M), 0.125 µl RNaseOUT (40 U/µl), 0.5 µl 
MMLV (200U/µl) and 1.375 µl of DNase- and RNase-free water was added to each well. 
The plate was then incubated at 37 °C for 50 minutes, followed by 70 °C for 15 
minutes.   
2.2.5.3 RNA extracted using RNeasy Mini Kit 
Method: Cytokine-containing DMEM was aspirated from all the wells of a 6-well plate 
following appropriate culture, serum-starvation and cytokine stimulation of cultured 
HAC. Each well was then washed twice with an excess of PBS, aspirating PBS after each 
wash. RLT Buffer (350 µl)+1% β-ME was added to each well. The HAC were then lifted 
from the tissue culture plastic with a cell scraper and the buffer containing the cells 
transferred to a 1.5 ml microcentrifuge (M/C) tube. These were then stored at -80 °C. 
All the frozen samples were allowed to warm up to room temperature. The entire 
sample volume was placed in a QIAshredder spin column and centrifuged at full speed 
(approximately 12,000 g) for 2 minutes. This homogenises the sample preventing 
clogging of the spin columns at later stages. Ethanol (350 µl) at 70 % was added to 
each homogenised sample and mixed with a pipette. The entire volume was 
transferred to an RNeasy spin column within a 2 ml collection tube and centrifuge at 
≥8000 g for 15 seconds. Flow through was discarded and 700 µl of RW1 Buffer was 
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added to the same spin column and centrifuge at ≥8000 g for 15 seconds. Flow 
through was discarded and 500 µl of RPE Buffer was added to the same column and 
centrifuge at ≥8000 g for 2 minutes. The spin column was then placed in a new 
collection tube and used collection tube and flow through within it discarded. Spin 
column was then centrifuged at full speed (approximately ≥8000 g) for 1 minute to 
eliminate any possible carryover of RPE Buffer into final buffer. The spin column was 
then placed in a new collection tube, 40 µl of RNase-free water added to the column 
and centrifuged at ≥8000 g for 1 minute to elute the RNA. 
RNA was quantified by spectrophotometry (Nanodrop ND 1000 spectrophotometer). 
RNA (200 ng) from each sample was then placed in a nuclease-free 0.2 ml PCR tube. To 
this 1 µl of random hexamers (Pd(N)6) (0.2 µg/ml) and 1 µl dNTPs (10 mM) were added 
as well as enough DNase- and RNase-free water to make a final volume of 13 µl. The 
tubes were then heated to 65 °C for 5 minutes and then immediately placed on ice and 
4 µl of 5x First Strand Synthesis Buffer, 2 µl DTT (0.1 M), 0.25 µl RNaseOUT (40 U/µl), 
0.25 µl SuperScript III (200 U/µl) and 0.5 µl of DNase- and RNase-free water was added 
to each well. The tubes were then incubated at 25 °C for 5 minutes, then at 50 °C for 1 
hour followed by 70 °C for 15 minutes. cDNA was then diluted 2.5-fold. A further 20-
fold dilution was carried out for house-keeping gene quantification. All cDNA was 
stored at -20 °C until required. 
2.2.6 Chromatin Immunoprecipitation (ChIP)   
This is a very powerful technique which provides a “snap-shot” of protein-DNA 
interactions occurring within cells at any given point following stimulation. This allows 
us to assess transcription factor binding to specific regions in the genome and offers 
insight into the transcriptional regulation of genes of interest. Briefly, the protocol 
consists of 5 stages: 
 Cross-linkage: Formaldehyde is added to the medium of cytokine-stimulated 
HAC leading to the cross-linkage of DNA and proteins. 
 Cell Lysis and Chromatin Shearing: These cells are then lysed in a SDS lysis 
buffer and subject to carefully optimised sonication which, shears the 
chromatin into approximately 500bp fragments. This is done in order to 
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increase the specificity of the procedure allowing us to determine the presence 
of a protein within a short region of the genome, e.g. the gene promoter. 
 Immunoprecipitation: Antibodies for specific proteins are then used to 
immune-select these proteins which when pulled-down with agarose beads co-
precipitate with genome fragments that were bound at the time of cross-
linkage. 
 DNA purification: Co-precipitated DNA is then eluted from beads, washed, 
detached from proteins and purified using spin columns.  
 Detection: The immune-selected co-precipitated DNA is then used in a real-
time PCR reaction with a primer set specific for a region of the genome you 
want to assess for transcription factor association. 
Reagents: 
 EZ-ChIP Kit: Chromatin Immunoprecipitation Kit (Millipore) 
 Formaldehyde solution-for molecular biology, 36.5-38 % in H2O (Sigma) 
Method: HAC were cultured until 80-90 % confluent in 10 cm culture dishes. The cells 
were then serum-starved overnight and then stimulated the following morning. After 
appropriate stimulation duration, formaldehyde solution 37 % (Sigma) was added to 
medium to a 1 % (w/v) final percentage. The plates were then incubated at room 
temperature for 5 minutes with frequent agitation. To quench the formaldehyde and 
stop cross-linkage, ice-cold glycine was added to the medium-formaldehyde solution 
with a final concentration of 0.125 M. Glycine has a free amine group and so competes 
for the formaldehyde-dependent amino/imino group cross linkage. The plates were 
then incubated at room temperature for 5 minutes with frequent agitation. The 
quenched solution was then removed and the cells washed twice with ice-cold PBS. 
PBS (1 ml) was supplemented with protease inhibitors (PI) and added to each 10 cm 
culture dish. The cells were then removed from the surface of the plate using a cell 
lifter (CoStar) and PBS containing cells transferred to 1.5 ml M/C tube. The cells were 
then centrifuged for 5 minutes at 700 g. Pellets were then snap frozen and stored at -
80 °C for further use. 
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Cell pellets were thawed on ice and then lysed with 200 µl of SDS Lysis Buffer 
supplemented with PI on ice for 15 minutes. The cell lysates were then placed in a 
Bioruptor (Diagenode). This high energy sonicating water bath yields reliable and 
uniform chromatin shearing whilst keeping sample temperature low. The samples 
were subject to three rounds of 5x 30 second pulses with each pulse followed by a 30 
second rest. In between rounds of sonication, a portion of water was removed and 
replaced with ice in order to reduce the temperature in the water bath in order to 
prevent protein denaturation. The concentration of chromatin was quantified by 
spectrophotometry (Nanodrop ND 1000 spectrophotometer) and 100 µg added to 
silconised 1.5 ml M/C tubes. The cell lysate was then diluted to 1 ml using ChIP dilution 
buffer supplemented with PI and pre-cleared with the addition of 60 µl of protein A/G 
agarose beads (Santa Cruz) incubated for 1 hour with rotation at 4 °C. Samples were 
then centrifuged at 4000 g for 1 minute. The supernatant was then removed and 
transferred to a new silconised 1.5 ml M/C tube. Immunoprecipitating antibody (5 µg) 
was then added to each sample and incubated overnight with rotation at 4 °C. 
The following morning 60 µl of protein A/G agarose beads was added to the sample 
and incubated for 1 hour with rotation at 4 °C in order to capture 
antibody/protein/chromatin complex. Samples were centrifuged at 4000 g for 1 
minute and supernatant removed. The antibody/protein/chromatin complex was than 
washed by resuspending the pellet with cold buffers in the order listed below and 
incubate samples for 4 minutes at 4 °C with agitation. Samples were than centrifuged 
at 4000 g for 1 minute and the supernatant removed.  
a) Low Salt Immune Complex Wash buffer, 1 wash 
b) High Salt Immune Complex Wash buffer, 1 wash 
c) LiCl Salt Immune Complex Wash buffer, 1 wash 
d) Tris-EDTA Buffer, 2 washes 
Following the removal of the final supernatant, 100 µl of Elution Buffer (5 µl 20 % SDS, 
10 µl 1 M NaHCO3 and 85 µl of sterile water) was added to each pellet, gently 
resuspended with pipette and then incubated at room temperature for 15 minutes. 
Agarose beads were then pelleted by centrifuging at 4000 g for 1 minute, collecting 
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the supernatant into new silconised 1.5 ml M/C tube. Another 100 µl of Elution Buffer 
was added to the agarose pellets, gently mixed and incubate as before, combining the 
eluates.  
Sodium chloride (NaCl) (8 µl at 5 M) was added to the samples and incubated at 65 °C 
with agitation for 4-5 hours to reverse the cross-links. RNase A (1 µl/1 U) was added 
and incubated at 37 °C with agitation for 30 minutes. This was followed by the addition 
of 4 µl 0.5 M EDTA, 8 µl 1 M Tris-hydrochloric acid (HCl) and 1 µl of Proteinase K (1 U) 
to each sample and incubation at 45 °C for 1-2 hours with agitation.  
Bind Reagent A (5 volumes) was added to each sample and gently mixed with a 
pipette. Half the volume was then transferred to a spin filter, placed in a collection 
tube and centrifuged at 13,000 g for 30 seconds. Liquid in the collection tube was then 
discarded, the second half of the sample added to the same spin filter and centrifuged 
as before. Liquid in the collection tube was then discarded and 500 µl of Wash Reagent 
B added to the spin filter and centrifuged as before. Liquid in the collection tube was 
then discarded. Spin filter was then placed back into the collection tube and 
centrifuged as before. The spin filter was then placed in a new collection tube and the 
used collection tube, along with any liquid was discarded. Elution Buffer C (50 µl) was 
added to the spin filter in the new collection tube and centrifuged as before. The spin 
filter was then removed and discarded. Purified gDNA was stored at -20 °C. 
Immunoselected, pull-down gDNA was then used in real-time PCR to assess fold 
enrichment of chosen proteins to specific regions in the genome. This was performed 
as described in the SYBR Green Real-Time PCR methodology section above. 
2.2.6.1 ChIP primer design 
A crucial element of a reliable ChIP protocol is stringent primer design. When assessing 
the fold enrichment of a protein to a specific region of the genome between different 
durations of cytokine stimulation with real-time PCR you have to be confident that 
your primers for that specific region reflect a doubling of template in the Ct read by 
the PCR machine. The gold standard of primer design is that a primer set leads to an 
increase of a single Ct following a doubling of the template DNA in the PCR reaction. As 
such any analysis of the data then reflects actual fold changes in enrichment and small 
discrepancies are not amplified during PCR. 
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Method: A region of approximately 4000 bp upstream and 1000 bp downstream of the 
transcription start site of a gene of interest was placed into a transcription factor 
binding site prediction software (PROMO 3). Based on predicted sites a region of 1000 
bp which sits over the proximal promoter and transcription start site was then placed 
into primer design software (Primer 3.0). A number of primer sets were then chosen 
based on their comparable melting temperature and the absence of predicted 
secondary structure, self-annealing or primer dimer. These primer sets were then 
tested with real-time PCR (as described in TaqMan Real-Time PCR methodology 
section above) at various concentrations using doubling dilutions of pooled-gDNA. The 
PCR products were checked for the absence of primer-dimer or secondary products by 
electrophoresing them on a 2 % agarose gel (as described in agarose gel 
electrophoresis methodology section, below).    
2.2.7 Semi-Quantitative PCR 
This method allows us to compare immune-selected gDNA from ChIP and their 
controls in order to assess whether or not successful ChIP has occurred. This is 
achieved by amplifying the gDNA pulled down in all samples equally thereby boosting 
the signal so it can be visualised by electrophoresing the PCR product on an agarose 
gel (see below). 
Reagents:  
 Titanium Taq Polymerase (Clontech) 
Method: In a single well of a 96-well PCR plate, PCR reaction was carried out in 15 µl 
containing 0.5 µl of gDNA, 0.075 µl of each primer at a concentration of 10 µM, 1.5 µl 
of 10x PCR buffer (500 mM KCl, 100 mM Tris-HCl pH 8.3), 0.8 µl, 1.2 µl or 1.8 µl of 25 
mM MgCl2 to a concentration of 1 mM, 2 mM or 3 mM respectively depending on the 
required MgCl2 concentration, 0.375 µl dNTPs (10nM), 0.08 µl of Titanium Taq 
Polymerase (1 U/µl) and made up to 15 µl with DNase- and RNase-free water. 
Thermocycling conditions were an initial denaturation at 95 °C for 14 minutes, 
followed by 35 cycles of 95 °C for 30 seconds annealing at temperatures between 55 °C 
and 65 °C depending on the specific conditions for the primers used, for 30 seconds, 72 
°C for 30 seconds and a final extension at 72 °C for 5 minutes. 
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2.2.7.1 Agarose Gel Electrophoresis 
This technique separates DNA fragments based on their size and was employed to 
visualise amplified ChIP-gDNA in order to compare abundance. It was also used to 
check for primer-dimer and secondary products following real-time PCR ChIP primer 
optimisation and also to confirm appropriate chromatin shearing following sonication 
of HAC. 
Reagents:  
 4x Loading Buffer: 0.125 M Tris (pH 6.8), 2 % (w/v) SDS, 10 % (v/v) glycerol and 
0.001 % (w/v) bromophenol blue 
 Tris-acetate-ethylenediamine tetraacetic acid (TAE) buffer:  0.04 M Tris (pH 8), 
5.7 % (v/v) glacial acetic acid and 0.001 M EDTA 
Method: Agarose 3 % (w/v) gels were prepared by dissolving agarose TAE buffer by 
boiling. Ethidium Bromide (3,8-Diamino-5-ethyl-6-phenylphenanthridinium bromide) 
was then added to the cooled agarose-TAE solution at a final concentration of 0.2 
µg/ml. This was poured into a gel form and allowed to set. Once set the gel was placed 
into an electrophoresis tank (BioRad Wide mini-gel Sub cell GT) and submerged in TAE 
buffer. Loading buffer was then added to samples to be electrophoresed and then 
samples, as well as DNA ladder, were loaded into the wells within the gel. A 100 V 
electric field was then applied across the gel attracting the negatively charged DNA 
fragments to the positive terminus. The DNA fragments were then visualised using 
ChemiGenius II BioImager (Syngene, Cambridge, UK). 
 
2.2.8 Subcellular Protein Fractionation 
This method allows the stepwise separation of cytoplasmic, membrane, nuclear 
soluble, chromatin-bound and cytoskeletal protein extracts from HAC. The first buffer 
allows the permeabilisation of cell membrane, releasing soluble cytoplasmic contents. 
The second buffer selectively dissolves plasma, endoplasmic reticulum/golgi and 
mitochondrial membranes without de-stabilising the nuclear membrane. The third 
buffer releases nuclear content. The same buffer is then supplemented with 
micrococcal nuclease which cleaves chromatin into 146 bp fragments allowing the 
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extraction of chromatin-bound proteins. A final buffer was added to the remaining 
insoluble pellet isolating cytoskeletal proteins. These extracts were then resolved by 
SDS-PAGE and analysed by western blotting to assess the abundance and distribution 
within the cellular compartments of specific proteins following various cytokine 
stimulations and durations. 
Reagents: 
 Subcellular Protein Fractionation Kit 
Method: HAC were cultured until 80-90 % confluent in 6-well plates. The cells were 
then subject to serum-starvation overnight and stimulated the following morning. 
After appropriate stimulation duration cytokine-containing medium was then 
aspirated off the wells and washed twice with ice-cold PBS. A cell scraper was then 
used to remove the cells from the tissue culture surface into 150 µl of ice-cold PBS. 
This was then transferred to a 1.5 ml M/C tube and centrifuged at 500 g for 3 minutes. 
The supernatant was then removed and discarded leaving a semi-dry pellet. A rough 
pellet volume was then estimated using known volume water comparisons. Pellet 
volume then governed the volumes of the buffers used throughout the procedure. For 
example, for every 10 µl packed cell volume, a 100 µl of cytoplasmic extraction buffer 
(CEB) and membrane extraction buffer (MEB) and 50 µl of nuclear extraction buffer 
(NEB) and pellet extraction buffer (PEB) are used in each stage. 
Ice-cold CEB containing protease inhibitors was then added to the pellet and incubated 
at 4 °C for 10 minutes with gentle agitation. Samples were then centrifuged at 500 g 
for 5 minutes and supernatant (Cytoplasmic extract) transferred to a clean, pre-chilled 
1.5 ml M/C tube. Ice-cold MEB containing protease inhibitors was then added to the 
pellet and vortexed for 5 seconds on the highest setting followed by incubation at 4 °C 
for 10 minutes with gentle agitation. Samples were then centrifuged at 3000 g for 5 
minutes and supernatant (Membrane extract) transferred to a clean, pre-chilled 1.5 ml 
M/C tubes. Ice-cold NEB containing protease inhibitors was then added to the pellet 
and vortexed for 15 seconds on the highest setting followed by incubation at 4 °C for 
30 minutes with gentle agitation. Samples were then centrifuged at 5000 g for 5 
minutes. During this time, chromatin-bound extraction buffer was prepared by 
combining 5 µl of 100 mM CaCl2 and 3 µl of micrococcal nuclease (300 units) per 100 µl 
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of room temperature NEB. The supernatant (soluble nuclear extract) was then 
transferred to a clean, pre-chilled 1.5 ml M/C tube. Room temperature NEB containing 
protease inhibitors, CaCl2 and micrococcal nuclease was added to the pellet and 
vortexed on highest setting for 15 seconds. Samples were then incubated in a water 
bath at a temperature of 37 °C for 5 minutes. The samples were then vortexed on the 
highest setting for 15 seconds and then centrifuge at 16,000 g for 5 minutes. The 
supernatants (chromatin-bound nuclear extract) were then transferred to clean, pre-
chilled 1.5 ml M/C tubes. Room temperature PEB containing protease inhibitors was 
added to the pellet, vortexed on the highest setting for 15 seconds and then incubate 
at room temperature for 10 minutes. Samples were then centrifuged at 16,000 g for 5 
minutes. The supernatants (cytoskeletal extract) was then transferred to clean 1.5 ml 
M/C tubes. All subcellular extracts were stored at -80 °C. 
2.2.9 Nuclear and Cytoplasmic Protein Extraction 
This method allows the stepwise separation of cytoplasmic and membrane protein 
extracts from cultured HAC. The first two buffers led to the disruption of the cell 
membrane and the release of cytoplasmic contents, yet leaving nuclear membranes 
intact. The third buffer disrupts the nuclear membrane allowing the isolation of 
nuclear protein. Protein extracts were then used in SDS-PAGE and western blotting to 
assess changes in abundance following different cytokine stimulation duration. 
Reagents:   
 NE-PER Nuclear and Cytoplasmic Extraction Reagents 
Method: HAC were cultured until 80-90 % confluent in 6-well plates. The cells were 
then subject to serum-starvation overnight and then stimulated the following morning. 
After appropriate stimulation duration, cytokine-containing medium was then 
aspirated off the wells and washed twice with ice-cold PBS. A cell scraper was then 
used to remove the cells from the tissue culture surface into 150 µl of ice-cold PBS. 
This was then transferred to a 1.5 M/C tube and centrifuged at 500 g for 3 minutes. 
The supernatant was the removed and discarded leaving a semi-dry pellet. A rough 
pellet volume was then established using known volume water comparisons. Pellet 
volume then governed the volumes of the buffers used throughout the procedure. For 
example, for every 10 µl packed cell volume, 100 µl of Cytoplasmic extraction reagent 
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(CER) I, 5.5 µl of CER II and 50 µl of Nuclear extraction reagent (NER) was used in later 
steps. 
Ice-cold CER I containing protease inhibitors was then added to cell pellet and vortexed 
on the highest setting for 15 seconds and incubated on ice for 10 minutes. Ice-cold CER 
II was then added and vortexed for 5 seconds on the highest setting. Samples were 
incubated on ice for 1 minute, then vortexed on highest setting for 5 seconds and 
centrifuged for 5 minutes at 16,000 g. The supernatant (cytoplasmic extract) was then 
transferred to a clean, pre-chilled M/C tube. The pellet was then resuspended in ice-
cold NER and vortexed on the highest setting for 15 seconds. Samples were incubated 
on ice for 40 minutes, vortexing every 10 minutes for 15 seconds. Samples were 
centrifuged for 10 minutes at 16,000 g and supernatant (nuclear extract) transferred 
to a clean, pre-chilled M/C tube. 
2.2.10 Preparation of total cell lysates 
For SDS-PAGE and western blotting protocols, cells within the sample must be fully 
lysed in order release the proteins of interest. In so doing the proteins are solubilised 
allowing them to be separated based on the size of each individual protein. In order to 
do this a lysis buffer which allows maximum cell lysis, supplemented with reagents that 
inhibit proteinases and phosphatases, is used to yield maximal protein levels whilst 
maintaining their stability and phosphorylation state.  
Reagents:  
 Whole Cell Lysis buffer: 50 mM Tris, pH 7.4, 10 % (v/v) glycerol, 1 mM EDTA, 1 
mM EGTA, 1 mM Na3VO4, 5 mM NaF, 10 mM β glycerol phosphate, 5 mM 
Na4P2O7, 1%  (v/v) Triton X-100,  1 μM microcystin-LF and 1 Complete protease 
inhibitor Mini tablet/10 ml of buffer 
Method: HAC were cultured until 80-90 % confluent in 6-well plates. The cells were 
subject to serum-starvation overnight and then stimulated the following morning. 
After appropriate stimulation duration cytokine-containing medium was then 
aspirated off the wells and washed twice with ice-cold PBS. Ice-cold Whole Cell Lysis 
buffer (150 µl/well) supplemented with 0.1 % (v/v) β-ME was then added. A cell 
scraper was then used to scrape the cells from the surface of the wells into the buffer 
52 
 
which was then transferred to a 1.5 ml M/C tube. Samples were vortexed for 10 
seconds and incubated on ice for 20 minutes, followed by centrifugation at 10,000 g at 
4 °C for 10 minutes.  The supernatant was then removed, snap frozen on dry ice and 
stored immediately at -80 °C.   
2.2.11 Non-Destructive Cytotoxicity Assay 
In the assessment of de novo protein synthesis following pro-inflammatory cytokine 
stimulation, Emetine, a protein synthesis inhibitor was used. This allowed me to reveal 
whether or not new protein synthesis was required for transcription of MMPs. Before 
these studies could be carried out, it was important to assess the cytotoxicity of this 
compound on HAC. This was because a lack of protein production or gene transcription 
may be accounted for by cell death rather than the inhibition of protein synthesis. As 
such a bioluminescent assay was used to evaluate cell death. This works on the 
principle that a damaged cell will lose plasma membrane integrity. As such a 
phosphotransferase enzyme, adenylate kinase (AK) is released from these damaged 
cells into the medium. AK converts ADP to ATP. This ATP is then used to catalyse a 
bioluminescent reaction which is measured with a luminometer. Emitted light intensity 
is linearly related to AK concentration and percentage cell death can then be 
calculated from controls. 
Reagents:   
 ToxiLight BioAssay Kit: Non-Destructive Cytotoxicity Assay  
Method: Prior the start of the assay 10 ml of Assay Buffer was added to the AK 
Detection Reagent and allowed to equilibrate for 15 minutes at room temperature 
with gentle agitation. HAC, cultured in 96-well plate, were removed from the incubator 
and 100 µl of the medium from the cells was transferred to a new 96-well plate. The 
remaining 100 µl of medium was then subject to repeated freeze-thaw cycles by 
freezing in the -80 °C freezer.  Freeze-thawing leads to a loss in cell membrane integrity 
and so was used as a control for complete cell death. The 100 µl of normal culture 
medium and freeze-thawed medium was allowed to return to room temperature. A 20 
µl volume was then taken from each sample and transferred to a luminescence 
compatible 96 well-plate. To this sample, 100 µl of reconstituted AK detection reagent 
was added and then incubated for 5 minutes at room temperature. The plate was then 
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placed in a luminometer and immediate 1 second integrated readings of appropriate 
wells were taken.  
2.2.12 Protein Quantification 
In order to more accurately assess protein quantity between samples following 
visualisation of western blot, equal amounts of protein from each sample must be 
added to the wells in SDS-PAGE. This means variation in protein loading can be 
discounted when assessing differences in protein quantity. Quantification is based 
upon maximal absorption changes of Coomassie dye upon protein binding. As the dye 
binds to proteins the dye is stabilised resulting in absorption change from 465 nm (un-
bound dye) to 595 nm (bound dye) with a concomitant colour change from brown to 
blue. Changes in absorbance are proportional to the amount of bound dye and hence 
the amount of protein. Quantity is estimated by comparing unknown sample to serial 
dilutions of known protein concentration. 
Reagents: 
 Bradford ULTRA 
 BSA 
Method: In a flat bottomed 96-well plate a serial dilution of BSA (0.4 µg/ml) ranging 
from 0 µg/ml to 4 µg/ml in 0.4 µg/ml increments was made up to 10 µl with lysis 
buffer. A 3 µl volume of each unknown sample is then added in triplicate to the plate, 
which are also made up to 10 µl with lysis buffer. Room temperature Bradford ULTRA 
(150 µl) was then added to all samples and standards. The flat bottomed plate 
containing the standards and sample were then placed in a Tecan Sunrise microplate 
reader and absorbance read at 595 nm.  
2.2.13 DNA affinity pull-down assay 
An in vitro technique that allows the user to assess interaction between proteins 
isolated from cell lysates and their binding to oligonucleotide containing consensus 
binding sites found in gDNA. Bioyinylated oligonucleotides and the proteins bound to 
the consensus binding sites contained within them can then be extracted using 
streptavidin-coated agarose beads. Subsequent elution of these proteins allows 
identification of bound proteins using SDS-PAGE and western blotting. This allows the 
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user to identify factors that have the potential to regulate the genes that these 
consensus sites precede in the genome. 
Reagents: 
 Streptavidin-coated agarose beads  
 Double stranded biotinylated-oligonucleotides (Sigma, UK): 5’-
CGCTTGATGACTCAGCCGGAA-3’; 3’-GCGAACTACTGAGTCGGCCTT-5’ 
 BSA  
 Poly deoxyinosinic-deoxycytidylic (dI-dC) (LiCor, USA) 
 Binding Buffer: 12 mM HEPES pH 7.9, 4 mM Tris-HCl, 60 mM KCl, 5% (w/v) 
glycerol, 0.5 mM EDTA, 1 mM DTT and 1 mini protease inhibitor cocktail 
tablet/10ml of buffer  
 5 x Final sample buffer (FSB): 0.625 mM Tris-HCl pH 6.8, 40 % (v/v) glycerol, 10 
% (w/v) SDS, 0.5 % (w/v) bromophenol blue, 5 % (v/v) -ME 
 
Oligonucleotide annealing method: Oligonucleotide stock was first prepared by 
adding RNase and DNase-free water to lyophilised single stranded oligonucleotide 
making a 100 pmol/µl concentration (volume indicated in data sheet). A volume of 3.5 
µl of both the sense and anti-sense oligonucleotide, along with 43 µl of RNase and 
DNase-free water were placed in a PCR tube and incubated to 100 °C and then left to 
cool to room temperature overnight. Complete annealing was checked by running 
annealed oligonucleotide on an agarose 3 % (w/v) gel. 
Binding reaction method: For each pull-down reaction: 40 µl of streptavidin-coated 
agarose beads were blocked in 1 ml of binding buffer, supplemented with BSA (0.5 
mg/ml), for 45 minutes at 4 °C with rotation; and 80 µg of nuclear protein extract 
incubated with 10 µl of the double-stranded biotinylated-oligonucleotides (35 pmol) in 
500 µl of binding buffer, supplemented with poly (dI-dC) (2 µg/ml), for 45 minutes at 4 
°C with rotation. The agarose beads were then briefly centrifuged to pellet, 
supernatant discarded and replaced with 500 µl of binding buffer containing protein-
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oligonucleotide complex. Samples were then incubated for 2 hours at 4 °C with 
rotation. Agarose beads were then pelleted by briefly centrifuging samples, 
supernatant discarded and pellet washed three times with 1 ml of binding buffer for 5 
minutes at 4 °C with rotation. Agarose beads were resuspended in 50 µl of final sample 
buffer and incubated at 100 °C for 5 minutes. Agarose beads were briefly centrifuges 
to pellet and supernatant removed for SDS-PAGE (as below). 
2.2.14 SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE)  
Samples containing protein, generated by subcellular protein fractionation, nuclear 
and cytoplasmic protein extraction or total cell lysis were subjected to SDS-PAGE, 
separating the proteins within these samples by their size. SDS plays a crucial role in 
ensuring that proteins are separated by size alone and not retardation through the gel 
due to other factors. SDS is an anionic detergent added to samples that binds to 
proteins at a ratio of 1 anion to 2 amino acids. This imparts a negative charge to the 
proteins which is proportional to unit mass. It also serves to prevent the formation of 
secondary and tertiary structures and linearize the proteins. β-ME is also added, 
thereby reducing disulphide bridges ensuring monomeric primary structure proteins. 
Denaturation of the proteins is also aided by heating of the sample to 100 °C in order 
to further denature proteins allowing comprehensive binding of SDS.   
Once charged and linearized, the samples are placed into a stacking gel. Due to the 
larger pore size compared to separating gel, movement through the stacking gel is 
dependent on the electric field applied rather protein size. This sharpens loaded 
samples into a single band before it enters the separating gel. This is achieved by 
difference in migration speed of ions within the gel and the electrophoresis buffer. The 
proteins are trapped within a narrow band between these migrating ions. Once they 
reach the separating gel, which has a smaller pore size, a higher pH and a higher salt 
concentration, the voltage gradient is lost allowing the proteins to be separated based 
on size. Large proteins are retarded by the gel and so move more slowly through the 
gel whereas smaller proteins move more freely and so move further through the gel. 
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Reagents: 
 4 x Lower gel buffer (LGB): 1.5 M Tris-base, pH 8.8, 0.4 % (w/v) SDS 
 4 x Upper gel buffer (UGB): 0.5 M Tris-base, pH 6.8, 0.4 % (w/v) SDS 
 Stacking gel: 40 % bis/acrylamide diluted to 4.5 % with water and 4 x UGB 
 10 x running buffer: 250 mM Tris-base, 2 M glycine, 10 % (w/v) SDS 
Method: Electrophoresis was performed in a Bio-Rad Mini-Protean Tetra system with 
1.0 mm spacers and combs. Polyacrylamide-bis-acrylamide was purchased as a 40 % 
(w/v) (37.5:1 acrylamide:bis) solution, diluted with water and 3 ml of 4 x LGB  to the 
required percentage (Table 5). A spacer plate and short plate were combined within a 
casting frame, fixed within a casting stand and checked for a clean seal with water. Gel 
mixture (12 ml) was polymerised by the addition of 20 μl TEMED and 60 μl APS (0.2 % 
w/v) and immediately poured into gel cassette assembly. The lower gel was overlaid 
with propan-2-ol to exclude oxygen and allowed to polymerise. Once set, propan-2-ol 
was washed off the gel and a 4.5 % bis/acrylamide stacking gel laid on top, combs 
inserted and the stacker allowed to set. Upper gel (5 ml) was set with 10 μl TEMED and 
30 μl 0.2 % (w/v) APS. The gel within the two plates was fixed into the electrode 
assembly which is then placed within the electrophoresis tank and surrounded with 1 x 
running buffer. Cell lysate samples were prepared as follows: 1 ml of 5 x sample buffer 
was mixed with 250 μl β-ME. Sample buffer (4 μl) was added to 20 μl of each cell lysate 
sample and heated to 105 C for 5 minutes. PageRuler pre-stained protein standards 
were loaded alongside samples in order to visualise molecular weight on membranes. 
Proteins were electrophoresed at a constant 80 V in running Buffer for approximately 
1 hour 30 minutes, until the dye front had run to the end of the separating gel. 
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Percentage gel (%) 40 % (w/v) 
acryl/bis solution 
(37.5:1) (ml) 
dH2O (ml) 4xLGB (ml) 
10 3 6 3 
7.5 2.25 6.75 3 
 
Table 6: Volumes of reagents that constitute agarose gels at 10 and 7.5 % (w/v). 
 
2.2.15 Western Blotting  
Following SDS-PAGE, separated proteins were transferred to polyvinylidene fluoride 
(PVDF) membrane. This transfer works on the same principle as SDS-PAGE: proteins 
that have a negative charge, imparted upon them by the binding of SDS, are 
transferred from the polyacrylamide gel onto to PVDF membrane by an electric current 
where they are tightly held in a mirror image of the proteins on the gel by electrostatic 
and hydrophobic interaction. This membrane is considerably more robust compared to 
the polyacrylamide gels and is therefore easier to handle during subsequent steps in 
the protocol. Before antibody incubation the PVDF membrane must first be “blocked”. 
The membrane has a high affinity for proteins, and so, to ensure that no proteins bind 
that could lead to unspecific binding of primary antibody, free sites on the membrane 
are blocked with skimmed milk protein. The membrane is then subject to antibody 
incubation firstly with antibody that has affinity for the protein of interest and then an 
HRP-conjugated antibody that has affinity for the primary antibody isotype. HRP then 
cleaves a chemi-luminescent substrate, emitting light which is then detected in the 
vicinity of the protein of interest (Figure 9).      
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Figure 9: Schematic representation of western blotting.  Primary antibody binds epitope on proteins that are 
hydrophobically bound to PVDF membrane. Secondary antibody, that are conjugated to HRP, bind to Fc region on 
primary antibody. HRP cleaves ECL detection reagent emitting light. Schematic adapted from [186]. 
 
Reagents: 
 Transfer Buffer: 39 mM glycine, 48 mM Tris-base, 0.0375 % (w/v) SDS and 20 % 
(v/v) methanol 
 Tris-buffered saline-Tween (TBS-T): 10 mM Tris-HCl pH 7.4, 0.15 M NaCl and 0.2 
% (v/v) Tween-20 
Method for BioRad Semi-dry Transfer Unit: PVDF membrane and 6 sheets of filter 
paper were cut to the size of the gel being transferred. The PVDF membrane was 
activated by placing in methanol for 5 minutes prior to transfer. PVDF membrane was 
then removed from methanol and along with the gel and filter paper, soaked in 
transfer buffer. A sandwich of 3 sheets of filter paper, PVDF membrane, gel and 
remaining filter paper was assembled within the transfer unit plates with the 
membrane closest to the anode plate and the gel closest to the cathode plate. Any 
bubbles within the sandwich were removed with a roller prior to sealing within the 
unit. Proteins were then transferred by running at 80 mA per gel (35 V, 200 W) current 
PVDF 
membrane
Protein
Primary 
Antibody
Secondary 
Antibody
Horse-Radish 
peroxidase 
(HRP)
Light 
emission
ECL detection reagent
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across the sandwich for 1 hour 40 minutes where upon the gel and two sets of filter 
paper were discarded.  
For some experiments, the iBlot gel transfer system (LifeTech) was used according to 
manufacturer’s instructions to simplify and standardise blotting. 
Blocking and Immunoblotting Method: Following transfer PVDF membranes were 
then placed in TBST-T containing 5 % (w/v) skimmed dried milk for 1 hour at room 
temperature to block. Blocking solution was then poured away and the blot briefly 
washed with TBS-T to remove any excess solution. The blot was then incubated with 
primary antibody diluted in TBS-T (containing 5 % BSA) overnight at 4 °C with agitation. 
Blots were then washed three times for 5 minutes in TBS-T. Blots were then incubated 
with secondary antibody diluted in TBS-T containing 5 % (w/v) non-fat dried milk for 1-
2 hours at room temperature with agitation. The secondary was then discarded and 
the blots washed three times for 5 minutes in TBS-T. Proteins were then visualised 
using Amersham ECL Western Blot Detection Reagents or Millipore Immobilon 
Western Chemiluminescent HRP substrate.   
2.2.16 Small interfering (si)RNA-mediated gene silencing 
In order to assess the roles of certain transcription factors in the regulation of MMP 
expression, genes were transcriptionally silenced using double-stranded RNA 
sequences that bind through complementarity to mRNA of specific genes, targeting 
them for degradation.  
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Figure 10: Schematic diagram of siRNA-mediated gene silencing. Taken from [187]. 
This process involves the initiation of the RNA interference pathway: dsRNA is 
delivered intracellularly using lipid vesicles which permeate the cell membrane. Once 
in the cell the dsRNA are cleaved into 21-23 bp small interfering (si) RNAs by Dicer 
which are then assembled into the RNA-induced silencing complex (RISC). This complex 
is targeted to a specific mRNA sequence of a specific gene leading to cleavage and 
degradation by exonucleases (Figure 10). This effectively silences the gene and its 
function within the cell. One is then able to assess the role of specific proteins in 
transcriptional regulation of MMPs via real-time PCR.  
Reagents: 
 Dharmacon ON-TARGET plus SMARTpools (ThermoFisher Scientific) or 
FlexiTube siRNA (Qiagen)GeneSolution of 4 specific siRNA duplexes (total of 
100 nM siRNA) 
 Dharmacon ON-TARGETplus  Non-targeting Pool control siRNA 
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 DharmaFECT Transfection reagent (ThermoFischer Scientific) 
 
Method: 
HAC were cultured until 70-80 % confluent in T75 cm2 tissue culture flasks. Culture 
medium was removed and the cell monolayer washed with PBS containing 200 IU/ml 
penicillin, 200 µg/ml streptomycin and 40 IU/ml nystatin. Trypsin-EDTA was then 
placed on the cells and incubated for 5 minutes at 37 °C until the cells had been 
released from the tissue culture surface. Cells were then suspended in serum-
containing medium, cells pelleted at 300 g for 10 minutes, supernatant containing 
trypsin removed and pellet resuspended in fresh serum-containing medium. The cells 
were then counted using a haemocytometer and re-seeded at 10,000 cells/well in 96-
well plates and/or 330,000 cells/well in 6-well plates. The cells were then allowed to 
adhere to the surface of the plate and cultured overnight until 50-70 % confluent, at 
which point the culture medium was replaced with 50 µl of serum-containing medium. 
Cells were then allowed to equilibrate for around 2-3 hours, during which time siRNA 
were prepared for transfection.  
DharmaFECT transfection reagent (0.26µl/well of 96-well plate) was added to serum 
free medium (15µl/well of a 96-well plate or 1ml/well of a 6-well plate) in a sterile 
bijou container. siRNA including non-targeting siRNA control pool was made up at a 
final concentration of 100 nM from a 20 µM stock in serum-free medium (15 µl/well of 
a 96-well plate or 1 ml/well of a 6-well plate) in separate bijou container. An equal 
volume of DharmaFECT transfection reagent was then added to siRNA. Complexes of 
siRNA within lipid vesicles were then allowed to form over 15-20 minutes at room 
temperature within the tissue culture hood. Following this, 30 µl of the lipid vesicle-
siRNA complexes were then added to the 50µl of serum-containing medium on the 
cells. Cells were then incubated with siRNA for 24-48 hours to allow transfection to 
occur. Following appropriate incubation, siRNA containing medium was removed, cells 
washed with PBS containing 200 IU/ml penicillin, 200 µg/ml streptomycin and 40 IU/ml 
nystatin and replaced with 100 µl of serum-free medium. The next day cells were 
stimulated with cytokines as previously described.    
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2.2.17 DNA microarray 
The DNA microarray study was outsourced to Cambridge Genomic services (Cambridge 
University, UK). RNA from validated populations underwent quality control procedures 
in order to check for contamination with protein or phenols carried through from the 
RNA extraction that may have affected the hybridisation efficiency. Once satisfied with 
the quality of the samples, RNA was then reverse transcribed to cDNA and amplified by 
In Vitro Transcription to generate biotin-labelled cRNA. Samples were placed on a 
HumanHT-12 v4 Expression Beadchip from Illumina (San Diego, CA). This chip has 
47,000 transcripts and known splice variants, known as features, spotted onto its 
surface. Complementarity between the cRNA and these features leads to hybridisation 
at specific regions on the chip. The beads are then washed in order to remove non-
specific binding and blocked, thereby preventing any further hybridisation. The chip is 
then stained with streptavidin-Cy3 molecules which bind to any biotinylated-cRNA 
hybridised to the features. Emission of fluorescence by Cy3 is then quantitatively 
detected. The greater the amount of transcript, the more hybridisation and so more 
fluorescence emitted. 
Data normalisation 
Raw data generated in the DNA microarray study was subject to standard analysis 
carried out by Cambridge Genomic services. This included: 
 Verification of quality controls using Illumina GenomeStudio software. 
 Normalisation of raw data output using quantile normalisation (R package lumi 
software). 
 Calculation of statistical significance using R microarray analysis of variance 
(maanova) software which corrects p-values for false positives of differential 
gene regulation that arise through multiple statistical tests. 
Analysis of results 
Following data normalisation I received the results which include raw and normalised 
data, a full report on the analysis and results of the comparisons with gene 
annotations, fold-change, p-value and corrected p-value. In order to further analyse 
this data with respect to my study I imported this data into GeneSpring 12 (Agilent). 
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This allowed for the exclusion of genes that did not have corrected p-values less than 
or equal to the user-specified p-value cut-off (p<0.05). The generation of an 
experiment with GeneSpring also allowed for improved visualisation of the data and 
comparisons of differentially expressed genes in one comparison group against those 
in another. 
2.2.18 Statistical analysis 
For ChIP analysis the difference between individual HAC population means was tested 
for statistical significance using ANOVA (analysis of variance): two-factor without 
replication with a post-hoc Bonferroni multiple comparison test. Real-time PCR data 
were normalised against 18S rRNA, then plotted as the fold induction of the target 
gene expression over control levels. Levels of statistical significance are shown as 
*p≤0.05, **p≤0.01 and ***p≤0.001. For clarity, only selected comparisons are 
presented in some figures. 
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3 Chapter 3: AP-1-dependent collagenase gene 
regulation in primary chondrocytes 
 
3.1 Introduction 
 
As mentioned previously, collagen degradation is a critical pathological process that 
once initiated leads to an irreversible loss of articular cartilage and subsequent loss of 
tissue function. The cleavage of type II collagen, the main structural component of 
articular cartilage, is effected by the collagenases MMP-1 and -13 [37, 44, 47]. Their 
aberrant expression in disease is, in-part, due to pro-inflammatory cytokine signalling 
via the chondrocyte. The gene regulation of these enzymes, that play a critical role in 
pathology, has been demonstrated to be controlled by a number of different signalling 
pathways as well as histone modification and DNA methylation. Activation of cis-
elements in the gene promoter also represents a crucial point of collagenase gene 
regulation in response to pro-inflammatory cytokine stimulus. AP-1 
homo/heterodimers are an example of one transcription factor family that play a 
significant role in IL-1+OSM-dependent collagenase gene transcription [82].  
Understanding of AP-1-dependent collagenase gene transcription is limited [112, 113], 
and how AP-1 regulates collagenase gene expression in chondrocytes in response to 
complex pro-inflammatory cytokine stimulation remains to be determined. The 
following study was performed in order to improve our understanding of AP-1 gene 
expression, protein induction and its impact on collagenase gene expression in the 
chondrocyte.  
3.1.1 Assessment of the functional role of c-Fos/c-Jun in collagenase gene 
regulation 
Previous studies have demonstrated that c-Fos/c-Jun binds to MMP-1 
promoter/luciferase reporter constructs and that the expression of this collagenase is 
dependent on AP-1 expression [82]. Further studies have shown that silencing of the c-
Fos/c-Jun genes using small interfering(si) RNA led to a significant reduction in both 
MMP1 and MMP13 gene expression [97]. Therefore, I firstly wanted to confirm that 
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these AP-1 transcription factors were functionally important for IL-1+OSM-dependent 
collagenase gene expression, such that my subsequent research would be based on 
proven and reproducible data. 
The AP-1 transcription factor FOS was silenced either alone, or in combination with the 
family member JUN. Silencing of FOS, either alone or in combination with JUN led to a 
significant decrease in MMP1 and MMP13 gene expression induced by IL-1+OSM 
stimulation, when compared to a non-targeting control siRNA (Figure 11). Silencing of 
JUN alone led to a slight decrease in gene expression of both collagenases but this was 
not statistically significant. There was no significant difference between FOS and 
FOS+JUN silencing on MMP13 gene expression compared to the control, whereas 
silencing of both these AP-1 factors resulted in a more significant decrease of MMP1 
expression compared the control, than FOS alone. These data demonstrate that c-Fos 
is an important regulator of MMP1 and MMP13 expression. Moreover, silencing both 
FOS and JUN highlights the importance of these AP-1 members to MMP1 expression.  
 
 
Figure 11: Real-time PCR analysis of the effect of FOS and JUN gene silencing on MMP gene expression in IL-
1+OSM stimulated HAC.  Following transfection with siRNA specific for FOS, JUN or non-targeting siControl 
(100nM), HAC were treated with IL-1 (0.05ng/ml) in combination with OSM (10ng/ml) for 24 hours. Real-time 
reverse transcription PCR of isolated RNA was performed for MMP1 and MMP13 and normalised to 18S rRNA 
housekeeping gene. Data are pooled from three separate HAC populations (each assayed in sextuplet) and 
expressed as a percentage of stimulated control (specific siAP-1 transfected versus siCon-transfected; mean ± S.D.; 
*, p <0.05; ***, p < 0.001).  
Having demonstrated that FOS and JUN silencing significantly reduced collagenase 
gene expression, I next wanted to confirm that the observations in Figure 11 were as a 
result of a reduction in AP-1 protein expression following gene silencing. Western blot 
analysis revealed that unstimulated HAC had no change in protein level between 
siControl and siRNA for either c-Fos or c-Jun (Figure 12). Stimulation of HAC using IL-
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1+OSM led to an increase in both AP-1 proteins in the presence of siControl, 
confirming data from Litherland 2010 et al [97]. Importantly, the expression of both c-
Fos and c-Jun protein, following IL-1+OSM stimulation, was markedly decreased 
following gene silencing. This confirms that the observed changes in collagenase 
expression (Figure 11) were due to a successful reduction of gene expression and 
protein production following siRNA gene silencing. 
 
Figure 12: Western blot for c-Fos and c-Jun following gene silencing.  A, HAC were transfected with siRNA specific 
for FOS and JUN or non-targeting siControl (100nM) prior to stimulation with IL-1 (0.05ng/ml) in combination with 
OSM (10ng/ml) for 1 hour as indicated. Nuclear extracts were isolated and proteins resolved by SDS-PAGE. 
Immunblots were probed using indicated antibodies. Blots shown are representative of three experiments using 
chondrocytes from different donors. Lamin A/C was used as a loading control. B, combined densitometric scans of 
three separate blots each from separate chondrocyte populations. Density is relative to unstimulated HAC 
transfected with siCON, where *, p<0.05 and **, p<0.01.  
 
3.1.2 Investigation of AP-1 protein induction and cellular localisation 
Having confirmed the functional importance of c-Fos and c-Jun in the expression of 
MMP-1 and MMP-13 expression, I next assessed the kinetics of AP-1 expression 
following IL-1+OSM stimulation. A greater understanding of this temporal profile 
would assist subsequent ChIP studies and allow comparison to the study by Martens et 
al. [158] which, using semi-quantitative PCR, demonstrated the kinetics of c-Fos and c-
Jun binding to the MMP-1 promoter following PMA stimulation of a glioblastoma cell 
line. These studies revealed that there was an ordered recruitment of regulatory 
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proteins to the collagenase promoter which included c-Fos and c-Jun. The study 
suggested that binding of c-Fos and c-Jun was transient and preceded the recruitment 
of other regulatory factors like transcriptional co-activator, p300. Though intriguing, 
these results were generated without a disease context and under an extremely 
potent chemical stimulation, also in addition there was relatively little quantification in 
the study. I used time points found relevant by Martens et al and previous study in our 
group [82], as a basis for my own experiments to assess when AP-1 is expressed in 
response to IL-1+OSM stimulation by primary articular chondrocytes isolated from 
patient cartilage samples. The use of primary cells not only provided my study with a 
greater degree of disease relevance, but interestingly, the widely used 
chondrosarcoma cell line (SW1353 cells) does not express FOS (Rowan, personal 
communication), though IL+OSM stimulation still synergistically induces MMPs [72]. 
Furthermore, Gebauer et al [188] has demonstrated limitations of using SW1353 cells 
as a model for HAC. However, the use of primary cells has logistical limitations: cell 
yields from enzymatic digestion of cartilage samples are limited by the amount of 
residual, macroscopically normal cartilage. As such, some experiments are limited in 
their scope and so I was unable to perform as extensive a time course study for AP-1 
enrichment on the collagenase promoters as described by Martens et al [158]. I 
therefore planned to limit the number of time points used within ChIP experiments by 
first investigating c-Fos/c-Jun protein localisation and temporal induction in order to 
then select pertinent IL-1+OSM stimulation durations for ChIP assays.      
I first confirmed the suitability of the subcellular protein fractionation protocol by 
taking samples from all five subcellular fractions from cultured HAC and resolving them 
with SDS-PAGE. Western blotting using antibodies specific to protein markers only 
found in each specific fraction (e.g. Histone H3 is a member of the histone octamer 
that facilitates the condensation of DNA into chromatin and as such is found tightly 
associated with DNA and therefore an ideal marker for the chromatin-bound fraction). 
As shown in Figure 13, marker proteins were only present in the fractions to which 
they are associated indicating good fractionation efficiency for subsequent use.      
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Figure 13: Confirmation of Protein subcellular fractionation.  HAC were subject to subcellular protein fractionation 
using the Subcellular Protein Fractionation Kit (ThermoScientific). Proteins from cytosolic (A), membrane-bound (B), 
soluble nuclear (C), chromatin-bound, (D) and cytoskeletal (E) subcellular fractions were resolved using SDS-PAGE 
and immunoblotted with the indicated antibodies. Immunoblots shown are representative of three separate 
experiments each using chondrocyte cultures from different donors.   
The expression and localisation of AP-1 transcription factors were then determined at 
0,1,3,6, and 24 hours post IL-1+OSM stimulation. Expression of c-Fos was not observed 
under unstimulated, basal conditions, however at 1 hour post-stimulation there was a 
marked increase in protein levels which then decreased at 3 hours (Figure 14A). 
Expression of c-Fos was still detectable at 6 hours in some (Figure 14A), but not all HAC 
populations, but had diminished substantially by 24 hours (Figure 14B). The c-Fos 
binding partner, c-Jun also displayed similar kinetics of protein phosphorylation, but 
was more transient than c-Fos, not being detected 6 hours post-stimulation (Figure 
14A and C). The localisation of both c-Fos and c-Jun appeared to be confined to the 
soluble nuclear fraction (lanes C, Figure 14) with IL-1+OSM duration having no obvious 
effect on AP-1 localisation.  
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Figure 14: Western blot for c-Fos and c-Jun AP-1 factors in subcellular protein fractions from HAC stimulated with 
IL-1+OSM.  A) HAC were stimulated with IL-1 (0.05ng/ml) in combination with OSM (10ng/ml) for the indicated 
durations. Cells were then subject to subcellular protein fractionation. Proteins from cytosolic (a), membrane-bound 
(b), soluble nuclear (c), chromatin-bound, (d) and cytoskeletal (e) subcellular fractions were resolved using SDS-
PAGE and immunoblotted with the indicated antibodies. Sample volumes loaded for SDS-PAGE were dependent on 
the relative volume into which the individual fractions were lysed. Immunoblots shown are representative of five 
separate experiments each using chondrocyte cultures from different donors. Images in this figure are cropped 
from larger exposure image. Full-length blots/gels are presented in Appendix 7.1, figure 48. Combined 
densitometric scans of separate blots (from separate chondrocyte populations) immunoblotted with antibodies 
against c-Fos (B) and P-c-Jun (Ser63) (C). Density is relative to unstimulated control (mean ± SD; where **, p < 0.01; 
***, p < 0.001). 
The high abundance of c-Fos protein within the soluble nuclear fraction may have 
resulted in the masking of other, less abundant, protein levels within other fractions. 
AP-1 is a transcription factor capable of binding to DNA, a process essential for its 
function as a transcriptional regulator. I therefore diluted the soluble nuclear fraction, 
1 in 5, in order to help ‘unmask’ proteins present within the chromatin-bound fraction 
that would otherwise be undetectable next to the robust signal observed in soluble 
nuclear fractions on western blot. In Figure 15 lane A, detection of both c-Fos and p-c-
Jun in the soluble nuclear fraction confirmed previously observed changes in protein 
with time as described in Figure 14. Proteins within the chromatin-bound fraction were 
now observable in both the c-Fos and c-Jun immunoblots. Although not as robust as in 
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the soluble nuclear fraction, levels of c-Fos protein increased from basal to peak at 1 
hour post IL-1+OSM stimulation, reducing thereafter. Low, but detectable levels of c-
Jun were observed at 1 and 3 hours post IL-1+OSM stimulation in the chromatin-bound 
fraction. These observations are reflected in the densitometric scans for c-Fos and p-c-
Jun (Ser 63) (Figure 15B and C). Together these data demonstrate that in the context of 
IL-1+OSM stimulation of HAC, c-Fos production and c-Jun activation occur rapidly and 
transiently, and binding of these factors to chromatin is relatively short-lived. 
 
Figure 15: Western blot for AP-1 factors in soluble nuclear and chromatin-bound protein fractions from HAC 
stimulated with IL-1+OSM. A) HAC were stimulated with IL-1 (0.05ng/ml) in combination with OSM (10ng/ml) for 
the indicated durations. Cells were then subject to subcellular protein fractionation. Proteins from 1 in 5 dilutions of 
soluble nuclear (a) and neat chromatin-bound (b) subcellular fractions were resolved using SDS-PAGE and 
immunoblotted with the indicated antibodies. Immunoblots shown are representative of five separate experiments 
each using chondrocyte cultures from different donors. Combined densitometric scans of separate blots (from 
separate chondrocyte populations) immunoblotted with antibodies against c-Fos (B) and P-c-Jun (Ser63) (C). Density 
is relative to unstimulated control (mean ± SD; where *, p < 0.05; **, p < 0.01; ***, p < 0.001). 
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3.1.3 Investigation of temporal FOS/AP-1 gene expression in chondrocytes 
The rapid induction of the c-Fos/c-Jun AP-1 factor (see Figure 14) confirmed the 
reported immediate early gene status for FOS and JUN [189]. [189]. I next wanted to 
correlate the kinetics of FOS and JUN mRNA expression with the concomitant kinetics 
of MMP1 and MMP13 expression.  Figure 16A demonstrates that expression of FOS 
gradually increased from basal (unstimulated) up to 1 hour post IL-1+OSM stimulation, 
but at time points after 1 hour stimulation, gene expression levels decreased 
dramatically to levels comparable with basal gene expression. Both MMP1 and 
MMP13 expression was not observed to increase until 6 hours post IL-1+OSM 
stimulation. This expression then increased through to 24 hours (Figure 16B and C, 
respectively). Furthermore, the expression of JUN was also observed to increase 
rapidly following IL-1+OSM stimulation, with expression peaking slightly earlier at 45 
minutes post stimulation (Figure 17). Though JUN decreased post-45 minutes IL-
1+OSM stimulation, JUN expression remained significantly elevated above basal gene 
expression levels at all subsequent time points measured up to 24 hours. These data, 
taken together with the protein studies, show that FOS and JUN are transient and that 
both gene expression and c-Fos production/c-Jun activation peaks around 1 hour IL-
1+OSM stimulation. In contrast, collagenase gene expression does not occur until 6 
hours post-IL-1+OSM stimulation. This highlights a temporal deficit between AP-1 and 
the initiation of collagenase gene expression. As such I next wanted to determine if, 
and when, c-Fos was binding to the promoter regions of MMP1 and MMP13 during 
this deficit. 
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Figure 16: Real-time PCR analysis of gene expression following different durations of IL-1+OSM stimulation.  HAC 
were treated with IL-1 (0.05ng/ml) in combination with OSM (10ng/ml) for the indicated durations. Cell lysates were 
subjected to real-time PCR and relative expression levels of FOS (A), MMP1 (B) and MMP13 (C) mRNA, normalized 
to the 18S rRNA housekeeping gene, were determined. Data are representative of three separate experiments each 
using chondrocyte cultures from different donors. Statistical analysis are shown for gene expression following 
indicated IL-1+OSM stimulation versus basal (mean ± SD; where **, p < 0.01; ***, p < 0.001). 
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Figure 17: Real-time PCR analysis of JUN gene expression following different durations of IL-1+OSM stimulation.  
HAC were treated with IL-1 (0.05ng/ml) in combination with OSM (10ng/ml) for the indicated durations. Cell lysates 
were subjected to treatment with DNase followed by real-time PCR and relative expression levels of JUN mRNA, 
normalized to the 18S rRNA housekeeping gene, were determined. Data are representative of three separate 
experiments each using chondrocyte cultures from different donors. Statistical analysis are shown for gene 
expression following indicated IL-1+OSM stimulation versus basal (mean ± SD; where *, p < 0.05; ***, p < 0.001). 
 
3.1.4 Assessment of the enrichment of AP-1 and markers of transcription on 
collagenase gene promoters 
 
With improved understanding of c-Fos/c-Jun AP-1 factor gene expression and protein 
production, it was evident that the functional effects of these transcription factors 
were almost immediate. The transient induction of both mRNA and protein indicated 
that the functional contribution was early and may not fully account for the temporal 
lag between c-Fos/c-Jun peak and collagenase expression. I therefore used ChIP to 
better assess the transcriptional regulation of collagenase genes by c-Fos. This allowed 
me to compare and contrast c-Fos gene expression and protein production data with 
its capacity to bind at the collagenase gene promoters. ChIP was also used to assess 
transcriptional activation of collagenase promoters, by assessing RNA polymerase II 
(pol II) phosphorylation which correlates with transcriptional initiation, allowing 
comparison between gene expression and c-Fos binding. This may also reveal if the 
regulation of pol II ‘pausing’ at the promoter [190] may be accounting for the temporal 
deficit. These studies allowed me to consider dynamic, functional changes that take 
place at the collagenase gene promoters in response to IL-1+OSM stimulation.    
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A key step in the ChIP technique is chromatin shearing which determines subsequent 
binding site prediction and primer design. Figure 18 confirms appropriate chromatin 
shearing at various concentrations of gDNA. At all three concentrations, chromatin 
shearing by high powered sonicating water bath produced fragments that were 
approximately 200 – 500bp in length. This meant that I could be confident that 
enrichment demonstrated in ChIP experiments was occurring within the promoter 
region. It also showed that I could sonicate concentrated sample volumes without 
compromising shearing efficiency and therefore multiple immunoprecipitations from 
the same sample could be sonicated at the same time. 
 
Figure 18: Agarose gel electrophoresis analysis of HAC gDNA fragment length following shearing. Three amounts 
of gDNA taken from an individual HAC population isolated from a singular patient sample was subject to cell lysis. 
The concentration of DNA was measured and split between 1.5 ml tubes at the indicated amounts made up to the 
same volume in lysis buffer. The samples were then subject to sonication, shearing the gDNA into small fragments. 
The product was then resolved on agarose gel (3%), supplemented with ethidium bromide, by electrophoresis. DNA 
fragments were visualised using syngene software. Markers indicate DNA fragment size. 
 
Using ChIP, Figure 19A shows the temporal changes in c-Fos enrichment at the 
proximal promoter and 3’UTR of MMP1 and MMP13. Following 1 hour stimulation, c-
Fos binding to the proximal promoter was increased for both collagenases when 
compared to basal. Post 1 hour IL-1+OSM stimulation, enrichment of c-Fos decreased 
to levels comparable with basal. There was no observable increase in c-Fos binding in 
the 3’UTR following any duration of IL-1+OSM stimulation. A further series of 
experiments confirmed the significant but transient enrichment of c-Fos to the 
collagenase promoters at the early, 1 hour IL-1+OSM stimulation (Figure 19B). These 
ChIP data confirm that, along with FOS expression and protein production, enrichment 
to the collagenase promoter following stimulation is also rapid but transient. 
gDNA (μg):    25 50        100
1000
500
400
300
200
75 
 
 
Figure 19: ChIP analysis of MMP gene enrichment by c-Fos. HAC were treated with IL-1 (0.05ng/ml) in combination 
with OSM (10ng/ml) for indicated durations. Cells were then subject to DNA-protein cross-linkage, lysis and DNA 
shearing. Immunoprecipitation for c-Fos and isolation of complexed gDNA allowed the assessment of c-Fos binding 
to indicated regions on the MMP1 and MMP13 genes by real-time PCR. Data were pooled from three (A) and six (B) 
separate HAC populations. Statistical analysis are shown for enrichment following 1 hour IL-1+OSM stimulation 
versus 4 hours (mean ± S.D.; *, p <0.05) and 1 hour versus unstimulated (mean ± S.D.; #, p <0.05). For details on 
ChIP primer sequences and their position in relation to TSS see table 4 in chapter 2.2.4.2. 
 
Pol II is the enzyme responsible for generating nascent mRNA from a gene. The 
phosphorylation of serine 5 (ser 5) in the carboxy N-terminal domain results in 
promoter escape and the initiation of active transcription [167]. I used pol II as a 
marker of active transcription at the collagenase proximal promoters. The fold 
enrichment of pol II (Ser 5 phos-CTD) over basal, on both the MMP1 and MMP13 
proximal promoters, was observed to increase gradually from 1 to 24 hours post IL-
1+OSM stimulation (Figure 20A). This observation was more striking for MMP1 
promoter enrichment. There was no observable increase in pol II (Ser 5 phos CTD) 
binding in the 3’UTR following any duration of IL-1+OSM stimulation. Repeating these 
data in 5 further HAC populations (Figure 20B) confirmed the significant enrichment of 
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pol II (Ser 5 phos CTD) on MMP1 and MMP13 proximal promoters at 24 hours 
compared to 1 hour of IL-1+OSM stimulation. These data taken with gene expression 
studies, show that collagenase gene expression correlates directly with recruitment of 
pol II (Ser 5 phos CTD). Therefore, pol II ‘pausing’ at the promoter does not appear to 
account for the time taken for collagenase gene expression to be initiated following 
the peak of c-Fos and c-Jun.  
 
Figure 20: ChIP analysis of MMP enrichment by RNA polymerase II (Ser5 phosphorylation of carboxy terminal 
domain).  HAC were treated with IL-1 (0.05ng/ml) in combination with OSM (10ng/ml) for the indicated durations. 
Cells were then subject to DNA-protein cross-linkage, lysis and DNA shearing. Immunoprecipitation for RNA 
polymerase II (Ser5 phosphorylation on carboxy-terminal domain) and isolation of complexed gDNA allowed the 
assessment of RNA polymerase II binding to indicated regions on MMP1 and MMP13 gene by real-time PCR. Data 
were pooled from three (A) and five (B) separate HAC populations. Statistical analysis are shown for enrichment 
following 24 hour IL-1+OSM stimulation versus 1 hour (mean ± S.D.; *, p <0.05) and 24 hours versus unstimulated 
(mean ± S.D.; #, p <0.05). For details on ChIP primer sequences and their position in relation to TSS see table 4 in 
chapter 2.2.4.2. 
 
Acetylation of histone H3 leads to nucleosome charge neutralisation, thus removing 
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crucial for the access of trans-activating transcription factors to cis-binding elements 
within gene promoters [163], allowing  transcription to occur. Acetylated histone H3 is 
therefore a useful marker of transcriptionally permissive chromatin. Levels of 
acetylated histone H3 associated with the proximal promoters of both MMP1 and 
MMP13 were found to increase from 1 to 24 hours following IL-1+OSM stimulation. 
Acetylated histone H3 levels were not elevated above basal at the 3’UTR of either 
collagenase gene following any duration of IL-1+OSM stimulation (Figure 21). As with 
pol II (Ser 5 phos CTD) data, histone acetylation correlated directly with collagenase 
gene expression. This means histone modifications that govern how permissive 
chromatin is to transcription may be a rate limiting step in collagenase gene 
expression.  
Observations from these ChIP data continually demonstrate higher fold enrichment at 
the MMP1 promoter compared to MMP13. MMP1 has been shown to be expressed at 
levels approximately 10 times greater than that of MMP13 in primary chondrocytes 
[45]. This disparity in expression levels between the collagenases may well be 
manifested at the level of transcription initiation and histone acetylation thereby 
accounting for the higher MMP1 promoter enrichment levels compared to MMP13.  
 
Figure 21: ChIP analysis of MMP enrichment by Acetylated Histone H3.  HAC were treated with IL-1 (0.05ng/ml) in 
combination with OSM (10ng/ml) for the indicated durations. Cells were then subject to DNA-protein cross-linkage, 
lysis and DNA shearing. Immunoprecipitation for acetylated histone H3 and isolation of complexed gDNA allowed 
the assessment of acetylated histone H3 association to indicated regions on MMP1 and MMP13 gene promoters by 
real-time PCR. Data were pooled from two separate HAC populations. For details on ChIP primer sequences and 
their position in relation to TSS see table 4 in chapter 2.2.4.2. 
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3.1.5 Investigation into the contribution of new protein synthesis on the 
regulation of collagenase gene transcription  
 
My previous findings confirmed that following IL-1+OSM stimulation, MMP1 and 
MMP13 are dependent on both c-Fos and c-Jun (Figure 11), and that FOS gene and c-
Fos protein induction were both rapid and transient. Together, these data indicate that 
there is a temporal deficit between c-Fos binding and initiation of MMP transcription. I 
therefore proposed that c-Fos was necessary, but not sufficient, to regulate 
collagenase gene expression. As such I carried out protein synthesis inhibition 
experiments to determine if newly produced or, constitutively active, regulatory 
factors were contributing to collagenase gene expression. 
Emetine is a protein synthesis inhibitor which acts by binding to the 40S ribosomal 
subunit, preventing ribosome translocation along mRNA, therefore inhibiting protein 
synthesis. Emetine was added at sequential time points up to 24 hours post IL-1+OSM 
stimulation. Stimulation of HAC for 24 hours with IL-1+OSM led to a significant 
increase in MMP1 gene expression over basal. Similarly, significant inductions of 
MMP1 were observed when emetine was added at 6 and 8 hours post the initiation of 
IL-1+OSM stimulation. However, the addition of emetine within the first 4 hours post 
IL-1+OSM stimulation strikingly resulted in no significant increase in MMP1 gene 
expression (Figure 22A). Furthermore, similar results were observed with MMP13 with 
significant expression only being observed when emetine was added 8 hours post IL-
1+OSM stimulation (Figure 22B). These data indicate that new protein synthesis is 
required post-c-Fos/c-Jun peak and that the expression of new factors that contribute 
to the regulation of collagenase genes are produced up to 6 and 8 hours (MMP1 and 
MMP13, respectively) after the initial stimulation.  
This above study suggests that, although important, c-Fos and c-Jun do not solely 
regulate collagenase transcription and that factors, expressed after c-Fos/c-Jun peak, 
are crucial in bringing about collagenase gene expression. Interestingly, this means 
that other contributing factors are yet to be revealed. I hypothesised that these factors 
are likely to be transcription factors themselves and that because these factors are 
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produced after c-Fos/c-Jun peak, they may too be regulated by AP-1.  Further study 
was then undertaken to try and elucidate these factors. 
 
Figure 22: Real-time PCR analysis of IL-1+OSM stimulation of HAC in the presence of protein synthesis inhibition. 
HAC were treated with IL-1 (0.05ng/ml) in combination with OSM (10ng/ml) for 24 hours. Emetine (10 mM), a 
protein synthesis inhibitor, was added at the indicated times following IL-1+OSM stimulation. Cell lysates were 
subjected to real-time PCR and the relative expression levels of MMP1 (A) and MMP13 (B) mRNA, normalized to the 
18S rRNA housekeeping gene, were determined. Data are representative of three separate experiments, each using 
chondrocyte cultures (assayed in hextuplet) from different donors. IL-1+OSM versus basal (mean ± SD; ###, p < 
0.001) and IL-1+OSM+emetine versus basal (mean ± SD; *, p <0.05; ***, p < 0.001) 
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3.2 Discussion 
 
Cartilage degradation by collagenases as a consequence of pro-inflammatory cytokine 
stimulation is an important pathological process [37, 191, 192], that subsequently 
results in the loss of articular collagen and cartilage architecture contributing to 
patient pain and disability [193]. Within IL-1+OSM-mediated collagenase gene 
expression, an apparent role has been demonstrated for the transcription factor AP-1. 
My data reveal that although the c-Fos/c-Jun AP-1 heterodimer is crucial for 
MMP1/MMP13 gene regulation there is a striking temporal deficit between c-Fos/c-
Jun expression and collagenase gene induction. My investigations suggest that there 
are clearly additional de novo generated factors which are required to mediate 
collagenase expression.  
A key finding within Chapter 3 was that there is a clear temporal deficit in AP-1 
expression and collagenase induction following IL-1+OSM stimulation, highlighting 
somewhat of a discrepancy in the AP-1-dependent transcriptional regulation of 
collagenase paradigm. Silencing FOS and JUN affects collagenase expression 
highlighting their functional importance to this process. These AP-1 factors are also 
rapidly and transiently induced, yet, collagenase expression, transcription initiation 
and chromatin unwinding all begin to increase at times after the point at which AP-1 
returned to unstimulated levels. This suggests that the AP-1 heterodimer of c-Fos/c-
Jun could act as a transcription initiator and is the first step in a sequence of complex 
molecular events that ultimately culminate in collagenase transcription. The 
mechanism by which this occurs is unclear. One mechanism I proposed was that after 
the initiation of gene expression by c-Fos/c-Jun, transcription machinery was 
established on the collagenase gene promoter. This complex would build transcript 
levels through continual recycling and re-initiation of the transcription cycle 
accounting for the observed gradual increase in collagenase gene expression over time 
[194]. Another theory is that AP-1 heterodimers were required to initiate a cascade of 
transcriptional and post-transcriptional events that gradually bring about the full 
complement of molecules necessary for optimal gene transcription. The transcription 
cycle is governed by the ordered recruitment and replacement of various co-factors in 
a cascade of events that leads to formation of a pre-initiation complex at promoters 
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and productive elongation [171]. Martens et al [158] and Schmucker et al [115] both 
highlight the sequential recruitment of various regulatory factors to the promoter 
region of MMP1 and MMP13, respectively. This includes c-Fos and c-Jun as well as pol 
II and chromatin remodelling factors and histone modifications. As such, there are 
many potential processes that could account for the temporal deficit. 
Pol II pausing is a regulatory process that occurs after the formation of the pre-
initiation complex on gene promoters. Studies have indicated that pausing is a key 
regulatory mechanism that acts to maintain the gene in a state ready for productive 
elongation to rapidly occur [190]. Two pause-inducing factors, DRB-sensitivity-inducing 
factor (DSIF) and negative elongation factor (NELF) halt the transcription complex soon 
after transcription initiation. The kinase P-TEFb then phosphorylates DSIF, NELF and 
CTD domain of pol II allowing elongation to occur [195]. I hypothesised that pol II 
pausing may be occurring on the collagenase promoter with c-Fos/c-Jun initiating 
transcription only for it to be immediately paused. The release of the transcription 
complex was then dependent on factors that were expressed during the temporal 
deficit. However, direct correlation between collagenase gene expression and pol II 
enrichment showed that pausing was unlikely to be occurring as transcription initiation 
resulted in simultaneous gene expression. Moreover, genes controlled in this manner 
are normally IEG that require rapid induction upon stimulation, such as FOS and MYC 
[196, 197], rather than secondary response genes, like MMP13 [198], that require 
activation by IEG.   
Another explanation for the temporal deficit was that the chromatin structure 
surrounding the collagenase genes could be delaying the binding and recruitment of 
transcriptional machinery. Histone modifications act to tighten or loosen chromatin, 
either directly by removing the attraction between histones and DNA or by providing 
docking sites for chromatin remodelling complexes such as SWI/SNF [162]. These 
modifications are targeted events thus allowing distinct regions of chromatin to open 
allowing access to the gene.  Previous studies have shown that histone modifications 
play a role in regulating MMPs [199-202] including the collagenases [158, 172] with 
one study showing binding of c-Fos/c-Jun dimer to a SWI/SNF subunit thereby 
governing trans-activation capacity [203]. My own data demonstrated a direct 
correlation between increasing histone H3 acetylation and pol II enrichment to 
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collagenase promoters, and collagenase expression. These data led me to hypothesise 
that following IL-1+OSM stimulation, histone modifications were gradually re-
modelling the chromatin structure around the collagenase genes over a 24 hour 
duration, resulting in more transcriptionally permissive chromatin and therefore 
increasing pol II enrichment and increasing gene expression. 
Histone modifiers such as, HDAC 1 and 2 and the histone acetylase (HAT), p300, are 
constitutively expressed in chondrocytes [158, 174, 204]. As such, histone 
modifications would be able to be carried out despite protein synthesis inhibition and 
therefore if collagenase gene regulation was dependent on histone modifications this 
inhibition would not affect MMP1 and MMP13 gene expression. However, my data 
demonstrate that protein synthesis inhibition abrogated collagenase gene expression 
for up to 8 hours following the initiation of IL-1+OSM stimulation. This was a crucial 
finding as it showed that histone modifications were not able to account for the 
observed temporal deficit. Furthermore, these findings also suggested that the basic 
building of transcript level over time was unlikely to account for the temporal deficit as 
transcription is unaffected by protein synthesis inhibition. Previous study is limited 
with regard to the effects of protein synthesis inhibition on MMP expression, with no 
literature in the context of pro-inflammatory stimulation of chondrocytes. Some 
literature corroborates my own findings in cancer cell lines following stimulation with 
TGF-β [198], while other studies in osteoblastic cell lines show that inhibition of de 
novo protein synthesis does not affect FOS, JUN or MMP13 expression following 
mechanical stress and ultrasound [205-207]. This is to be expected in the case of FOS 
and JUN as they are both IEG, however, the lack of effect on the known secondary 
response gene, MMP13, which, by its definition, requires de novo protein synthesis for 
its expression is somewhat questionable. 
An observation I found interesting was that FOS silencing had a greater effect on 
MMP1 and MMP13 expression than JUN. A reason for this may be attributed to c-Jun 
promiscuity. c-Jun is capable of dimerising with proteins from either Fos or Jun families 
whereas c-Fos can only dimerise with Jun family members [208]. Therefore, when FOS 
is silenced the induction of c-Jun by IL-1+OSM may lead to a high proportion of c-Jun 
homodimers, an AP-1 complex that is less capable of DNA binding than heterodimers 
[138, 209]. Conversely, JUN silencing could still result in heterodimers of c-Fos with 
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other Jun members that retain a slightly reduced DNA binding capacity [210]. This 
would also go some way to explain why there was no difference in MMP13 expression 
between FOS silencing alone or in combination with JUN silencing. MMP1 expression 
however does decrease more significantly when both FOS and JUN are silenced 
compared to FOS alone. This could be due to differential regulation of MMP1 and 
MMP13 that has been postulated previously by Catteral et al [82] and Litherland et al 
[97, 104]. Indeed, the component members of the AP-1 homo/heterodimer govern the 
induction of different genes, at different times in many cells types throughout the 
body [208]. The regulation of MMP1 may be more strictly regulated by c-Fos/c-Jun 
heterodimer and so more susceptible to JUN silencing and altered heterodimer 
partners than MMP13. In-line with this, though not significant, MMP1 expression 
decreased to a greater extent compared to MMP13 following JUN silencing. Evidence 
for this differential regulation of functionally similar genes by different AP-1 dimer 
constituents is observed in the control of cell cycle progression [139].  
siRNA gene silencing was employed to determine the role of AP-1 factors in 
collagenase expression. Although siRNA gene silencing is a useful tool to understand 
gene regulation it has limitations. Transfection efficiency is never 100%, and thus, the 
degree of gene silencing achieved is subject to the transfection efficiency and potency 
of the siRNA.  Furthermore, gene knock-down occurs only transiently as the finite 
amount of siRNA transfected into the cell is degraded along with the target mRNA by 
RISC [211]. As such it is the cellular process hijacked by the in vivo administration of 
dsRNA that ultimately leads to siRNA degradation. This means that, over time, FOS and 
JUN silencing will diminish, allowing for new protein synthesis to occur and their 
function within the cell to be detected. However, in this context I demonstrate the 
rapid transient gene induction of FOS has returned to unstimulated levels following 
approximately 2 hours of IL-1+OSM stimulation. The loss of gene silencing, therefore, 
should not significantly affect knock down. Another potential concern is the difference 
in transfection efficiency within different HAC populations. The ECM surrounding 
cultured HAC severely affects transfection efficiency [212, 213]. Some HAC populations 
may be capable of synthesising ECM at a greater rate than others, a characteristic that 
may well be exemplified by the individual populations differing capacity for gene 
expression following cytokine stimulation [72]. As such increased ECM deposition 
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would impede transfection to a greater extent and therefore lead to less efficient gene 
silencing in that population of HAC. Another consideration when using siRNA gene 
silencing is that many commercially available gene-specific siRNA have a certain degree 
of non-specific, “off-target” gene silencing [214, 215]. Alongside the obvious unwanted 
effects of non-specific gene silencing, the specifically targeted genes may, 
consequently, be subject to less efficient silencing. Differences in FOS and JUN siRNA 
efficiency will therefore also contribute to the differences in protein induction and the 
expression of collagenases. There are many alternative methods that could be used 
including short hairpin (sh)RNA, antisense oligonucleotides and morpholinos. There are 
also inhibitors that selectively inhibit c-Fos binding to AP-1 elements in murine models 
[159]. However, these methods also have their own disadvantages and when 
considering the experimental questions being asked in my study, siRNA-mediated gene 
silencing was an appropriate technique that was succesfully used to answer them. 
One of the more striking observations from the above study was that c-Fos, at the level 
of gene and protein induction, was rapidly and transiently induced. Other studies have 
demonstrated this characteristic of FOS: Pre-adipocytes stimulated with growth 
hormone [216], monocytes stimulated with TPA [217], and pulmonary smooth muscle 
cells stimulated with serotonin [218] all display this transient gene expression. The 
variety of stimuli and cell type that elicit the same response coupled with similar work 
carried out in chondrocytes stimulated with IL-1 alone or in combination with OSM 
[82] suggest that this rapid induction and equally rapid degradation curtails protein 
function. A rapid and robust onset acts like an ‘on’ switch resulting in a relatively 
instant abundance of mRNA and protein. Coupled with rapid protein degradation [219] 
and high mRNA instability (dependent on a 3’UTR mRNA destabilising element) [220, 
221], c-Fos is only allowed to function in a very short period of time. The FOS gene is 
therefore termed an IEG in that there is no or very little expression occurring at basal 
conditions with rapid and transient induction following stimulus [189]. This is a very 
important level of regulation, as c-Fos is crucial in cell differentiation and proliferation 
[222]. Thus, c-Fos oncogenic function is well documented to play a role in both cancer 
growth and the down regulation of tumour suppressor genes [223] with over 
expression of c-Fos  correlating to many types of cancers and their individual severities 
[223-226]. The speed with which the c-Fos signal is returned to unstimulated levels 
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therefore abrogates oncogenic potential. This rapid and transient induction thus 
confirms that c-Fos is an important transcriptional regulator immediately after the 
initiation of IL-1+OSM stimulation of HAC. It also shows that aberrant collagenase 
expression is not as a result of a loss in c-Fos regulation.  
c-Jun also adheres to a similar temporal profile at the level of both gene and protein 
induction as c-Fos (supported in further studies [227-229]). Furthermore, FOS 
exhibited a very distinct transient peak in expression, whereas JUN expression, 
although decreased post 1 hour, remained significantly enhanced throughout the 24 
hour IL-1+OSM time course. A potential explanation for this is that c-Jun activity is 
dependent not only on its mere presence (as with c-Fos) but also by post-translational 
modifications that improve its ability to bind to DNA. The JNK-mediated 
phosphorylation of serine 63 in the NH2-terminal transactivation domain of c-Jun 
dramatically enhances transcription factor activity [230-232]. As such gene expression 
does not require the strict control enacted upon it through protein and mRNA 
degradation as seen with c-Fos and therefore no functional consequences of 
persistently high mRNA levels are seen. Previous experimentation has shown that use 
of pan-c-Jun antibody revealed no effect on protein levels following IL-1+OSM 
stimulation [97]. Accordingly, western blot analysis for c-Jun was carried out with an 
antibody specifically for endogenous serine 63 phosphorylated c-Jun and as such could 
explain why protein levels were more transient than c-Fos. The proto-oncogene 
capacity of JUN [233, 234] shows the need for strict regulation of its activity, like that 
required for FOS. As such, c-Jun effector function is as rapid and transient as c-Fos, 
however, this functional profile is imparted at the level of post-translational 
phosphorylation, whereas c-Fos is regulated at the level of gene expression and 
degradation. This demonstrates that although JUN expression was not as robust or as 
transient as FOS, it is still capable of contributing equally to gene regulation. 
An interesting observation was that the decreases in FOS expression post 1 hour IL-
1+OSM stimulation occurred in not only gene expression but also c-Fos protein 
production and DNA binding. However, changes in protein levels are not as transient 
as gene expression or DNA binding. In the case of c-Fos promoter enrichment, it would 
be expected that this would correlate with protein and not gene expression. The 
reason for this may simply be that as the transcription machinery is assembled at the 
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promoter post c-Fos binding, the epitope to which the c-Fos antibody binds is ‘masked’ 
preventing antibody binding and pull down of gDNA cross-linked to it [235]. Another 
explanation may be that due to the high amount of c-Fos generated in the chondrocyte 
following 1 hour IL-1+OSM stimulation, there may be non-functional binding to AP-1 
elements on proximal promoters that otherwise would not readily allow factor 
binding. ChIP may therefore demonstrate a false positive at this stimulation duration. 
However, this is unlikely as protein levels (Figure 15) indicated that c-Fos binding to 
chromatin was more finite than its presence within the soluble nuclear fraction, 
perhaps, in-part, due to saturation of binding sites within the genome. This in itself is 
worth taking into consideration in that chromatin-bound levels are an indicator of total 
c-Fos binding, not collagenase promoter binding. This means that c-Fos enrichment 
may well be as finite as indicated in my ChIP studies and that soluble nuclear and 
chromatin-bound protein levels are misleading as they do not demonstrate binding to 
a specific gene. The assembly of transcriptional machinery is a dynamic system by 
which factors are recruited, modified and replaced rapidly [236]. c-Fos bound to the 
promoter may, therefore, be concealed within the growing transcriptional complex 
being assembled at the promoter [171] and therefore c-Fos is unable to be 
immunoprecipitated. As such I cannot be entirely sure that the binding of c-Fos to 
collagenase promoters is as transient as my ChIP data suggest. This does not call into 
question the need for other contributing factors but does suggest that c-Fos may have 
a less transient role in collagenase gene regulation. 
Study in this chapter serves to highlight the false assumption that c-Fos/c-Jun AP-1 are 
solely responsible for the regulation of collagenase genes. It is now evident that other 
regulatory factors are being produced subsequent to c-Fos/c-Jun which significantly 
contribute to this complex mechanism of transcriptional regulation. Further study, 
therefore, will focus on trying to elucidate these factors.     
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3.2.1 Summary 
 
 c-Fos/c-Jun gene expression, protein production and collagenase promoter 
binding occur rapidly yet transiently following IL-1+OSM stimulation in HAC.  
 There is a temporal deficit between the transient gene induction/collagenase 
promoter enrichment of c-Fos and the initiation of collagenase gene 
transcription.  
 Though important, c-Fos/c-Jun is not the sole transcriptional regulator of 
collagenase genes, with the induction of other contributing factors after the 
transient induction of AP-1 necessary in order to allow effective transcription. 
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4 Chapter 4: Identification of novel factors 
contributing to collagenase transcriptional 
regulation 
 
4.1 Introduction 
 
Observations within Chapter 3 demonstrated a temporal deficit between the transient 
induction of c-Fos/c-Jun AP-1 factors and the initiation of collagenase transcription. I 
hypothesised that new factors, critical for the transcriptional activation of 
collagenases, were being synthesised post-AP-1 induction in order to effect the 
subsequent IL-1+OSM-mediated collagenase gene expression in HAC. 
The concept that collagenase transcriptional regulation is more complex than simply c-
Fos/c-Jun promoter binding is rarely addressed. Long standing dogma states that only 
a very limited number of transcription factors are of critical transcriptional importance, 
other than AP-1 [112, 113]. Moreover, there is little reference to temporal recruitment 
of AP-1 members in chondrocytes [158]. As such, this level of regulation and the 
dynamic changes that occur over time in response to IL-1+OSM remain under-
investigated. Greater knowledge about the transcriptional regulation of collagenases 
may highlight factors that display specificity toward the expression of the enzymes that 
drive collagen degradation in arthritis.  
With its ubiquitous nature in orchestrating early gene regulatory events, AP-1 factors 
were also believed to be playing a role, not only in the regulation of collagenase gene 
expression but also in the expression of these other contributing factors. This 
hypothesis was based on the fact that rapid induction of FOS did not result in 
immediate collagenase gene expression, yet the AP-1 heterodimer, c-Fos/c-Jun, has 
proven functional importance in collagenase gene expression [97, 158, 159]. As such, I 
postulated that AP-1-dependent transcriptional regulation was due in-part, to indirect 
gene regulation of other factors that themselves contribute to collagenase gene 
regulation.  
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I therefore needed to determine what kinds of factors were governing this 
transcription, post-AP-1 peak; this would have implications on the method by which I 
elucidated these factors. I decided that assessing global gene expression with the use 
of DNA microarray would allow me to be able to observe changes in expression 
patterns of genes between certain time points. It would also allow for internal 
validations to be carried out, thereby allowing me to compare expression data with 
previous observations in order to confirm appropriate HAC gene expression in 
response to IL-1+OSM. This would highlight genes that could be potentially regulated 
by AP-1, or at least be expressed within the temporal deficit between peak AP-1 
induction and the start of collagenase gene expression.  
Using prior validation and quality controls, genome-wide gene expression changes 
were assessed using a DNA microarray of IL-1+OSM-stimulated HAC for durations 
intended to reveal genes contributing to collagenase transcriptional regulation. This 
was followed by rigorous assessment of genes and post-hoc control analysis. 
4.1.1 Individual chondrocyte population validation prior to DNA microarray 
analysis 
Before I could begin to extract RNA from HAC the durations of IL-1+OSM stimulation, 
intended to elucidate contributing genes, needed to be determined. This was 
necessary because stimulations for experimental validation and RNA isolation for the 
DNA microarray were carried out in parallel. This meant that I could not validate 
individual HAC populations prior to RNA extraction. Therefore, I had to treat each 
population as a potential candidate for DNA microarray study. 
The decision as to which stimulation durations were used to assess changes in gene 
expression via the DNA microarray was of great importance. The HumanHT-12 v4 
Expression Beadchip used for DNA microarray analysis contains 12 wells each 
containing 47,000 transcript probes dotted on to their surface. I decided that I would 
carry out the gene expression analysis in 3 HAC populations and pool the data. 
Consequently, I was able to stimulate each population at a maximum of 4 different 
durations. Enrichment of the collagenase gene promoter region by c-Fos, FOS 
expression and c-Fos protein induction all reached their maximal levels following 1 
hour IL-1+OSM stimulation. Furthermore, MMP1 and MMP13 expression peaks 
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following 24 hour stimulation. As such 1 hour and 24 hours durations, as well as 
unstimulated condition, were chosen for use as controls and comparators for one 
other duration. I decided that this duration had to be after 1 hour in order to reveal 
gene expression that could be accounting for the temporal deficit. It also had to be 
very soon after 1 hour in order to improve the likelihood of elucidating AP-1-
dependent gene expression. In Figure 23, the reduction in FOS expression, following 1 
hour maximal expression to 1.25 hours was greater than that of 1.25 to 1.5 hours 
indicating the extremely transient nature of FOS and the potential for rapid induction 
of the genes being regulated by it. As such I decided that 1.25 hour stimulation may 
reveal genes that contribute to collagenase gene regulation and along with 1 and 24 
hours, as well as unstimulated control, were used in subsequent experiments (as 
discussed in section 4.2).  
 
 
Figure 23: Real-time PCR analysis of FOS gene expression following different durations of IL-1+OSM stimulation. 
HAC were treated with IL-1 (0.05ng/ml) in combination with OSM (10ng/ml) for indicated durations. Cell lysates 
were subjected to real time PCR and relative expression levels of FOS mRNA, normalized to the 18S rRNA 
housekeeping gene, were determined. Data are representative of two separate experiments (each assayed in 
hextuplet) each using chondrocyte cultures from different donors (Mean ± SD; where *, p < 0.05; **, p < 0.01; ***, 
p < 0.001 vs basal). HAC populations were confirmed to demonstrate synergistic expression of MMP1 following 24 
hour IL-1+OSM stimulation versus IL-1 or OSM alone (data not shown).   
 
4.1.1.1 Selection of HAC populations to be analysed via DNA microarray 
 
Gene expression responses by HAC can be highly variable [72], in that some 
populations will respond poorly to enzymatic digestion and consequently cells can fail 
to grow correctly and/or have little response to synergistic IL-1+OSM stimulation. To 
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avoid the failure of microarray analysis based on erroneous HAC responses, I subjected 
isolated HAC populations to a strict series of validations and quality controls to confirm 
both gene expression and the ability of IL-1+OSM to synergistically induce collagenase 
expression.  
Figure 24 to Figure 27 present the experimental evidence that was used to select HAC 
populations that demonstrated appropriate, previously described characteristics. I 
then selected samples for DNA microarray based on the following criteria:  
1) Populations demonstrated a robust, high magnitude expression of MMP1 and 
MMP13 expression over basal levels [72, 82, 237]. 
2) The expression of collagenases by individual HAC populations, in response to IL-1 
alone and in combination OSM, was synergistic [72, 82, 237]. 
3) Gene expression (FOS, MMP1 and MMP13) and protein induction (c-Fos) at 
stimulation durations intended to elucidate factors contributing to collagenase 
transcriptional regulation in the DNA microarray corroborate with previous study 
in chapter 3. 
4) RNA isolated from these populations met with the quality control standards 
required for use with DNA microarrays. This included my own spectrophotometric 
analysis of sample purity and external quality control checks (carried out by 
Cambridge Genomic services) using Agilent 2100 Bioanalyzer.  
HAC were isolated from cartilage samples taken from 13 individual donors and 
assessed for MMP1 gene expression. Figure 24 demonstrates the variation of MMP1 
expression in response to IL-1+OSM stimulation. Based on these results, the 6 
populations that had the highest fold expression of MMP1 (highlighted in red) were 
then subject to further validations of their gene expression. This was because HAC 
populations that demonstrated more robust gene expression, were more likely to 
better represent normal, IL-1+OSM-responsive chondrocytes.  
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Figure 24: Real-time PCR analysis of IL-1+OSM stimulation response in 13 patient samples.  HAC were treated with 
IL-1 (0.05ng/ml) in combination with OSM (10ng/ml) for 24 hours. Cell lysates were subjected to real-time PCR and 
relative expression levels of MMP1 mRNA, normalized to the 18S rRNA housekeeping gene, were determined. Each 
data point represents a separate chondrocyte culture from a different patient donor. Data points in red indicate 
donor populations used for further study. 
Based on the synergistic response of chondrocytes to IL-1 in combination with OSM 
[76], Barksby et al [72] demonstrated that although the magnitude of collagenase 
expression changed between HAC populations, all the populations had a similar 
relative fold increase following stimulation with IL-1+OSM compared to IL-1 alone. As 
such, the expression levels of the 6 HAC populations selected from Figure 24 gave an 
indication of their validity for further study but did not confirm whether or not they 
demonstrated synergistic collagenase expression. 
I next assessed if the 6 HAC populations exhibited enhanced collagenase expression 
following synergistic IL-1+OSM stimulation. Figure 25 demonstrates that MMP1 
expression, in all 6 populations, was significantly increased above basal conditions 
following 24 hour stimulation with IL-1 alone and in combination with OSM. 
Furthermore, in the majority of the HAC populations IL-1+OSM stimulation resulted in 
a significant increase in MMP1 expression compared to IL-1 alone. In addition, the 
majority of the HAC populations exhibited increased MMP13 expression following 24 
hour stimulation with IL-1 alone and in combination with OSM. Only one population 
(donor 3) showed significant increase in expression following IL-1+OSM stimulation 
compared to IL-1 alone. As such, the lack of synergy was taken in to account when 
selecting the populations used for the DNA microarray. 
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Figure 25: Real-time PCR analysis of MMP1 and MMP13 gene expression following IL-1 and OSM stimulation in 6 
populations of HAC.  6 HAC populations taken from different donors (as indicated) were treated with IL-1 
(0.05ng/ml), OSM (10ng/ml) alone and in combination for 24 hours. Cell lysates were subjected to real-time PCR 
and relative expression levels of MMP1 and MMP13 mRNA, normalized to the 18S rRNA housekeeping gene, were 
determined. Each population assayed in octuplet (stimulated vs basal; mean ± S.D. where *, p <0.05; **, p <0.01; 
***, p < 0.001. I+O versus IL-1; mean ± S.D. where ††, p <0.01; †††, p < 0.001) 
 
To assess the IL-1+OSM-mediated induction of c-Fos in HAC population, protein was 
isolated, concomitantly with RNA, from the majority of the 13 HAC populations 
acquired. It must be noted that nuclear protein from only 4 of the 6 populations 
selected from Figure 24 was isolated because the nuclear localisation protocol failed to 
isolate protein and was changed during the time taken to acquire all the samples from 
different populations. In the 4 populations shown in Figure 26, c-Fos was not present 
in unstimulated conditions as previously observed. Following 1 hour IL-1+OSM 
stimulation c-Fos was present in all populations with levels returning to unstimulated 
levels (donor 2 and 3) or markedly decreasing (donors 4 and 6) following 24 hour 
stimulation. Levels of c-Fos protein remained comparable between 1 and 1.25 hours in 
donors 2, 4 and 6, with levels in donor 3 decreasing. This meant that of the populations 
tested, temporal c-Fos protein profile of donor 2 and 3 were in-line with previous 
Basal IL-1 IL-1+OSM
0
10
20
M
M
P
1
/1
8
S
 r
R
N
A
(f
o
ld
 b
a
s
a
l 
c
h
a
n
g
e
)
Basal IL-1 IL-1+OSM
0
10
20
30
M
M
P
1
3
/1
8
S
 r
R
N
A
(f
o
ld
 b
a
s
a
l 
c
h
a
n
g
e
)
***
††
†††
††
***
**
*
***
***
*
**
***
**
***
†† ***
51 2 3 4 6
***
†††
††
94 
 
observations in chapter 3. These results were taken into account when selecting the 
populations to be used in DNA microarray study. 
 
Figure 26: Western blotting for c-Fos in nuclear lysates generated from HAC stimulated with IL-1+OSM 4 HAC 
populations taken from different donors were stimulated with IL-1 (0.05ng/ml) in combination with OSM (10ng/ml) 
for the indicated durations. Cells were then subject to cytoplasmic-nuclear protein fractionation. Proteins from 
nuclear fraction were resolved using SDS-PAGE and immunoblots probed using c-Fos antibody. Donor 2 blot was re-
probed for Lamin A/C and used as loading control. 
 
The six HAC populations that demonstrated the highest fold increase in MMP1 
expression, as shown in Figure 24, underwent final validation in order to determine the 
suitability for use in DNA microarray study (Figure 27). Control genes (FOS, MMP1 and 
MMP13) were assessed following IL-1+OSM stimulation at 1, 1.25, or 24 hours. As 
previously demonstrated, MMP1 and MMP13 expression remained low at both 1 and 
1.25 hours post IL-1+OSM stimulation, whereas 24 hours post stimulation resulted in a 
marked increase in expression of collagenase genes. Furthermore, each population 
exhibited the previously observed increase in relative MMP1 expression compared to 
MMP13 ([45] and in Chapter 3). In addition, the six HAC populations exhibited 
enhanced FOS expression following 1 hour IL-1+OSM stimulation compared to basal, 
which rapidly decreased after 1.25 hours stimulation duration (as observed in Figure 
23) and were barely detectable following 24 hours stimulation. This confirmed that 
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expression of control genes, as assessed from the RNA extracted for use in the DNA 
microarray, were responsive to IL-1+OSM, as previously demonstrated. 
Following experimental validations outlined in Figure 24 to Figure 27, I selected 3 
populations (donors 1-3) that I believed to be good representations of synergistically 
responsive HAC, based on the combined selection criteria (as above). DNA microarray 
analysis was then performed on HAC populations 1-3 including the experimental 
conditions: basal, and 1, 1.25, and 24 hours post IL-1+OSM stimulation.  
 
 
Figure 27: Real-time PCR analysis of MMP1, MMP13 and FOS following IL+OSM stimulation of HAC.  6 HAC 
populations taken from different donors (as indicated) were treated with IL-1 (0.05ng/ml) in combination with OSM 
(10ng/ml) for indicated durations. RNA was isolated from cells and subject to real time PCR and relative expression 
levels of FOS, MMP1 and MMP13 mRNA, normalized to the 18S rRNA housekeeping gene, were determined. 
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4.1.2 DNA microarray   
The RNA samples were then hybridised on to a HumanHT-12 v4 Expression Beadchip 
(Illumina) which has 47,000 transcripts and known splice variants, known as features, 
spotted onto its surface. Relative hybridisation to these features is then measured 
giving a raw data value. The data from all 3 populations at each time point was then 
subject to comprehensive analysis and data visualisation with GeneSpring software. 
This allowed a vast amount of raw, arbitrary hybridisation values to be compared and 
contrasted between the different IL-1+OSM durations. It also enabled the pooling of 
relative gene expression from the different populations and subsequent statistical 
analysis.  
GeneSpring also allowed the integrated analysis of heterogeneous data. The degree of 
heterogeneity was evident from hierarchical clustering of the genome in the different 
populations at the different stimulation durations. Clustering in this manner identifies 
linkages and concordant expression patterns to cluster the genes in a dendrogram 
(tree diagram) as seen in Figure 28A and, specifically, for the 65 most significantly 
altered genes in Figure 28B. There are notable observations that came as a 
consequence of this hierarchical clustering. Firstly, all 24 hour stimulation durations 
from all three HAC populations clustered together, independently of other durations in 
those populations. This indicates that there is marked difference in global gene 
expression between very early and late time points. This could be due to the fact that 
very few genes respond with such immediacy to IL-1+OSM stimulation. It could also 
mean that few genes demonstrated any responsiveness to IL-1+OSM stimulation 
within the cell, which is entirely possible considering many genes are constitutively 
active in all cells and/or in differentiated cells, like chondrocytes. Also of note is that 
donor 1 samples (apart from 24 hour duration) cluster together, whilst donor 2 and 3 
cluster together according to duration, not donor. This is evidence that, despite 
extensive validations in order to control for HAC population variability, difference in 
population gene expression had occurred. As such gene expression at early time points 
and basal controls in donor 1 was different to that of donor 2 and 3 which had similar 
temporal gene expression patterns to one another.  
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In Figure 29, the FOS gene expression for individual donors was taken from the raw 
data of the DNA microarray and re-plotted with separate histograms for each. This 
figure demonstrates that although the populations used for the microarray varied in 
the magnitude of FOS expression, the change in expression between durations in the 
same population is relatively similar in all three donors. I therefore decided that it was 
not necessary to omit data from donor 1, based on the fact that in Figure 28 the 
donors clustered differently, as all demonstrated similar relative FOS expression. 
 
Figure 28: Genome-wide heat map analysis.  HAC populations isolated from different donors (Donor 1-3) were 
stimulated with IL-1 (0.05ng/ml) in combination with OSM (10ng/ml) for the indicated durations. RNA was isolated 
from cell lysates and hybridised on HumanHT-12 v4 Expression Beadchip kit to assess changes in gene expression. A, 
global representation of changes in gene expression within the genome of the 3 populations. B, representation of 
expression of the first 65 clustered genes. Green represents genes with increased expression, red for decreased 
expression and black for genes with no change in expression.  
 
A B
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Figure 29: Relative FOS gene expression in HAC populations isolated from three separate donor samples. 3 HAC 
populations were taken from different donors (as indicated) and treated with IL-1 (0.05ng/ml) in combination with 
OSM (10ng/ml) for indicated durations. RNA was then isolated from cell lysates and hybridised on a HumanHT-12 v4 
Expression Beadchip to assess changes in gene expression. FOS expression is plotted relative to unstimulated 
control.  
In Figure 30, the mean values of the fold change in expression of individual genes 
generated by the array for the three populations at each IL-1+OSM duration of 
stimulation were plotted on Volcano plots. As such every gene that changed in its 
expression between the indicated IL-1+OSM stimulations is represented as a single 
data point. Genes that exhibited a significant change in expression, with a corrected p-
value ≤ 0.05, were plotted in combination with a two-fold change threshold 
demonstrating the cut-off point at which genes below this expression level would be 
omitted from the study. This was a higher threshold than other microarray studies in 
this research area [238-240] and so was intended to strictly limit the pool of genes 
carried forward for further study. It also meant that genes demonstrating a robust 
change in expression were more likely to be relevant to study than those with only 
moderate fold change. The change in threshold for 1 to 1.25 hours (Figure 30D) was 
due to the fact that only one entity from the DNA microarray was significantly elevated 
≥2 fold and this entity did not code for a gene but for a miscellaneous RNA transcript. 
Lowering this relatively high threshold meant that I could compare the few genes that 
changed in their expression in this comparison group. 
The genes of interest highlighted in red within these Volcano plots serve as controls for 
appropriate IL-1+OSM-dependent gene expression (FOS, JUN, MMP1 and MMP13) and 
candidates for genes that either increase in their expression after FOS peak or remain 
up-regulated between early time points (AXUD1, ATF3, EGR1 and EGR2). For example, 
in Figure 30A FOS is one of the most highly expressed genes following 1 hour IL-1+OSM 
stimulation. In Figure 30B it remains highly expressed but the fold change is 
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dramatically decreased compared to Figure 30A. This observation is complemented by 
Figure 30D, E and F which show that FOS is consistently one of, if not the most down-
regulated genes at stimulation durations after 1 hour. The expression of MMP1 and 
MMP13 only increase in Figure 30C, E and F. These graphs all compare gene expression 
changes between early time points (C, basal; E, 1 hour; and F, 1.25 hours) and 24 
hours. These observations indicate that the expression of FOS is early and transient 
and that collagenases are expressed at much later time points, in line with previous 
observations. With the lack of any substantial increase in genes between 1 to 1.25 
hours none of the 11 genes, comprised of chemokines, receptors and non-coding RNA 
were deemed to be relevant to the study. The focus of the study then shifted to genes 
that increased from basal to both 1 hour and 1.25 hour. EGR2 and ATF3, along with 
FOS, are significantly up-regulated following 1 hour stimulation (Figure 30A) however 
following 1.25 hours (Figure 30B) EGR2 and ATF3 remain up-regulated whereas FOS 
has significantly decreased (Figure 30D). This shows that these genes may well be 
candidates for further investigation.  
As a result of these data, genes possibly contributing to collagenase regulation were 
selected from just two comparison groups:  genes changing in expression from basal to 
1.25 hour post IL-1+OSM stimulation and from basal to 1 hour. By comparing these 
sets of genes in combination with genes up-regulated from basal to 24 hours I was able 
to discount genes that had not returned to low levels following 24 hours stimulation 
and thus did not demonstrate transient gene expression. Moreover, by not including 
genes only increasing in expression from basal to 1 hour I was able to omit genes that 
were unlikely to be contributing to transcription at time points after AP-1 induction. 
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Figure 30: Volcano plots showing changes in gene expression between different durations of IL-1+OSM 
stimulation of HAC. Scatter plot diagrams showing fold up and down regulated gene expression changes between 
two IL-1+OSM stimulation durations and their significance. Data represent the average fold gene expression of 3 
HAC populations. 2 fold (A, B, C, E and F) and 1.5 (D) fold threshold lines are indicated on individual plots. Gene 
expression comparison as follow: A, 1 hour IL-1+OSM vs Basal, B, 1.25 hour IL-1+OSM vs Basal, C, 24 hour IL-1+OSM 
vs Basal, D, 1.25 hour IL-1+OSM vs 1 hour IL-1+OSM, E, 24 hour IL-1+OSM vs 1 hour IL-1+OSM, and F, 24 hour IL-
1+OSM vs 1.25 hour IL-1+OSM. Genes of interest have been highlighted in red. 
 
4.1.2.1 Candidate genes selected for further study 
The purpose of the microarray was to elucidate factors that may be contributing to the 
transcriptional regulation of collagenase genes soon after or as a consequence of c-
Fos/c-Jun regulation following IL-1+OSM stimulation. By comparing the changes in 
global gene expression between early time points and control time points I was able to 
identify genes that may be relevant for further study. The selection process by which 
these genes were then chosen was based on several parameters that were intended to 
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highlight the most pertinent genes in the context of collagenase transcriptional 
regulation. These parameters were as follows: 
1) Change in fold expression of genes was ≥2. 
2) The change in gene expression had a significant corrected p-value. 
3) Gene expression was induced after 1 hour IL-1+OSM stimulation and increased or 
remained high between 1 hour and 1.25 hours.  
4) Literature search of genes adhering to parameters 1-3 indicated their possible 
relevance in the context of transcriptional regulation. 
5) Assessment of the promoter of collagenases demonstrated that factors had the 
potential capacity to bind to specific sites within the promoter. 
To assess the temporal expression of the individual candidate genes in each donor and 
assess whether these genes adhered to the third selection parameter (as above) I 
assessed the raw data values from the genome-wide expression analysis of the 
candidate genes. The majority of the genes in Figure 31 adhered to the third selection 
parameter; increasing from 1 to 1.25 hours and exhibiting reduced expression 
following 24 hours IL-1+OSM stimulation. This expression pattern was in-keeping with 
my previous hypothesis, whereby genes expressed after FOS peak may be contributing 
to the temporal lag that precedes the initiation of collagenase expression and that 
these may also be dependent on AP-1 for their own expression. MMP1, MMP13, FOS 
and JUN gene expression were also isolated from the genome-wide expression data to 
confirm validations carried out prior to the array (Figure 27). These selected candidates 
that may be contributing to collagenase regulation included the gene ATF3.  ATF 
members can dimerise with members from the AP-1 family and bind to AP-1 elements 
[241] highlighting the possibility that cross-family dimerisation between ATF3 and AP-1 
factors could contribute to the regulation of the collagenases. Similarly, there are 
many AP-1 factors other than FOS and JUN that increased in expression from 1 hour to 
1.25 hours indicating that although important, c-Fos/c-Jun dimers may not be the only 
constituents of regulatory AP-1 dimers for collagenase gene regulation. It is also 
interesting that many members of the same transcription factor family also display the 
same gene expression profile (3 out of the 4 early growth response (EGR) and 
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immediate early response (IER) family members). This may simply be due to the fact 
they all have similar, overlapping function within the chondrocyte and so there is no 
differential regulation. Even so, they may all contribute to collagenase regulation. 
Although not adhering to parameter 3, Hypoxia-inducible factor-1alpha (HIF1A) is 
interesting as chondrocytes are subject to a hypoxic environment associated with OA 
progression [242] and so this induction may be of interest outside the postulated gene 
expression profile. 
In Figure 32, a small proportion of the RNA extracted for the experimental validations 
for the 6 HAC populations (Figure 25 and Figure 27) was used to assess gene 
expression using real-time PCR with primers for the specific genes of interest in 
combination with probes from the universal probe library. One of these genes includes 
Axin-1-induced gene (AXUD1) which demonstrated notably similar gene expression 
profile in all 6 populations. Little study exists regarding this transcription factor and 
therefore it may prove to be a very interesting, novel candidate. As with HIF1A, bone 
morphogenetic protein (BMP)2 does not strictly adhere to parameter 3 but previous 
study has demonstrated it to be key to chondrocyte maturation [243], a process which 
leads to hypertrophy and aberrant collagenase expression [244]. The similar temporal 
changes in gene expression in the majority of the 6 populations for each of these genes 
allows for a greater confidence in the selected genes potentially playing a role in 
collagenase gene regulation. 
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Figure 31: Relative gene expression generated from microarray 3 HAC populations were taken from different donors (1, ●; 2, ▲; 3, ■) and treated with IL-1 (0.05ng/ml) in combination with OSM 
(10ng/ml) for indicated durations. RNA was then isolated from cell lysates and hybridised on HumanHT-12 v4 Expression Beadchip kit to assess changes in gene expression. Gene expression relative to 
unstimulated control of individual population was plotted for the indicated genes. Mean ±S.D.  
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Figure 32: Real-time PCR analysis of gene expression. 6 HAC populations taken from different donors (1, ●; 2, ■; 3, ▲; 4, o; 5, □; 6, Δ) were treated with IL-1 (0.05ng/ml) in combination with OSM 
(10ng/ml) for indicated durations. RNA was isolated from cells and subject to reverse transcriptase-PCR and relative expression levels of indicated genes, normalized to the 18S rRNA housekeeping 
gene, were determined. Mean ±S.D. 
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Genes that were deemed to be relevant and had trans-activating capacity were then 
subject to binding site prediction within the proximal promoters of MMP1 and MMP13 
genes. The online software tool, PROMO [245], allows the identification of putative 
transcription factor binding sites within a designated section of DNA. A graphical 
representation is generated which combined with information on sequence specificity 
shows regions of transcription factor binding on the collagenase promoters (Figure 33).  
Analysis of one such transcription factor of interest, Nuclear factor of activated T-cells 
cytoplasmic 1 (NFATC1), showed that it had multiple binding sites within both the 
MMP1 and MMP13 promoter indicating that it may be involved in trans-activation of 
these genes. Calcineurin is a phosphatase that de-phosphorylates NFATC1 allowing it 
to shuttle into the nucleus [246]. The calcineurin inhibitors, cyclosporine and 
tacrolimus are used in combination with methotrexate to successfully treat active RA 
[247]. Other studies have also shown that the treatment of an OA mouse model with 
cyclosporine attenuates cartilage degradation [248]. These studies, taken with its 
potential to bind and trans-activate both the collagenase promoters means that 
NFATC1, as well as these other highlighted factors, is a very interesting gene candidate 
for further study.  
 
Figure 33: Diagrammatic representation of MMP1 and MMP13 proximal promoters and predicted transcription 
factor binding sites. Transcription factor binding site software was used to predict where certain indicated factors 
may possibly bind in the proximal promoter regions of MMP1 and MMP13. The distance from the transcription start 
site for each binding site is denoted below. 
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4.2 Discussion 
 
In chapter 4 I aimed to identify potential regulatory factors contributing to collagenase 
gene expression within the temporal deficit discovered in chapter 3. I assessed 
experimentally validated HAC populations by DNA microarray at 1, 1.25, and 24 hours 
post IL-1+OSM stimulation. The DNA microarray analysis revealed a number of exciting 
candidate genes, relevant to the transcriptional regulation of collagenases, that 
warranted further study.  
The genes selected were all associated with compelling evidence indicating their 
potential role in collagenase gene regulation in HAC in response to pro-catabolic 
cytokine stimulation. This included many members of the AP-1 transcription factor 
family. This was an interesting finding as previous study carried out by our group and 
others had only focused on c-Fos/c-Jun dimers [82, 97, 115, 158]. As such, this 
represented a good opportunity to assess which of these AP-1 factors may contribute 
to collagenase regulation. Catterall et al [82] showed that AP-1 consensus sequences 
are bound in unstimulated chondrocytes demonstrating a potential capacity for AP-1 
factors to repress gene expression. Previous study on the Jun family member JunB has 
indicated that it is capable of both activating and repressing collagenase gene 
expression. Deng and Karin [249] demonstrate that the JunB/c-Jun dimer is associated 
with transcriptional repression. Chiu et al. [250] also demonstrated JunB-mediated 
repression of c-Jun-dependent MMP1 promoter constructs activation. However, when 
in the presence of c-Fos, JunB activated these promoter constructs. These studies 
suggest that in the context of my study, JunB may well be acting as a repressor. c-Jun 
has a positive feedback loop in which it activates its own expression [251]. JunB may 
be leading to repression of c-Jun-dependent JUN expression following stimulation. It 
may also be forming dimers with c-Jun at times after the 1 hour FOS peak, repressing 
the collagenase promoter thereby accounting for the time taken to initiate collagenase 
gene expression. Alternatively, JunB may be forming dimers with c-Fos which may 
contribute to the activation of collagenases or of other factors that are themselves 
capable of regulating the collagenases. Another of the AP-1 factors selected in this 
chapter, FosB is capable of dimerising with JunB inducing MMP2 expression in cardiac 
myocytes [252]. This study also demonstrated that another AP-1 factor, Fra-1 (FOSL1) 
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highlighted in my study, could also form dimers with JunB and activate expression in 
the same way. Other studies implicate Fra-1 in the regulation of the collagenase MMP8 
through an interaction with STAT3 [253]. This is of interest as silencing of STAT3 in IL-
1+OSM stimulated HAC has been shown by our group to lead to the marked reduction 
of c-Fos and collagenase expression [97]. As such STAT3 may not only be regulating 
collagenase expression in-directly through c-Fos, but also directly in combination with 
Fra-1. These studies all serve to emphasise the need to better understand collagenase 
gene regulation and whether or not these AP-1 factors selected following the study 
carried out in this chapter are contributing to this regulation. 
Another interesting set of candidate genes are EGR1-3. Previous study has shown that 
EGR1 is an IEG expressed in chondrocytes in response to IL-1 [254]. This transcriptional 
regulator has also been shown to be co-regulated with FOS and has been 
demonstrated to have very similar expression kinetics to FOS [255]. Moreover, both 
FOS and EGR1 expression are induced in collagenase-expressing RA synoviocytes [146, 
256]. Taken together with studies implicating EGR1 in the regulation of MMP14 
expression [257], there is compelling evidence that EGR1 may well be regulating 
collagenase gene expression, possibly in collaboration with c-Fos, thereby leading to 
cartilage destruction in arthritic disease. EGR2 has been shown to be activated in 
hypertrophic chondrocytes and is crucial in developmental pathways [258]. Although 
literature searches do not reveal any direct links to collagenase gene regulation or 
control of chondrocyte proliferation, EGR3 (as well as EGR2) has been shown to be 
involved in T and B lymphocyte proliferation [259]. This suggests that this family of 
transcription factors may potentially be playing a role in chondrocyte proliferation into 
a mature phenotype which is a process that underpins cartilage ossification into bone 
[260]. The re-initiation of these developmental pathways and the maturation of 
chondrocytes in OA is a key pathological step which leads to the aberrant expression of 
MMP13 which degrades cartilage [244]. 
Other factors of interest selected from DNA microarray analysis are linked to 
chondrocyte proliferation. BTG2 for example, has been shown to have a potential role 
as a transcriptional co-regulator in cell growth and cell cycle control in neurones [261, 
262]. Another such factor is BMP2, a member of the transforming growth factor (TGF) 
β superfamily, which also plays a critical role in developmental pathways in neuronal 
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cell phenotype development and also in orchestrating programmed cell death in 
embryonic limb formation [263-265]. However, it is perhaps the critical role of BMPs in 
cartilage and bone formation for which the majority of study of BMP2 has taken place. 
BMPs are crucial in the differentiation of mesenchymal stem cells to osteoblast and 
osteoclasts and the regulation of their cellular function, thus orchestrating bone 
formation and its remodelling [266]. A great deal of study has also highlighted the 
importance of BMP2 in all levels of chondrogenesis including chondrogenic lineage 
development [267], chondrocyte proliferation and maturation [243] and ECM 
deposition [268]. At odds with this anabolic function, BMP2 also leads to increased 
expression of MMP13 by chondrocytes in response to IL-1 [269-271]. However, both 
collagen deposition and degradation are characteristics of OA chondrocytes. 
Interestingly, as well as MMP13, BMP2 also increases the expression of SOX9 [272]. 
This is a transcription factor that is critical in the differentiation of mesenchymal stem 
cells to chondrocytes [273]. This is interesting because BMP2 has been demonstrated 
to lead to Sox-9 binding with CREB, promoting DNA binding [273]. Bui et al [102] 
demonstrated that CREB binding was necessary for induction of MMP13 expression in 
OA chondrocytes. Therefore, autocrine/paracrine BMP2 signalling, induced by IL-
1+OSM stimulation, may be facilitating CREB binding to the MMP13 promoter 
accounting for elevated expression in OA. It must be noted that BMP2 is not a 
transcription factor and so did not meet the expression parameters for gene selection 
(as above). However, its association with aberrant collagenase production and its 
potential in-direct role in MMP13 regulation made it a compelling gene for further 
study.  
Similar to BMP2, other selected genes did not exhibit the gene expression profile 
outlined in parameter 3. However, evidence implicating these transcription factors in 
arthritic disease meant that further study would be of great interest; HIF1A was one 
such factor. This factor plays a critical role in the response of cells to hypoxia. It is a 
secondary response transcription factor and has been shown to be regulated by NFκB 
[274] and has been shown to cooperate with c-Jun/AP-1 in gene regulation [275]. A 
great deal of compelling evidence exists linking HIF1A to arthritis; this factor is up-
regulated in patient samples taken from both RA and OA sufferers [276] and HIF1A 
transcripts correlate with areas of articular cartilage degradation [277]. With regards 
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to pro-inflammatory cytokine stimulus, the up-regulation of HIF1A expression in 
articular chondrocytes has been shown to be induced by IL-1 stimulation [277-279]. 
Moreover, IL-1-dependent MMP1 and MMP13 expression in synovial fibroblasts has 
been shown to be HIF1A-dependent [280]. The functionally related HIF2A has also 
been shown to induce MMP1 and MMP13 expression in chondrocytes. Moreover, 
HIF2a-deficiency in mice led to the abrogation of induced arthritis model [281]. 
Previous study therefore made HIF1A a very interesting factor in the context of IL-
1+OSM-mediated collagenase gene expression in chondrocytes. Although this factor 
did not adhere to the experimental parameters as set out in this chapter, and since the 
transcriptional regulation of collagenases was proving to be highly complex, I deemed 
that discounting such an IL-1+OSM-induced factor that has been so heavily linked to 
arthritic disease and cartilage degradation would be unnecessarily limiting further 
study in this instance.  
The decision as to how one might elucidate factors that were affecting the expression 
of the collagenase genes was crucial. It was evident from observations in chapter 3 
that gene regulation, governed by factors that are constitutively expressed in the 
chondrocytes, were not as critical as those that required the induction of their own 
gene expression, subsequently or in parallel, with AP-1 expression. As such it was 
decided that a DNA microarray would identify novel genes that were induced by IL-
1+OSM and that by comparing their expression pattern at certain time points, I would 
be able to deduce whether their expression could account for the observed temporal 
lag in the previous chapter. It must be considered that the induction of gene 
expression and the translation into protein are distinct processes and therefore raises 
the question as to the appropriateness of assessing changes in mRNA and not protein. 
There exist many post-transcriptional gene regulatory mechanisms that dictate the 
rate at which nascent pre-mRNA is processed and translated into protein. However, 
the majority of pre-mRNA generated through transcription of genes, is immediately 
spliced into mRNA [282]. The polyadenylation of the mRNA, protecting it from 
exonucleases and targeting it for transport out of the nucleus also occurs in relatively 
rapidly following splicing [283]. Moreover, the transport of mRNA to translation sites 
outside of the nucleus is carried out by transport factors that bind co-transcriptionally 
allowing immediate shuttling to ribosomes for translation [284]. In the context of a 
110 
 
substantial temporal deficit between AP-1 rapid, transient induction and the late-onset 
of MMP expression, these processes provide a negligible contribution to this lag and 
so, gene expression and protein production are considered to be closely correlated. 
Furthermore, considering the short stimulation durations used, gene expression and 
concomitant production of protein is maintained, supporting the use of DNA 
microarray. Short stimulations allow the induction of IEG, such as AP-1 factors to be 
observed. As mentioned previously, the transient nature of IEG governs the function of 
their corresponding protein [189]. In the case of AP-1, the rapid induction and equally 
rapid reduction means that the action of this transcription factor is finite and therefore 
is unable to elicit any unwanted oncogenic functioning [223]. As such any factors 
capable of being induced after relatively short stimulation durations are likely to be 
translated in a similarly rapid manner. Combined with prior knowledge of the 
technique I concluded that DNA microarray assessing genome-wide gene expression 
changes was an appropriate method for elucidating novel genes.  
With this understanding I reasoned that by investigating gene expression changes at 
these early time points I would be able to establish which factors, that remained un-
synthesised during protein synthesis inhibition studies, were contributing to the 
transcription of the collagenases. Alternatively, I could have assessed differences in 
actual protein profile by carrying out mass spectrometry studies between these 
different durations. Such quantitative proteomic techniques such as isotope-coded 
affinity tags (ICATs) would be very informative in terms of trying to account for the 
protein synthesis occurring in the temporal deficit between peak c-Fos and initiation of 
collagenase transcription that may contribute to this gene regulation. Whilst this was a 
viable option for the elucidation of contributing factors, I decided that assessing gene 
expression changes allowed me to validate the appropriate induction of control genes, 
such as FOS and MMP1, with greater ease and accuracy than by assessing protein. As 
such this allowed me to compare pre- and post-DNA microarray gene validations with 
data yielded from the DNA microarray itself thus providing confidence in the observed 
gene expression changes for potential contributing gene regulatory factors. The 
practicalities of assessing temporal gene expression of many different candidate genes 
were far easier to overcome than if I were trying to evaluate the same number of 
proteins. The fact that I had hypothesised that some of these contributing factors may 
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also be AP-1-dependent meant that the analysis of gene expression attributed to 
regulation by AP-1 more accurately than protein production. Finally, lower costs, time 
constraints and the presence of expertise within the group to prepare samples and 
analyse the data generated by DNA microarray meant that this analysis was the most 
viable option for factor elucidation in this instance.     
Study in this chapter has provided me with a selection of factors that may be 
contributing to the regulation of collagenase genes at points within the temporal 
deficit between FOS peak and the initiation of collagenase gene expression. In the next 
chapter I will investigate these factors in greater detail by silencing these genes in HAC 
stimulated with IL-1+OSM and assessing the effect on MMP1 and MMP13 expression. 
 
4.2.1 Summary 
 
 Multiple HAC populations were experimentally validated for appropriate 
collagenase and AP-1 gene expression. Isolated RNA from those populations 
deemed suitable for further study was used for analysis of gene expression 
using DNA microarray. 
 In-depth bioinformatic analysis of DNA microarray data and subsequent 
experimental validation highlighted a number of genes that were governed to 
be capable of contributing to collagenase gene expression in concert with 
and/or as a result of AP-1 regulation.   
 The following genes were identified and deemed suitable for further study: 
ATF3, AXUD1, BMP2, BTG2, EGR1/2/3, FOSB, FOSL1 (Fra-1), HIF1A, IER2/3/5, 
JUNB and NFATC1. 
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5 Chapter 5: Investigation of novel regulators of 
collagenase transcription 
 
5.1 Introduction 
 
Chapter 4 revealed a number of genes potentially relevant to IL-1+OSM-dependent 
transcriptional regulation of the collagenases during the AP-1-collagenase temporal 
deficit. Within this Chapter I aimed to determine which of these genes were 
functionally relevant to collagenase expression and to also investigate if c-Fos/c-Jun 
AP-1 factors are responsible for the regulation of these factors. 
5.1.1 Functional assessment of candidate gene 
 
In order to ascertain the functional relevance of these genes in IL-1+OSM-mediated 
MMP1 and MMP13 expression, each gene was individually silenced using siRNA. Prior 
to siRNA transfection, the effect of transfection reagent alone and in combination with 
control siRNA upon expression of the collagenases was assessed. Figure 34 
demonstrated that there was no significant difference in IL-1+OSM-dependent 
collagenase gene expression in HAC treated with transfection reagent alone or in 
combination with siRNA control. This therefore confirmed that in subsequent 
experiments, any changes in collagenase expression observed were as a result of siRNA 
knock-down. Furthermore, all three HAC populations from individual donors 
demonstrated synergistic MMP1 and MMP13 expression in-line with previous 
observations [72]. This response was used in subsequent experiments to ensure that 
inappropriate HAC responses to stimulation were unlikely to account for any changes 
in gene expression following knock-down. 
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Figure 34: Real-time PCR analysis of the effect of transfection reagent, Dharmafect and siRNA control on MMP 
gene expression in IL-1+OSM stimulated HAC. HAC were treated with IL-1 (0.05ng/ml) alone or in combination with 
OSM (10ng/ml) for 24 hours. Cell lysates were subjected to real-time PCR and the relative expression levels 
of MMP1 and MMP13 mRNA, normalized to the 18S rRNA housekeeping gene, were determined. Data are from 
three separate chondrocyte cultures from different donors. (Stimulated vs Basal; mean ± S.D. where *, p <0.05; **, 
p <0.01; ***, p < 0.001; I+O vs. IL-1; mean ± S.D. where ††, p <0.01; †††, p < 0.001) 
Collagenase gene expression was then assessed following 24 hour IL-1+OSM 
stimulation, in the presence or absence of individual siRNA against the genes identified 
by the DNA microarray (listed, for reference, in Table 7). Figure 35 shows the effect of 
this silencing on both MMP1 (Figure 35A) and MMP13 expression (Figure 35B) as a 
percentage of IL-1+OSM-stimulated control (denoted as siCON). The silencing of a 
number of genes such as BMP2, AP-1 factors FOSB and FOSL1 and all three IER genes 
led to a significant reduction in the expression of both collagenases (Figure 35A and B, 
black bars). The silencing of factors that led to decreased expression of both 
collagenases showed that work performed in chapter 4 had elucidated a number of 
genes that in the majority played a significant role in transcriptional regulation within 
the chondrocyte. Conversely, some genes that were highlighted in chapter 4 study did 
not affect the IL-1+OSM-mediated expression of MMP1 or MMP13, following their 
silencing (Figure 35A and B, open columns). BTG2 and EGR1 are two such 
transcriptional regulator genes that, despite playing a role in differentiation and 
cellular growth [261, 262, 285, 286] , a process key to chondrocyte hypertrophy in 
arthritic disease [244], do not affect gene expression when silenced. This was also the 
case for HIF1A, a promising candidate transcription factor which has been shown to be 
associated with areas of articular cartilage degradation [277] and is up-regulated in 
both RA and OA [276]. These results indicate that although these transcription factors 
adhered to gene expression profile parameters outlined in chapter 4, they were not 
functionally relevant in the context of collagenase gene regulation in chondrocytes. 
Interestingly, a number of these selected genes, when silenced, only led to the 
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reduced expression of one collagenase and not the other. These included ATF3, 
AXUD1, and EGR2. Previous studies have shown that MMP1 and MMP13 are 
differentially regulated [82, 97, 104, 112, 113]. As such, further investigation into these 
genes represents an important opportunity to better understand how these catabolic 
enzymes from the same protease family are regulated independently of each other.  
For this reason I decided to focus on these genes, deeming them worthy of more 
directed and thorough investigation for the remainder of my studies. 
JUNB also demonstrated differential regulation (significant reduction observed in 
MMP1 expression, Figure 35A, but no effect on MMP13 expression, Figure 35B) but 
was not investigated further. This was because it is an AP-1 member which is usually 
associated with repression of collagenases [153, 249] and so I decided that there were 
other genes of greater interest to investigate. I decided that along with ATF3, AXUD1 
and EGR2, NFATc1 was also worthy of further investigation. This is because NFATc1 
regulates the expression of ADAMTS-9 in IL-1-stimulated HAC [287] and its inhibition 
attenuates IL-1-mediated expression of MMP1 in OA chondrocytes [248]. Moreover, 
silencing data shows that silencing has more of an effect on MMP1 expression than 
MMP13 suggesting at possible role in differential regulation. 
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siRNA-silenced gene Protein name 
FOS (c-Fos)  FBJ murine osteosarcoma viral oncogene homolog 
JUN (c-Jun) Jun proto-oncogene 
ATF3 Activating transcription factor 3 
AXUD1 Axin-1-induced gene 
BMP2 Bone morphogenetic protein 2 
BTG2 B-cell translocation gene 2 
EGR1/2/3 Early growth response factor 1/2/3 
FOSB FBJ murine osteosarcoma viral oncogene homolog B 
FOSL1 (Fra-1) Fos-related antigen 1 
HIF1A Hypoxia-inducible factor 1 alpha 
IER2/3/5 Immediate early response gene 2/3/5 
JUNB Jun B proto-oncogene 
NFATC1 Nuclear factor of activated T-cells cytoplasmic 1 
 
Table 7: The fifteen potential transcriptional regulators, plus FOS and JUN, identified by the DNA microarray: Each 
gene was silenced by specific siRNA to assess the impact on IL-1+OSM-mediated MMP gene expression.  
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Figure 35: Real-time PCR analysis of the effect of gene silencing on MMP gene expression in IL-1+OSM stimulated 
HAC. Following transfection with siRNA specific for indicated genes or non-targeting siControl (100nM), HAC were 
treated with IL-1 (0.05ng/ml) in combination with OSM (10ng/ml) for 24 hours. Real-time PCR of isolated RNA was 
performed for MMP1 and MMP13 and normalised to 18S housekeeping gene. Data are pooled from three separate 
HAC populations (each assayed in octuplet) and expressed as a percentage of stimulated control (specific siRNA 
transfected vs. siCon-transfected; mean ± S.D.; *, p <0.05; **, p <0.01; ***, p < 0.001). Diagonal lined columns 
denote significant reduction in MMP1 expression alone following the silencing of the indicated genes; chequered 
for MMP13 alone; and black for both MMP1 and MMP13. Open columns indicate no significant inhibition. 
 
Having confirmed that siRNA gene silencing of ATF3, AXUD1, EGR2 and NFATc1 led to a 
significant reduction in collagenase expression, I next aimed to confirm that siRNA 
knock-down also resulted in a decrease in protein expression. In Figure 36, all 4 
proteins, following IL-1+OSM stimulation were observed to decrease in expression 
compared to siCON. Reduction in AXUD1 and EGR2 protein was also observed between 
siCON and specific gene knock-down at basal levels. ATF3 and NFATc1 levels were 
unaffected in unstimulated HAC transfected with specific siRNA.  This confirms that the 
observed changes in collagenase expression (Figure 35) were due to a successful 
reduction of gene expression and protein production following siRNA gene silencing. 
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Figure 36: Western blot for ATF3, AXUD1, EGR2 and NFATc1 following gene silencing. HAC were transfected with 
siRNA specific for ATF3, AXUD1, EGR2, NFATc1 or non-targeting siControl (siCON, 100nM) prior to stimulation with 
IL-1 (0.05ng/ml) in combination with OSM (10ng/ml) for 3 hours as indicated. Nuclear extracts were isolated and 
proteins resolved by SDS-PAGE. Immunblots were probed using the indicated antibodies. Blots shown are 
representative of three experiments using chondrocytes from different donors. Lamin A/C was used as a loading 
control. 
 
5.1.2 Temporal assessment of functionally relevant genes  
I next investigated the expression kinetics of the candidate genes. Having generated 
mRNA from three independent HAC populations I firstly confirmed the expression of 
FOS and MMP1 and MMP13 expression over a detailed time course. As previously 
shown, data in Figure 37 confirm that FOS is expressed both rapidly and transiently 
following IL-1+OSM stimulation and that expression of both MMP1 and MMP13 
expression did not significantly increase until 6 hours post IL-1+OSM stimulation. 
Increased gene expression was then maintained through to 24 hours. This confirmed 
that the HAC populations used to assess candidate gene expression kinetics 
demonstrated previously observed temporal gene expression profiles. 
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Figure 37: Real-time PCR analysis of control gene expression following different durations of IL-1+OSM 
stimulation. HAC were treated with IL-1 (0.05ng/ml) in combination with OSM (10ng/ml) for the indicated 
durations. Cell lysates were subject to real-time PCR and relative expression levels of mRNA, normalized to the 18S 
rRNA housekeeping gene, were determined for the indicated genes. Data are representative of three separate 
experiments each using chondrocyte cultures from different donors. Statistical analyses are shown for gene 
expression following IL-1+OSM stimulation versus basal (mean ± SD; where ***, p < 0.001). 
I then assessed the changes in ATF3, AXUD1, EGR2 and NFATc1 gene expression over 
the same time course (Figure 38) allowing for direct comparison of FOS and MMP1/13 
expression with newly identified regulatory factors. ATF3, AXUD1 and EGR2 gene 
expression increased from basal levels up to 1.25 hour IL-1+OSM stimulation. ATF3 
expression decreased after 1.25 hour yet remained significantly elevated above basal 
levels for the remainder of the time-course. AXUD1 and EGR2 gene expression also 
decreased after 1.25 hours remaining significantly elevated above basal levels until 4 
hours post IL-1+OSM stimulation but then decreased to levels comparable with basal 
gene expression. NFATc1 expression significantly increased from 1 to 1.25 hour 
stimulation, remained significantly increased following 2 hour stimulation and 
subsequently decreased to levels comparable with basal gene expression. These data 
indicate that, similar to FOS, expression of these factors is rapid, reaching a peak 
following short durations of IL-1+OSM stimulation. However, this expression is not as 
transient suggesting that these genes may not be conventional IEGs. These data also 
confirm DNA microarray data that show peak expression following FOS and JUN, 
suggesting a possible role for AP-1 factors in regulating these genes that contribute to 
collagenase expression. It must be noted that in Figure 38 each plot has a different 
scale on the Y axis meaning that each gene has different magnitudes of expression. 
Whilst ATF3, AXUD1 and EGR2 have robust gene expression compared to unstimulated 
levels, NFATc1 expression, though significant, is not nearly as robust as the other genes 
studied.  
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 Figure 38:Real-time PCR analysis of gene expression following different durations of IL-1+OSM stimulation. HAC 
were treated with IL-1 (0.05ng/ml) in combination with OSM (10ng/ml) for the indicated durations. Cell lysates were 
subject to real-time PCR and the relative expression levels of mRNA, normalized to the 18S rRNA housekeeping 
gene, were determined for the indicated genes. Data are representative of three separate experiments each using 
chondrocyte cultures from different donors. Statistical analysis are shown for gene expression following indicated 
IL-1+OSM stimulation versus basal (mean ± SD; where *, p < 0.05; **, p < 0.01; ***, p < 0.001) 
Having established the kinetics of gene expression, I then assessed candidate protein 
induction and the cellular localisation following IL-1+OSM stimulation time course used 
in previous study (chapter 3, Figure 14). As with gene expression in Figure 38, I was 
able to compare and contrast known changes in c-Fos and c-Jun protein levels with 
those of the newly identified contributing factors. Assessing cellular localisation would 
also give an indication if these factors were being regulated at the level of nuclear 
localisation [288, 289] which could explain the lack of robust changes in NFATc1 
expression observed in Figure 38.  
Figure 39A demonstrates that ATF3 protein was only found in the soluble nuclear 
fraction and was at very low level in basal conditions. Upon IL-1+OSM stimulation 
protein levels increased up to 3 hours and remained high until 6 hours post-stimulus. 
However, by 24 hours post IL-1+OSM stimulation protein levels had decreased to 
levels comparable with 1 hour post stimulations. In Figure 40A, EGR2 protein was only 
found in the soluble nuclear fraction with levels increasing up to 3 hours stimulation. 
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Expression of EGR2 marginally decreased by 6 hours post IL-1+OSM stimulation and 
had also returned to levels comparable with basal conditions following 24 hour 
stimulation. In Figure 41A, AXUD1 protein was observable in both soluble nuclear and 
chromatin-bound fraction. Protein levels in the soluble nuclear fraction increased 
following 1 hour stimulation and slightly increased from 1 hour to 3 hour IL-1+OSM 
stimulation where levels were maintained up to 6 hours post stimulation. Following 24 
hours IL-1+OSM stimulation AXUD1 protein levels had returned to levels comparable 
with basal. In the chromatin-bound fraction AXUD1 is present following all stimulation 
durations as well as basal control (Figure 41A). Protein levels all modestly increase 
above basal conditions following 1 hour IL-1+OSM stimulation (Figure 41C). NFATc1 
protein was present in cytoplasmic, membrane-bound and soluble nuclear fractions. 
There was no significant change in protein level of NFATc1 following any stimulation 
duration in any of the fractions in which NFATc1 is present (Figure 42A and B). 
Densitometric analysis of repeated HAC populations statistically confirms these 
observations following Western blot analysis for ATF3 (Figure 39B), EGR2 (Figure 40B), 
AXUD1 (Figure 41B and C) and NFATc1 (Figure 42B).  
These data indicate that these factors are unlikely to be regulated at the level of 
nuclear localisation as ATF3, EGR2 and AXUD1 are not observed in the cytoplasm and 
once translated are seemingly shuttled rapidly into the nucleus. Although NFATc1 is 
regulated at the level of nuclear localisation in response to increasing intracellular 
calcium signalling [246, 290] there are no observable changes in localisation between 
cytoplasmic and soluble nuclear fractions suggesting that NFATc1 may not be IL-
1+OSM-dependent. The observation that ATF3 and EGR2 protein levels increase over 
basal, peaking at stimulation durations later than the c-Fos peak, suggest that the time 
taken for their transcription and translation may partially account for the temporal 
deficit between c-Fos peak and initiation of collagenase expression. The robust and 
transient changes in AXUD1 gene expression are not reflected at the protein level 
indicating that there may be some other level of regulation occurring that may explain 
the lack of marked protein level changes.  
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Figure 39: Western blot for ATF3 in subcellular protein fractionation and densitometry from HAC stimulated with 
IL-1+OSM. HAC were stimulated with IL-1 (0.05ng/ml) in combination with OSM (10ng/ml) for the indicated 
durations. A) Cells were subject to subcellular protein fractionation. Proteins from cytosolic (a), membrane-bound 
(b), soluble nuclear (c), chromatin-bound, (d) and cytoskeletal (e) subcellular fractions were resolved using SDS-
PAGE and immunobloted with ATF3 antibody. Sample volumes loaded for SDS-PAGE were dependent on the 
relative volume into which the individual fractions were lysed. Images in this figure are cropped from larger 
exposure image. Full-length blots/gels are presented in Appendix 7.3, figure 50. Immunoblots shown are 
representative of three separate experiments each using chondrocyte cultures from different donors. B) Combined 
densitometric scans of three separate blots each from separate chondrocyte donor populations. Density is relative 
to unstimulated control (mean ± SD; where *, p < 0.05; **, p < 0.01; ***, p < 0.001). 
 
 
Figure 40: Western blot for EGR2 in subcellular protein fractionation and densitometry from HAC stimulated with 
IL-1+OSM. HAC were stimulated with IL-1 (0.05ng/ml) in combination with OSM (10ng/ml) for the indicated 
durations. A) Cells were subject to subcellular protein fractionation. Proteins from cytosolic (a), membrane-bound 
(b), soluble nuclear (c), chromatin-bound, (d) and cytoskeletal (e) subcellular fractions were resolved using SDS-
PAGE and immunoblotting with EGR2 antibody. Sample volumes loaded for SDS-PAGE were dependent on the 
relative volume into which the individual fractions were lysed. Images in this figure are cropped from larger 
exposure image. Full-length blots/gels are presented in Appendix 7.3, figure 52. Immunoblots shown are 
representative of three separate experiments each using chondrocyte cultures from different donors. B) Combined 
densitometric scans of three separate blots each from separate chondrocyte donor populations. Density is relative 
to unstimulated control (mean ± SD; where *, p < 0.05; **, p < 0.01; ***, p < 0.001). 
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Figure 41: Western blot for AXUD1 in subcellular protein fractionation and densitometry from HAC stimulated 
with IL-1+OSM. HAC were stimulated with IL-1 (0.05ng/ml) in combination with OSM (10ng/ml) for the indicated 
durations. A) Cells were subject to subcellular protein fractionation. Proteins from cytosolic (a), membrane-bound 
(b), soluble nuclear (c), chromatin-bound, (d) and cytoskeletal (e) subcellular fractions were resolved using SDS-
PAGE and immunoblotting with AXUD1 antibody. Sample volumes loaded for SDS-PAGE were dependent on the 
relative volume into which the individual fractions were lysed. Images in this figure are cropped from larger 
exposure image. Full-length blots/gels are presented in Appendix 7.3, figure 51. Immunoblots shown are 
representative of three separate experiments each using chondrocyte cultures from different donors. B) and C) 
combined densitometric scans of indicated subcellular protein fractionation of three separate blots each from 
separate chondrocyte donor populations. Density is relative to unstimulated control (mean ± SD; where *, p < 0.05; 
**, p < 0.01; ***, p < 0.001). 
 
Figure 42: Western blot for NFATc1 in subcellular protein fractionation and densitometry from HAC stimulated 
with IL-1+OSM. HAC were stimulated with IL-1 (0.05ng/ml) in combination with OSM (10ng/ml) for the indicated 
durations. A) Cells were subject to subcellular protein fractionation. Proteins from cytosolic (a), membrane-bound 
(b), soluble nuclear (c), chromatin-bound, (d) and cytoskeletal (e) subcellular fractions were resolved using SDS-
PAGE and immunoblotting with NFATc1 antibody. Sample volumes loaded for SDS-PAGE were dependent on the 
relative volume into which the individual fractions were lysed. Images in this figure are cropped from larger 
exposure image. Full-length blots/gels are presented in Appendix 7.3, figure 53. Immunoblots shown are 
representative of three separate experiments each using chondrocyte cultures from different donors. B) Combined 
densitometric scans of soluble nuclear fraction of three separate blots each from separate chondrocyte donor 
populations. Density is relative to unstimulated control (mean ± SD; where *, p < 0.05; **, p < 0.01; ***, p < 0.001). 
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5.1.3 Assessment of AP-1 regulation on genes contributing to collagenase 
transcription 
Having demonstrated that as with FOS and JUN, gene silencing of ATF3 led to a similar 
reduction of collagenase expression, I then wanted to identify whether or not ATF3 
was bound to the promoter region of MMP13 using ChIP. It was decided that ATF3 
would be investigated and not the other contributing factors as primary cell numbers 
were limited and a “ChIP-grade” ATF3 antibody was readily available. Prior to ATF3 
ChIP experiments, in vitro binding of ATF3 to AP-1 consensus sites present within the 
MMP13 promoter was demonstrated (Figure 43). Although these oligonucleotides did 
not contain consensus ATF3 binding sites, the AP-1 consensus is bound with equal 
avidity [241]. Only ATF3 was bound to this AP-1 oligonucleotide sequence following 6 
hour IL-1+OSM stimulation, unlike following 3 hour stimulation where c-Fos and p-c-
Jun (Ser 63) were also bound. This suggests that ATF3 is potentially capable of 
regulating the expression of collagenase genes subsequent to, and in the absence of, 
AP-1 factors. However, this may well be an observation that is dependent on protein 
abundance in the nuclear lysate which is mirrored in AP-1 pull-down and not 
necessarily due to regulated changes in transcription factor binding. This observation 
also reveals a potential mechanism for ATF3-dependent regulation of MMP13. ATF3 
can dimerise with members of the Jun family and activate gene expression [241, 291]. 
As such the constituents of the dimer bound on AP-1 binding sites on the MMP13 
promoter could be changing over time; as new genes are expressed these factors may 
then replace those previously bound to the promoter e.g. ATF/Jun dimer replacing c-
Fos/c-Jun dimer.   
In highlighting this binding capacity I gained some assurance that ATF3 protein levels 
were sufficiently high enough in order to bind following this IL-1+OSM duration. It also 
allowed me to keep subsequent ChIP experiments succinct without the need for 
extensive time course studies as in chapter 3, thereby reducing the number of HAC 
that I required. However, repeated attempts failed to show ATF3 binding to either 
collagenase promoters following 3 hours IL-1+OSM stimulation using ChIP. This could 
be accounted for by three possible scenarios: the first is that ATF3 does bind to one or 
both of these proximal promoters but the practicalities of carrying out ATF3 ChIP in 
primary cells is too difficult to overcome; secondly, ATF3 could be bound to an 
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enhancer element that is not encompassed within the resolution of my MMP13 
proximal promoter primer sets; and thirdly, ATF3 may not be bound to the promoter 
of either collagenase following IL-1+OSM stimulation. 
 
Figure 43: Western blot for indicated proteins following affinity pull-down assay using an AP-1 consensus site. 
HAC populations taken from different donors were stimulated with IL-1 (0.05ng/ml) in combination with OSM 
(10ng/ml) for the indicated duration. Cells were then subject to cytoplasmic-nuclear protein fractionation. A portion 
of nuclear lysates were incubated with double-stranded biotinylated oligonucleotide containing the AP-1 consensus 
binding site. Bound proteins were then subject to streptavidin coated agarose bead pull-down. Proteins were 
resolved using SDS-PAGE and immunobloted with the indicated antibodies. 
 
In the final stages of this study, I investigated the validity of the hypothesis which 
proposed that factors contributing to collagenase gene expression may themselves be 
regulated by AP-1 factors. Given that AP-1 factors play a role in regulating a large 
number of genes [292], I suggested that not only do they regulate collagenase 
expression but also these regulatory genes. Preliminary investigation using binding site 
prediction software [245], demonstrated that the three genes, with markedly induced 
gene expression, all contain multiple consensus AP-1 binding sites within the 2 kbp 
proximal to their TSS (Figure 44). This indicates that these genes were capable of being 
regulated by AP-1 through direct trans-activator binding to cis-elements.  
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Figure 44: Diagrammatic representation of ATF3, AXUD1 and EGR2 proximal promoters and predicted AP-1 
binding sites. Transcription factor binding site software was used to predict where AP-1 factors (denoted by red 
oval) may possibly bind to the proximal promoter region of indicated genes. The distance from the transcription 
start site for each binding site is indicated below the predicted binding site. 
 
Figure 45 demonstrates that ATF3 gene expression following 1.25 hour IL-1+OSM 
stimulation significantly decreased following FOS and JUN silencing indicating the 
importance of these AP-1 factors in the expression of this transcription factor. 
Interestingly, AXUD1, only exhibited a significant decrease in expression upon FOS 
silencing alone, whereas EGR2 expression was only reduced when JUN alone was 
silenced implying a degree of differential regulation. Together these data confirm that 
c-Fos and c-Jun indirectly regulate collagenases by regulating other transcription 
factors expression which themselves contribute to collagenase gene regulation. 
Study within this chapter has confirmed a role for ATF3, AXUD1 and EGR2 in the 
transcriptional regulation of collagenases. These findings have gone some way toward 
accounting for the IL-1+OSM-dependent gene regulatory events that occur following 
loss of c-Fos/c-Jun expression and the initiation of MMP1 and MMP13 expression in 
chondrocytes.   
 
 
 
 
-60-315-1029
ATF3
AXUD1
EGR2
-352
-126-1031-1429-1660-1755-1881
-40-572-640-1078-1640
126 
 
 
Figure 45: Real-time PCR analysis of the effect of FOS and JUN gene silencing on contributing factor gene 
expression in IL-1+OSM stimulated HAC. Following transfection with siRNA specific for FOS, JUN or non-targeting 
siControl (100nM), HAC were treated with IL-1 (0.05ng/ml) in combination with OSM (10ng/ml) for 1.25 hours. Real-
time reverse transcription PCR of the isolated RNA was performed for ATF3, AXUD1 and EGR2 and normalised to 
18S rRNA housekeeping gene. Data are pooled from two separate HAC populations (each assayed in octuplet) and 
expressed as a percentage of stimulated control (specific siAP-1 transfected vs. siCon-transfected; mean ± S.D.; *, p 
<0.05; **, p < 0.01; ***, p < 0.001). 
 
5.2 Discussion 
 
In this chapter I assessed if the genes identified by DNA microarray analysis had a 
functional role in the regulation of IL-1+OSM-mediated collagenase expression in HAC. 
I demonstrated that ATF3, AXUD1 and EGR2 are key factors regulating MMP1 and 
MMP13 expression. 
The finding that ATF3 is playing a role in regulating MMP13 expression is a novel and 
exciting one. Previous study has not demonstrated this role in chondrocytes before 
now. However, there has been a great deal of study carried out for the family member 
ATF2 in chondrocytes. Many studies highlight its role in proliferation and maturation. 
Beier et al [293] showed that cyclin D1, which is crucial to chondrocyte proliferation, is 
regulated by ATF2, with ATF2-/- mice exhibiting defective cartilage development. Other 
studies have shown that ATF2 in combination with Smad are key regulators of 
chondrocyte maturation following stimulation with TGF-β [294, 295], a common 
precursor for development of OA [296]. ATF2 has also been shown to have a role in 
JNK and p38-mediated MMP1 expression in fibroblasts. There is one study however, 
that demonstrated that ATF3 has a similar function to ATF2 in chondrocytes. James et 
al [297] showed that ATF3 induction correlated with terminal differentiation of 
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chondrocytes. The study went on to suggest that this was due to ATF3-dependent 
increase in Runx-2. This factor not only contributes to chondrocyte hypertrophy [298, 
299] but also directly regulates MMP13 expression [113, 300, 301] which is itself a 
marker for chondrocyte hypertrophy [244]. This re-initiation of developmental 
signalling pathways (e.g. Wnt [302, 303]) in the chondrocyte is a key pathological 
process in OA [244]. Processes that are characteristic of OA, including cartilage 
remodelling, vascularisation and focal calcification of joint cartilage forming 
osteophytes, are also characteristics of normal skeletal development by endochondral 
ossification. These data in combination with my own findings demonstrate a credible 
possibility that ATF3 has a critical role in this key pathological process that underpins 
OA. Moreover, this observed differential regulation of the collagenases complements 
this observation as MMP-13 is highly associated with OA, whilst MMP-1 production 
correlates with RA [304]. I therefore suggest that ATF3 may well be a valid candidate 
for further study in to providing therapeutic intervention for OA. ATF3 knock-out mice 
[305] could be utilised in combination with arthritic mouse models to identify if the 
loss of this factor attenuates disease. Inhibitors which prevent DNA binding, similar to 
those generated for c-Fos [159], could then be developed. In the consideration that 
this intervention would be administered at a time where development pathways 
would only be occurring as a consequence of disease, ATF3 inhibition represents 
specificity as well as potential efficacy.  
Another interesting result from study carried out in this chapter is that ATF3 is bound 
to AP-1 consensus sequence following 6 hour IL-1+OSM stimulation duration and c-Fos 
and c-Jun are not. This suggests the potential involvement of other regulatory factors 
and/or co-activators being recruited to AP-1 binding site within the MMP promoters 
when AP-1 factors are not. It must be said that although informative, DAPA is an in 
vitro technique which does not reflect specific promoter binding or account for 
complex regulatory mechanisms involved in gene expression. However, it does provide 
clues as to how ATF3 could contribute directly to MMP13 regulation. The ATF family 
consist of transcription factors that contain a leucine-zipper motif which allows 
promoter binding. The different members of this family are able to dimerise with one 
another and themselves, a characteristic which imparts varying DNA binding capacity 
and effector function [306]. Interestingly, the ATF binding element is almost identical 
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to that of AP-1. Moreover, ATF and AP-1 can bind to one another’s binding element 
with equal avidity [241] and they can also form dimers between the different members 
of the two families [128, 307-309]. These studies also demonstrate that dimers 
between ATF members and Fos family members bind to DNA less efficiently than 
ATF/Jun family dimers. I therefore suggest that ATF3 may be forming heterodimers 
with Jun family members at times following stimulation where c-Fos is no longer 
present i.e. at 6 hours-post stimulation as shown in DAPA study. Shortly after 
stimulation c-Fos/c-Jun dimer binds to the MMP13 promoter initiating gene regulation 
processes. Over time this dimer dissociates and is replaced with ATF3/Jun dimer which 
then contributes further to orchestrating gene expression. ATF homodimers are 
unlikely to contribute as they are transcriptional repressors [310]. I propose that JunD 
could be a possible binding partner as my own studies show that JunB regulates MMP1 
expression not MMP13, active c-Jun is not present following 6 hour IL-1+OSM 
stimulation and previous study has shown that ATF3/JunD dimer is a positive regulator 
of gene expression [311, 312]. The contribution of ATF3 could therefore account for 
the c-Fos-collagenase temporal deficit either by taking over trans-activation from 
Fos/Jun dimers during this time or by regulating transcription factors key to 
chondrocyte maturation. 
With the aforementioned limitations associated with DAPA I repeatedly attempted to 
establish whether or not ATF3 was enriched on the MMP13 promoter using ChIP. 
However, I could not do so. This may have been due to a number of reasons. One of 
them may simply be that I could not get this technique, which is renowned for its 
logistical difficulties, to work appropriately resulting in isolated gDNA that did not 
reflect actual in vivo enrichment. Another practical issue may be that the antibody 
used in immunoprecipitation was not ChIP validated, despite being ‘recommended for 
Gel Supershift and ChIP applications’. As such the epitope on ATF3 to which this 
antibody binds may be hidden within a complex of transcriptional machinery and 
higher-order chromatin structure. Fragments of gDNA that are enriched by ATF3 could 
therefore not be pulled-down by agarose beads due to a lack of antibody binding. A 
negative result does not necessarily mean that there was error in the technique. 
Furthermore, ATF3 may not be bound to the promoter following 3 hours IL-1+OSM 
stimulation investigated. Enrichment may well be occurring at other time points. This 
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would require time-course ChIP studies as in chapter 3. In the case of c-Fos, 
enrichment was very transient with binding only demonstrated at 1 hour stimulation. 
This may, therefore, be the case for ATF3 and the correct stimulation duration was not 
used to elucidate this binding. Alternatively, ChIP experiments were carried out 
correctly and ATF3 simply does not bind to MMP13 promoter following IL-1+OSM 
stimulation of chondrocytes. Yet, with evidence demonstrating that ATF3 plays a role 
in the expression of MMP13, as discussed above, it could be suggested that ATF3 
indirectly contributes to collagenase gene regulation by directly regulating contributing 
factors like RUNX2 expression. This hypothesis would account for the extended 
temporal lag that would be only partially accounted for by AP-1-dependent ATF3 
expression and protein production.  
I propose that the absence of detectable ATF3 on MMP13 promoter may be because it 
is bound elsewhere on the gene. Enhancer elements are functionally well defined 
regions present within a great number of genes. These cis-acting regions contain a 
number of transcription factor binding sites, which act to increase the level of 
transcription of a gene found on the same molecule of DNA. However, enhancer 
elements can be found up to 50 kbp up- and down-stream of the TSS. They exert their 
function by looping of the DNA in order to bring these distal regions into close 
proximity with trans-activators bound close to the TSS, thus contributing to the 
assembly of the regulatory complex necessary for transcription [313]. Early trans-
activation studies of MMP1 identified a TPA-responsive enhancer element relatively 
close to the TSS [314]. However, recent study has identified an IL-1-responsive 
enhancer element for MMP13 in chondrocytes. Schmucker et al. [115] demonstrated 
the presence of a distal enhancer element 20 kbp, 5’ of the TSS of MMP13. This study 
showed the enrichment of c-Fos and c-Jun to this enhancer. The study also showed 
that this enhancer was associated with transcriptionally permissive chromatin and RNA 
polymerase recruitment. Chromatin capture also showed that this distal element 
interacted with the proximal promoter a process critical to the optimal expression of 
MMP13. I therefore suggest that ATF3 could be binding to this enhancer region 
following stimulation. As such, by using primers for the proximal promoter I was 
unable to detect the distal binding of ATF3. 
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An interesting finding from the assessment of the temporal gene expression of the 
contributing factors was that ATF3, AXUD1 and EGR2 were not nearly as transient as 
FOS. Unlike FOS and other IEG, the expression of these three genes did not return to 
levels comparable with basal conditions. It could be suggested, therefore, that these 
genes are not conventional IEG. Freter et al. [127] proposes that IEG can actually be 
subdivided into “fast” and “slow” groups; fast IEG, for example FOS, are rapidly 
induced following stimulus and are capable of reaching peak induction following only 
30 minutes of stimulation with levels returning to basal levels within 2 hours [315, 
316]. Slow IEG, such as MYC, exhibit a 60-90 minute lag prior to the induction of the 
gene [317]. Moreover, the expression of these genes persists for much longer 
compared to the fast IEG which rapidly return to basal levels [318]. This expression 
pattern mirrors observation in ATF3 expression. I therefore suggest that following IL-
1+OSM stimulation of HAC both subclasses of IEG are contributing to collagenase 
expression; fast IEG, FOS followed by induction of slow IEG, which include the 
candidates, ATF3, AXUD1 and EGR2. It must be stressed that if ATF3 and EGR2 are 
indeed regulated by AP-1, as my study has suggested, then this means that they are 
not strictly IEG. IEG require no de novo synthesis in order to be expressed [117], 
however previous study indicates that ATF3 and EGR2 are IEG [319-321]. Previous 
study has shown that AP-1 factors demonstrate auto-activation [251, 322, 323]. One 
specific study demonstrated that c-Jun required both itself and ATF2 for full auto-
activation [324]. Therefore evidence suggests that IEG can be regulated by other IEG. 
As such, I suggest that following IL-1+OSM stimulation, AP-1 contribute to the 
expression of ATF3 and EGR2 rather than governing whether or not they are induced. 
Unlike ATF3 and EGR2, AXUD1 protein was present at high levels in the chromatin-
bound fraction in both stimulated and unstimulated chondrocytes. Moreover, there 
were only modest changes in chromatin-bound levels over the IL-1+OSM time-course. 
This means that the IL-1+OSM-mediated induction of gene expression and protein 
production only serves to slightly increase chromatin binding rather than initiating it. A 
potential explanation for this may be that AXUD1 can both activate and repress gene 
transcription, a characteristic demonstrated by other IEG like MYC [325]. In 
unstimulated chondrocytes, AXUD1 may be bound to some gene promoters, 
repressing them. Upon stimulation, the AXUD1 induced binds to MMP1 promoter 
131 
 
positively regulating expression which is observed as a modest increase in the 
chromatin-bound fraction. It is difficult to assess specificity when looking at chromatin 
binding throughout the genome with Western blotting and so investigating the role of 
AXUD1 on MMP1 regulation in this way is not as informative as ChIP studies for 
example. Although continuous chromatin binding by AXUD1 is intriguing it is difficult to 
say how this relates to MMP1 regulation.  
A great deal of previous study has implicated NFATc1 in arthritis and cartilage 
degradation; It has been shown to be expressed in the synovium of RA patients [326] 
and that increases in the expression of ADAMTS-9 in IL-1-stimulated HAC was 
dependent on NFATc1 [287]. Moreover, Yoo et al [248] showed that inhibition of the 
NFAT activation led to decreased IL-1-mediated collagenase gene expression in OA 
chondrocytes and protected against experimentally induced arthritis in mice. Despite 
the lack of robust gene expression, these studies warranted the inclusion of NFATc1 in 
siRNA screening. However, following the assessment of temporal protein induction 
and gene expression, NFATc1 showed very little change following IL-1+OSM 
stimulation. The data therefore suggest that, although important in collagenase gene 
regulation, NFATc1 is not induced and that what minor effect on gene expression there 
is by stimulating with IL-1+OSM does not correspond to increased protein induction. 
Previous studies have demonstrated an IL-1-dependent induction of NFATc1 by 
chondrocytes that peaks following 3 hour stimulation [287]. I suggest that with the 
addition of OSM to the stimulus there may be a change in signalling pathways rather 
than simply initiation of additional pathways. Such OSM-dependent changes in 
signalling are observed in Litherland et al. [97] where the addition of OSM to the an IL-
1 stimulus leads to a change in the PKC isoforms regulating collagenase expression. As 
such the calcium (Ca2+)/calcineurin/NFATc1 pathway is surpassed by a more robust, 
alternate signalling pathway. It must also be highlighted that study demonstrating IL-1-
dependent induction of NFATc1 [287] used human chondrocytes after at least 3 rounds 
of passage. The effect of this process in primary cells leads to phenotypic changes and 
altered gene expression which could potentially account for differences in induction 
between this study and my results [327]. The fact that NFATc1 is not induced does not 
necessarily mean that it is not contributing to the regulation of the collagenases, with 
my own gene silencing data suggesting it is. However, this means that NFATc1 
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expression and protein production do not account for any part of the temporal lag 
between peak c-Fos/AP-1 and the time in which all the constituents of effective 
transcriptional machinery have been produced (as demonstrated in protein synthesis 
inhibition studies, chapter 3). This means that when selecting NFATc1 from the DNA 
microarray study, I may have chosen a gene that rather than increasing in expression 
following modest induction at 1.25 hours actually peaked at that time. Previous studies 
have demonstrated that IL-1 stimulation of chondrocytes leads to the release of 
intracellular calcium stores and a transient increase of calcium [290, 328]. This should 
then lead to the binding of calcineurin to calmodulin and which then dephosphorylates 
cytoplasmic NFATc1 which can then translocate to the nucleus binding to gene 
promoters and regulating their expression [246]. As such, NFATc1 may be 
constitutively expressed in chondrocytes, as demonstrated in the isoforms NFATc2 and 
3 in T and B lymphocytes [329]. Therefore, IL-1-dependent Ca2+ increases could 
potentially control NFATc1 activation and subsequent collagenase gene regulation as 
opposed to increases in NFATc1 gene induction.  
 
5.2.1 Summary  
 
 siRNA screening of a number of genes selected from DNA microarray were 
found to have a significant effect on collagenase gene expression. 
 Assessment of temporal kinetics at the level of protein and mRNA indicated 
that certain selected genes, including ATF3, AXUD1 and EGR2, were reaching 
peak induction after 1 hour IL-1+OSM stimulation, a duration that 
corresponded to peak AP-1 induction. 
 The silencing of FOS and JUN in HAC stimulated with IL-1+OSM indicates that 
these contributing transcription factors are themselves regulated by AP-1. 
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6 Chapter 6: General Discussion 
 
Cartilage degradation due to the aberrant expression of proteolytic enzymes 
(specifically the collagenases MMP-1 and MMP-13) is a key pathological process that 
occurs in arthritic disease [37, 41, 43-45]. It has been demonstrated that the 
combination of pro-inflammatory cytokines, IL-1 and OSM, which are both significantly 
elevated in disease [65, 76, 84] can elicit a robust induction of collagenase gene 
expression, protein production and subsequent enzyme-dependent collagenolysis, all 
orchestrated by the chondrocyte [57, 73, 75, 76]. The initiation of this process brings 
about the irreversible loss of articular cartilage architecture which leads to an 
impairment of tissue function, resulting in pain and disability in those suffering from 
the disease [25]. The present study was carried out in order to improve the 
understanding of the transcriptional regulation of collagenases in HAC following 
stimulation with IL-1 in combination with OSM which models the complex pro-
inflammatory cytokine milieu found in disease.  
My study began by investigating the AP-1 transcription factor family members, c-Fos 
and c-Jun. These factors form heterodimers that have been shown to regulate the 
transcription of a number of genes within the genome [292]. Previous study 
demonstrated that these AP-1 factors play a key role in the transcriptional regulation 
of collagenases in the chondrocyte following pro-inflammatory cytokine stimulation 
[330, 331] and specifically IL-1+OSM [97]. However, detailed knowledge of AP-1 in the 
context of this disease model is poor, with most studies perpetuating the dogma of c-
Fos/c-Jun-dependent collagenase expression in the chondrocyte. I therefore utilised 
time-course studies looking at temporal changes in the level of c-Fos/c-Jun mRNA, 
protein and collagenase promoter recruitment. This led to the discovery of a temporal 
deficit between the transient peak in FOS induction and the initiation of MMP1 and 
MMP13 gene expression. Protein synthesis inhibitor studies then demonstrated that 
de novo synthesis of protein was required after the peak in FOS in order to elicit 
collagenase gene expression, showing that although important, c-Fos/c-Jun is not 
solely responsible for the transcriptional regulation of the collagenases.  
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Through the use of DNA microarray, investigation into changes in global gene 
expression following IL-1+OSM stimulation for durations immediately after the peak in 
FOS expression identified a number of genes that could potentially regulate 
collagenase gene expression. Subsequent siRNA screening highlighted a subset of 
these genes that encode factors that were functionally relevant to collagenase gene 
expression. Analysis of the temporal gene expression and protein production levels of 
the factors ATF3, AXUD1 and EGR2 indicated that their peak induction was within the 
temporal deficit. It was also demonstrated, through siRNA-mediated FOS and JUN 
silencing, that these factors were being regulated by c-Fos and/or c-Jun. This study has 
provided evidence that the transcriptional regulation of the collagenases following 
potent synergistic cytokine stimulation is a complex process that involves a number of 
factors that contribute to the aberrant expression of collagenases by the chondrocyte.  
The in vitro model which I used to study cartilage degradation as a consequence of 
complex pro-inflammatory cytokine stimulation is a well-established and robust 
indicator of potential processes that occur within the articular cartilage of patients 
suffering from arthritis. In vitro models have their obvious failings however these in 
vitro findings form the basis of subsequent work that extrapolates to ever more 
biologically relevant studies. However, this does not mean that this in vitro work could 
not be further improved upon in order to provide a greater understanding of 
collagenase regulation in the disease context. Other cell types that reside within 
synovial joints have the capacity to contribute to the aberrant expression of 
collagenases within the joint in disease pathology. The expression of MMP13 is mainly 
limited to chondrocytes, however, macrophages and fibroblasts also demonstrate 
expression [36, 37]. Conversely, MMP1 is ubiquitously expressed throughout many cell 
types residing within the synovial joint which, as well as chondrocytes, includes 
macrophages, fibroblasts, osteoclasts, endothelial and epithelial cells [36, 37, 151]. As 
such, it would be incorrect to assume that chondrocytes were the sole contributors of 
collagenase production in arthritic disease. It would therefore be interesting to 
substitute chondrocytes for these other cell types within this model of inflammation-
dependent MMP expression in order to assess whether or not transcriptional 
regulation of collagenase is common to all cell types or is in fact cell specific. The 
potential for conserved gene regulation between different cell types in response to 
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these cytokines would suggest that therapeutic intervention may result in a more 
comprehensive reduction in collagenase production in the joint. Alternatively, it may 
also suggest that targeting collagenase gene regulation may not be specific enough to 
mitigate side effects. If the differential gene regulation demonstrated in this study 
occurs exclusively in chondrocytes then therapeutic intervention could be highly 
specific and therefore only attenuating collagenase activity at the site of cartilage 
degradation. 
The substitution of IL-1 and/or OSM with other pro-inflammatory cytokines that are 
capable of synergistic collagenase induction [75-77], would also be highly informative. 
The limitation of only using two cytokines to model a complex cytokine milieu is that 
the effect of other significantly elevated cytokines found in disease are unaccounted 
for. Though IL-1 in combination with OSM are valid candidates for this model, other 
pro-inflammatory cytokines may well be bringing about the regulation of collagenases 
in a manner distinct from IL-1+OSM. Conversely, a myriad cytokines, growth factors 
and cell surface receptor activation have all been shown to signal through MAPK 
pathways which culminate in the induction of AP-1 gene expression [111, 152, 332, 
333]. Therefore, substitution with other combinations of cytokines may not affect the 
way collagenases are regulated in the chondrocyte and so provide a point of common 
convergence in response to all pro-inflammatory cytokines which could be targeted 
therapeutically. 
Despite the focus of this study being on the gene regulation of the collagenases MMP1 
and MMP13, the findings presented may contribute equally to the gene regulation of 
other MMPs involved in arthritis. Previous study has mapped a number of putative 
binding sites for various trans-activating factors on the proximal promoter region of 
MMPs [2, 111, 114]. A great many MMP promoters have been shown to contain 
multiple AP-1 consensus binding sites found close to the TSS. The gelatinase, MMP-9 
and stromelysin, MMP-3 are two such MMPs. Both are elevated in arthritic disease 
[11, 54, 334-336] and in response to IL-1, their expression has been shown to be 
dependent on AP-1 in chondrocytes [107, 337]. As well as MMP-3, other MMP 
containing AP-1 binding sites within their promoters have increased expression in 
chondrocytes following IL-1+OSM stimulation [72]. This includes MMPs that have 
direct collagenolytic function (MMP-1, MMP-9, MMP-13 and MMP-14 [338, 339]) and 
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those which cleave pro-collagenases to their active form (MMP-3 and MMP-10 [340, 
341]). These studies indicate that many MMP gene products that are capable of either 
directly, or indirectly degrading cartilage, may be regulated in a very similar manner in 
response to pro-inflammatory cytokine stimulus. As such my study may also improve 
our understanding of how MMPs, other than the collagenase MMP-1 and MMP-13 
which are typically associated with arthritis are regulated in the context of disease.  
Although collagen cleavage is a key pathological process in arthritic disease, the 
functions of MMPs are also crucially implicated in the pathology of a number of other 
diseases that, similar to arthritis, are driven by inflammatory responses, including: 
chronic inflammatory airway disease (e.g. asthma) [342] and chronic pancreatitis [343] 
as well as cardiovascular disease [344] and brain disorders [345]. However, the role of 
MMPs in different diseases is not as definite as in arthritis. Chronic liver disease and 
the resulting hepatic fibrosis are associated with chronic inflammation and the 
activation of hepatic stellate cells within the liver. This activation leads to the 
production and deposition of excess ECM [346]. However, the distinct role of MMPs in 
fibrogenesis and fibrolysis is not clear. MMP can degrade the excess ECM [347], 
however, they have also been shown to be down-regulated in disease [348] allowing 
fibrosis to perpetuate. Equally, MMP have been shown to regulate the inflammatory 
process underpinning stellate cell activation and fibrogenesis [349]. The conflicting 
roles of MMP in liver fibrosis is demonstrated in de Meijer et al [350]. Following broad-
spectrum MMP inhibition in a murine model of chronic CCl4-induced hepatic injury 
there was a decrease in hepatic injury and down-regulation of pro-fibrogenic factors. 
However, pan-MMP inhibition also led to increased fibrosis in the liver demonstrating 
that a lack of MMP inhibition specificity can be as detrimental as it is beneficial. This 
contradiction in pathophysiological roles is also evident in tumourgenesis. Increased 
AP-1-dependent MMP-3 and MMP-9 levels are associated with both arthritis and 
cancer development. However, in tumourgenesis these MMP have rather 
contradictory roles, with MMP-3 shown to have a protective function [351] whereas 
MMP-9 is associated with tumour development and angiogenesis [352]. Interestingly, 
the collagenase MMP-8 which is generally shown not to contribute to cartilage 
degradation [53], has a protective role in metastasis [353, 354]. These studies 
therefore highlight the myriad of functions of MMPs and therefore the necessity for 
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their differential regulation in the body. Targeting of AP-1-mediated MMP for the 
treatment of arthritic disease, without specificity, may well prevent cartilage 
degradation but may also lead to the removal of homeostatic mechanisms that 
prevents fibrosis and/or tumour development. The insight gained through my study 
into the differential regulation of collagenases may be the first step toward targeted 
therapy. For example, ATF3 inhibition could lead to reduced MMP-13 production and 
cartilage degradation whilst leaving other MMP-dependent processes unperturbed. 
Although my study demonstrates differential regulation between two key collagenases 
in arthritic disease, it is yet to be shown whether this specificity at the level of 
transcriptional regulation is also the case in comparison to other MMPs.  
A key piece of evidence that validated my early hypothesis of post-c-Fos/c-Jun 
production of factors necessary for the complete transcriptional activation of 
collagenases came from protein synthesis inhibition studies (chapter 3). I went on to 
reveal novel factors that contributed to collagenase gene expression, whose 
production may account for the time taken for gene expression to be initiated. 
However, of the factors elucidated in this study, their gene expression peaked 
immediately after 1 hour stimulation (maximal FOS expression and c-Jun activation). 
Furthermore, their protein levels also reached maximal levels before the point at 
which the gene expression of collagenases no longer required the de novo synthesis of 
proteins. This means that other factors produced after ATF3, EGR2 and/or AXUD1 may 
be required to bring the about complete initiation of transcription. Therefore, this 
study, although going some way to explaining the aforementioned temporal deficit, 
still does not account for it in its entirety. This present study may serve to improve our 
knowledge of the sequence of events which culminate in the initiation of collagenase 
transcription, yet may still not account for all the factors in this process. As previously 
referred to, tissue specific factor Runx-2 regulated the expression of MMP13 [113] and 
is itself regulated by ATF3 in the chondrocyte [297] and as such Runx-2 could be at the 
end of this sequence and therefore potentially fully capitulate this cascade of gene 
induction thereby accounting for the full temporal deficit.  
In order to refine my search for contributing factors that could regulate collagenase 
transcription I established criteria that allowed me to identify only the most pertinent 
genes in the context of my study. One of these criteria was that factors corresponding 
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to these genes had the capacity to trans-activate genes. In retrospect I would now go 
back to the gene expression data generated by the DNA microarray and widen my 
search criteria. This would therefore allow me to assess the role of other factors that 
increase in their gene expression following short IL-1+OSM stimulations. Though 
important, trans-activation of gene promoters is not the only gene regulatory 
mechanism. For example, DNA methylation is a key repression process exhibited 
throughout the genome. Bui et al. [102] demonstrated that osteoarthritic HAC have 
decreased DNA methylation at the proximal promoter of MMP13 which correlated 
with increased transcription factor binding (CREB) and increased MMP13 gene 
expression. This study demonstrated that methylation state is altered in disease. It 
could therefore be suggested that other factors highlighted in gene expression analysis 
could be contributing to this regulation (e.g. through expression of enzymes that 
control DNA methyl-transferases) and that these were not highlighted due to the 
alternate research focus. Similarly, histone modifications in order to bring about 
transcriptionally permissive chromatin [172], the re-structuring of chromatin to bring 
enhancers into closer proximity to proximal elements [115] and assembly and 
activation of the transcriptional machinery at the TSS are all potential levels of 
regulation that could be controlled by factors elucidated by DNA microarray but which 
were initially overlooked as a consequence of gene search criteria. 
The differential regulation of the collagenases has been highlighted in previous studies 
[93, 97, 104, 355]. These show that the differential expression of MMP1 and MMP13 is 
manifested at the level of intracellular signalling pathways in the chondrocyte. 
However, some of these studies also highlight the fact that many other cell types that 
do not produce collagenases exhibit similar induction of these signalling pathways 
following the same pro-inflammatory stimulus. As such, they suggest that “expression 
must be due to other factors that enable tissue-specific expression of the gene” [93]. I 
suggest that not only are collagenases differentially regulated at the level of 
intracellular signalling but also by gene trans-activation in response to stimulus. Data in 
the present study demonstrate that silencing of specific genes in chondrocytes 
stimulated with IL-1+OSM lead to the decreased expression of one collagenase and not 
the other. Moreover, I suggest that these factors could act as a more appropriate 
target for therapeutic intervention. In disease there are a number of elevated pro-
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inflammatory cytokines present which can be attributed to the aberrant expression of 
collagenases [356, 357]. These cytokines signal via a great number of signalling 
pathways, which are capable of “cross-talk” between different pathways resulting in 
very complex signalling in the chondrocyte [2, 358, 359]. However, many of these 
pathways still converge upon transcriptional activation of collagenases. As such greater 
understanding and therapeutic targeting of factors regulating individual collagenase 
expression would target the hub of pathological signalling in the chondrocyte.  
6.1 Future work 
 
During the course of these studies a number of key issues have been highlighted that 
require further investigation. This would serve to further improve the understanding of 
transcriptional regulation of collagenases following IL-1+OSM stimulation and the 
process of cartilage degradation in arthritis. 
Initially I would silence AP-1 factors in combination with novel contributing factors, 
ATF3, EGR2 and AXUD1 in order to assess the effect on collagenase expression. By 
silencing these factors in combination with AP-1 factors I would be able to understand 
if their regulation is entirely dependent on AP-1 regulation or if other factors also 
contribute to their regulation. For example, if there was no further reduction in 
collagenase expression following AP-1+ATF3 silencing compared to AP-1 silencing 
alone, this may suggest that ATF3 is entirely dependent on AP-1 and therefore there is 
no ATF3 present to silence further. Conversely, if there were a greater reduction in 
collagenase expression when AP-1 and ATF3 were both silenced then this may suggest 
that ATF3 is still being expressed in order to be silenced and though important, AP-1 is 
not solely regulating ATF3. As ATF3 and EGR2 have both been previously demonstrated 
to be IEG [319-321] like FOS [315, 360], I would hypothesise that AP-1 are enhancing 
the expression of these factors rather than regulating them as IEG should not require 
prior protein de novo synthesis for their regulation [119]. I therefore postulate that 
silencing a combination of these factors would lead to a greater reduction in 
collagenase gene expression than silencing them individually. Although this may prove 
difficult, using siRNA, the group is currently developing shRNA-mediated gene knock-
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down which, with sustained silencing, may be better able to tease apart these 
regulatory events.  
I would also vary the model of inflammation-dependent collagenase expression by 
substituting IL-1 and/or OSM with other pro-inflammatory cytokines that are elevated 
in disease and exhibit synergy in collagenase induction [75-77]. By using other relevant 
inflammatory mediators in this model I would be able to see if different cytokines 
elicited different transcriptional regulation or that regulation is, in fact, common to the 
majority of pro-inflammatory cytokines elevated in disease. In addition to the above 
alterations to the model of inflammation-dependent collagenase expression, I would 
also assess whether or not IL-1+OSM stimulation of other collagenase-producing cells 
within the synovial joint were capable of regulating collagenase in the same way as 
chondrocytes.  
As previously discussed, studies indicate that RUNX2 may be regulated by ATF3 [297] 
and that Runx-2 regulates MMP13 expression but not MMP1 [113]. This not only 
accounts for the differential regulation shown by ATF3 but also the fact that the 
present study still does not fully capitulate the temporal lag between AP-1 peak and 
initiation of collagenase expression. As such, I would assess genome-wide gene 
expression changes in HAC stimulated with slightly longer durations (e.g. 2 hours) of IL-
1+OSM thereby elucidating genes which were beginning to be expressed after/as a 
result of contributing factors highlighted in this study. This would involve new DNA 
microarray studies and the assessment of RUNX2 temporal gene expression.  
Although data from the DNA microarray could be further utilised in order to look at 
how factors other than those which demonstrated trans-activating capacity could 
affect collagenase gene regulation, I am convinced that in the case of transcription 
factor elucidation, further study using ChIP-seq would prove highly informative. This 
technique allows the user to elucidate the regions at which certain factors are 
associated with DNA within the entire genome [361]. This involves ChIP using an 
antibody against a factor of interest to pull-down fragments of DNA which are then 
sequenced in order to identify specific factor binding sites throughout the genome. 
With this technique I would be able to ascertain all the sites enriched with c-Fos in the 
genome following IL-1+OSM stimulation in chondrocytes. This would allow me to 
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determine whether the genes of factors that are contributing to collagenase 
expression identified in this study are controlled directly by AP-1. Moreover, I would 
be able to identify other genes that require c-Fos recruitment to their promoters 
following different durations of IL-1+OSM stimulation, thereby providing greater 
insight into which other c-Fos/c-Jun-dependent factors may be contributing to the 
regulation of collagenase genes. This technique could be further utilised with 
antibodies for other factors, such as ATF3, in order to assess their binding to 
collagenase gene promoters but also other genes which themselves may contribute to 
collagenase transcription.  
Not only does ChIP-seq allow for detailed assessment of factor binding at a genome-
wide scale but it also gives insight into how regions that are relatively close to the gene 
are populated with certain factors. By knowing where c-Fos or ATF3 cis-binding occurs 
in the genome it may be possible to identify possible enhancer or repressor elements 
that could be playing a role in their collagenase gene regulation as demonstrated in 
Schmucker et al [115]. If candidate regions were identified, chromatin conformation 
capture could be used to confirm the association of these with more proximal regions 
and gain insight into the dynamic chromatin remodelling required to regulate these 
genes. 
In order to bring about the initiation of transcription a complex of many factors 
controlling various levels of gene regulation must assemble around the TSS of genes. 
As such elucidating the components of this complex at the TSS of collagenases would 
reveal proteins necessary for transcription and therefore the regulatory mechanisms 
utilised. It would also provide a basis for screening these components and identifying 
which are the most crucial in gene regulation of collagenases and can therefore be 
targeted for further study. This could be achieved by IP with an antibody for a ‘target 
protein’ (potentially ATF3) which is a crucial component of this complex. Proteins could 
then be purified following cell lysis and subject to mass spectrometry analysis which 
identifies the proteins that co-precipitated with the ‘target protein’. 
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6.2 Summary     
 
This study into the transcriptional regulation of the collagenases, MMP1 and MMP13, 
in chondrocytes following stimulation with IL-1+OSM has resulted in a greater 
comprehension of the complexity with which this process is orchestrated. Following a 
cascade of intracellular signalling events in the chondrocyte following stimulation 
culminating in STAT activation/dimerisation and promoter binding [82, 97], the IEG 
FOS is rapidly and robustly induced (Figure 46a and Figure 47a) at both mRNA and 
protein level. It is then found enriched on the proximal promoter of collagenase genes 
MMP1 and MMP13 (section 3.1.4), where it could be potentially acting as an initial 
anchor for the assembly of other co-factors essential for transcription. In parallel, c-
Fos/c-Jun is also enhancing the increase in expression of other factors such as ATF3, 
EGR2 (Figure 46b) and AXUD1 (Figure 47b), by potentially binding to promoter regions. 
These genes are then induced and increase in expression, peaking at a point after c-
Fos/c-Jun factors. These factors themselves go on to contribute to the transcriptional 
regulation of collagenases following the loss of c-Fos enrichment on the collagenase 
promoters following 1 hour IL-1+OSM stimulation. For MMP13 expression (Figure 46) 
my findings combined with previous studies have revealed a number of ways in which 
the gene may be regulated: ATF3 may be recapitulating the AP-1 dimer bound to 
MMP13 promoter with a member of the Jun family, potentially JunD, following the loss 
of c-Fos enrichment (Figure 46d); EGR2 may be binding a distal consensus binding site 
upstream of MMP13 TSS in concert with ATF3 binding at the proximal promoter 
(Figure 46e); ATF3 may also be regulating factors such as Runx-2, a factor shown to 
regulate MMP13 gene expression (Figure 46f); furthermore, some or all of these 
mechanisms may well be occurring at either proximal promoter region or distal 
enhancer element (Figure 46g). 
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Figure 46: Diagram summarising the potential orchestration of events that lead to MMP13 gene expression in 
HAC. Following stimulation of HAC with IL-1+OSM a cascade of intracellular signalling events leads to the increase in 
c-Fos/c-Jun AP-1 heterodimer in the nucleus via STATs (a). c-Fos/c-Jun heterodimer then regulate ATF3 and EGR2 
gene expression (b). ATF3 may then also regulate RUNX2 (c). These factors then contribute to MMP13 gene 
expression in a number of potential mechanisms, some of which are highlighted (d-g). 
 
For MMP1 expression (Figure 47) AXUD1 was shown to contribute to the regulation of 
this collagenase and like ATF3 for MMP13, AXUD1 may well be acting directly (Figure 
47c) or in-directly through other factors that regulate MMP1 (Figure 47d). Again this 
could well involve a much more complex mechanism comprised of many factors acting 
in concert at various binding regions. 
 
Figure 47: Diagram summarising the potential orchestration of events that lead to MMP1 gene expression in HAC.  
Following stimulation of HAC with IL-1+OSM a cascade of intracellular signalling events leads to the increase in c-
Fos/c-Jun AP-1 heterodimer in the nucleus via STATs (a). c-Fos/c-Jun heterodimer then regulate AXUD1 gene 
expression (b). This factor then contributes to MMP1 gene expression directly (c) or in-directly the regulation of an 
unknown gene (d).  
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The majority of therapeutic interventions in arthritis are based on reducing 
inflammation and/or treating symptoms. Current treatment therefore does little to 
mitigate the irreversible damage done as a result of proteolytic cartilage degradation. 
Therapies that have targeted cartilage degradation have proved to be unsuccessful. 
Broad spectrum inhibition of MMP leads to unwanted side effects that more than 
offset decreased cartilage destruction [1, 31]. As such the potential of targeted 
interventions of this pathological process that brings about pain and disability in 
arthritic patients is considerable. The present study improves our understanding of 
how collagenases, which facilitate cartilage degradation, are regulated in response to 
pro-inflammatory stimulus and provides a number of potential targets for therapy. By 
exploiting the differential regulation of collagenases, it may be possible to specifically 
abrogate collagenases associated with chondrocytes and cartilage degradation in 
disease whilst mitigating the effects on other MMPs necessary for normal homeostasis 
thereby reducing side effects and removing the barrier to successful treatment. 
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7 Appendix 
 
7.1 Generation of subcellular fractionation western blot figures 
In order to elucidate the temporal protein production of c-Fos and the phosphorylation 
activation of c-Jun, I utilised subcellular fractionation, as outlined in methods section 
(2.2.8). In order to allow direct comparison of protein level and localisation between 
different I+O stimulations of HAC, I electrophoresed all 5 subcellular fractions from 
each I+O duration on a single mini gel. Larger electrophoresis tanks were unreliable 
and often resulted in irregular migration of proteins and so the samples from the 
individual stimulation durations were simultaneously electrophoresed on separate 
mini gels (methods section 2.2.14). Each mini gel was transferred at the same time 
onto one sheet of PVDF. For ease of use and to minimise antibody wastage, the PVDF 
membrane was cut into sections which corresponded to each mini gel. All PVDF 
membrane washes, antibody incubations, exposures to chemiluminescent detection 
reagents and blot image capture were carried out simultaneously resulting in one 
single image which contained all exposed membranes as demonstrated in Figure 48. 
Densitometric scanning was then carried out on these images. In order to best present 
protein distribution and localisation findings, this single image was cropped using 
Windows Powerpoint software and arranged into a final figure which was then 
combined with histograms of relative image density. In Figure 48 the regions 
highlighted were cropped for the generation of c-Fos western blots in Figure 14Figure 
12. 
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Figure 48: Example of image cropping utilised for generating subcellular fractionation western blot figures HAC were stimulated with IL-1 (0.05ng/ml) in combination with OSM (10ng/ml) for the 
indicated durations. Proteins from cytosolic (a), membrane-bound (b), soluble nuclear (c), chromatin-bound, (d) and cytoskeletal (e) subcellular fractions were resolved using SDS-PAGE and 
immunoblotted with c-Fos antibody. Image shows simultaneous exposure of 5 PVDF membranes each corresponding to indicated I+O stimulation. Each rectangular outline corresponds to the 
representative image used in the results figure 14 (c-Fos). Molecular weight markers (kDa) are annotated adjacent to each I+O duration outline.   
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7.2 Subcellular fractionation and c-Jun loading controls 
A key technique used in my studies was subcellular fractionation and western blotting 
in order to demonstrate temporal protein distribution and localisation following 
different durations of I+O stimulation. In Figure 49, only the soluble-nuclear fraction 
taken from each, individual I+O stimulation duration was loaded on to a single mini-
gel. The altered loading confirms the observed temporal protein distribution 
demonstrated in Figure 14. The same blot was stripped and re-probed for pan-c-Jun 
antibody. This shows that alterations in levels of p-c-Jun (Ser63) over time were not 
accounted for by varying c-Jun protein levels. Lamin A/C control confirms equal protein 
loading.      
 
Figure 49: Loading controls for subcellular fractionation P-c-Jun (Ser 63) HAC were stimulated with IL-1 (0.05ng/ml) 
in combination with OSM (10ng/ml) for the indicated durations. Cells were then subject to subcellular protein 
fractionation. Proteins from soluble nuclear subcellular fractions were resolved using SDS-PAGE and immunoblotted 
with the indicated antibodies. Sample volumes loaded for SDS-PAGE were dependent on the relative volume into 
which the individual fractions were lysed.  
 
 
7.3 Full length, uncropped gel images of temporal protein distribution 
and localisation of factors highlighted from siRNA screening 
DNA microarray study and functional validation using siRNA highlighted a number of 
factors that contributed to transcriptional regulation of the collagenase genes. The 
induction and the cellular localisation of these proteins were assessed following IL-
1+OSM stimulation time course. Figures 50-53 show the full length, uncropped, gel 
images used to generate Western blot figures 39-43, respectively, as described in 
appendix 7.1. 
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Figure 50: Full length, uncropped, gel image for Western blot for ATF3 in subcellular protein fractionation from HAC stimulated with IL-1+OSM. HAC were stimulated with IL-1 (0.05ng/ml) in 
combination with OSM (10ng/ml) for the indicated durations. Proteins from cytosolic (a), membrane-bound (b), soluble nuclear (c), chromatin-bound, (d) and cytoskeletal (e) subcellular fractions 
were resolved using SDS-PAGE and immunoblotted with ATF3 antibody. Image shows simultaneous exposure of 5 PVDF membranes each corresponding to the indicated I+O stimulation. Each 
rectangular outline corresponds to the representative image used in the results figure 39. Molecular weight markers (kDa) are annotated to the left of each I+O duration outline.   
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Figure 51: Full length, uncropped, gel image for Western blot for AXUD1 in subcellular protein fractionation from HAC stimulated with IL-1+OSM.HAC were stimulated with IL-1 (0.05ng/ml) in 
combination with OSM (10ng/ml) for the indicated durations. Proteins from cytosolic (a), membrane-bound (b), soluble nuclear (c), chromatin-bound, (d) and cytoskeletal (e) subcellular fractions 
were resolved using SDS-PAGE and immunoblotted with AXUD1 antibody. Image shows simultaneous exposure of 5 PVDF membranes each corresponding to the indicated I+O stimulation. Each 
rectangular outline corresponds to the representative image used in the results figure 40. Molecular weight markers (kDa) are annotated adjacent to each I+O duration outline.   
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Figure 52: Full length, uncropped, gel image for Western blot for EGR2 in subcellular protein fractionation from HAC stimulated with IL-1+OSM.  HAC were stimulated with IL-1 (0.05ng/ml) in 
combination with OSM (10ng/ml) for the indicated durations. Proteins from cytosolic (a), membrane-bound (b), soluble nuclear (c), chromatin-bound, (d) and cytoskeletal (e) subcellular fractions 
were resolved using SDS-PAGE and immunoblotted with EGR2 antibody. Image shows simultaneous exposure of 5 PVDF membranes each corresponding to the indicated I+O stimulation. Each 
rectangular outline corresponds to the representative image used in the results figure 41. Molecular weight markers (kDa) are annotated adjacent to each I+O duration outline.   
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Figure 53: Full length, uncropped, gel image for Western blot for NFATc1 in subcellular protein fractionation from HAC stimulated with IL-1+OSM.  HAC were stimulated with IL-1 (0.05ng/ml) in 
combination with OSM (10ng/ml) for the indicated durations. Proteins from cytosolic (a), membrane-bound (b), soluble nuclear (c), chromatin-bound, (d) and cytoskeletal (e) subcellular fractions 
were resolved using SDS-PAGE and immunoblotted with NFATc1 antibody. Image shows simultaneous exposure of 5 PVDF membranes each corresponding to the indicated I+O stimulation. Each 
rectangular outline corresponds to the representative image used in the results figure 42. Molecular weight markers (kDa) are annotated adjacent to each I+O duration outline.   
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